AU2003254557B2 - Indoline derivatives substituted in position 6, production and use thereof as medicaments - Google Patents
Indoline derivatives substituted in position 6, production and use thereof as medicaments Download PDFInfo
- Publication number
- AU2003254557B2 AU2003254557B2 AU2003254557A AU2003254557A AU2003254557B2 AU 2003254557 B2 AU2003254557 B2 AU 2003254557B2 AU 2003254557 A AU2003254557 A AU 2003254557A AU 2003254557 A AU2003254557 A AU 2003254557A AU 2003254557 B2 AU2003254557 B2 AU 2003254557B2
- Authority
- AU
- Australia
- Prior art keywords
- methylene
- alkyl
- phenyl
- indolinone
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Description
81674pct.211 Indolinone derivatives substituted in position 6, production and use thereof as medicaments 5 The present invention relates to indolinone derivatives, substituted in the 6-position, of the formula R4 R3 N I x N R2N 0 (1), to their tautomers, enantiomers, diastereomers, their mixtures and their salts, in particular their physiologically acceptable salts, which have useful pharmacological properties, to medicaments comprising these compounds, to their use and to 5 processes for their preparation. The above compounds of the formula I have useful pharmacological properties, in particular an inhibiting effect on various kinases, especially on receptor tyrosine kinases, such as VEGFR1, VEGFR2, VEGFR3, PDGFRat, PDGFRP, FGFR1, o FGFR3, EGFR, HER2, c-Kit, IGF R and HGFR, Flt-3, and on the proliferation of cultivated human cells, in particular that of endothelial cells, for example in angiogenesis, but also on the proliferation of other cells, in particular tumour cells. Accordingly, the present invention provides the above compounds of the formula 1, 5 which have useful pharmacological properties, medicaments comprising these pharmacologically active compounds, their use and processes for their preparation.
2 Moreover, the present invention provides the physiologically acceptable salts of the compounds according to the invention, medicaments comprising these compounds which in addition, if appropriate, contain one or more inert carrier materials and/or diluents, and their use for preparing a medicament suitable in particular for treating 5 excessive or anormal cell proliferations. The present invention furthermore provides processes for preparing this medicament, characterized in particular in that the compounds according to the invention or their physiologically acceptable salts are incorporated into one or more inert carrier 0 materials and/or diluents. 1. In the above formula 1, X is an oxygen atom, 5 R1 is a hydrogen atom,
R
2 is a fluorine, chlorine or bromine atom or a cyano group, o R 3 is a phenyl group or a phenyl group which is monosubstituted by a fluorine, chlorine, bromine or iodine atom or by a C 1
-
3 -alkoxy group, where the abovementioned unsubstituted and the monosubstituted phenyl groups may additionally be substituted in the 3- or 4-position 5 by a fluorine, chlorine or bromine atom, by a cyano group, by a C 1
-
3 -alkoxy or C1- 2 -alkyl-carbonyl-amino group, 0 by a cyano-C 1
-
3 -alkyl, carboxy-C 1
-
3 -alkyl, carboxy-ClA-alkoxy, carboxy
C
1
-
3 -alkylamino, carboxy-C1-3-alkyl-N-(C 1
-
3 -alkyl)-amino, C 1 4-alkoxy carbonyl-C 1
-
3 -alkyl, C1-4-alkoxy-carbonyl-Cl- 3 -alkoxy, C 1 -4-alkoxy- 3 carbonyl-C 1
-
3 -alkylamino, C1-4-alkoxy-carbonyl-Cl- 3 -alkyl-N-(C- 3 -alkyl) amino, amino-C1- 3 -alkyl, aminocarbonyl-C 1
-
3 -alkyl, (C 1
-
2 -alkylamino) carbonyl-C.
3 -alkyl, di-(CI- 2 -alkyl)-aminocarbonyl-C 1
-
3 -alkyl, (C1- 2 -alkyl carbonyl)-amino-C 1
-
3 -alkyl, (C,4-alkoxy-carbonyl)-amino-C.
3 -alkyl, (C 3 . 5 6 -alkyl-carbonyl)-amino-C 1
-
3 -alkyl, (phenyl-carbonyl)-amino-C 1
-
3 -alkyl, (C3- 6 -cycloalkyl-carbonyl)-amino-C 1
-
3 -alkyl, (C 3
-
6 -cycloalkyl-C1- 3 -alkyl carbonyl)-amino-C1- 3 -alkyl, (thiophen-2-yl-carbonyl)-amino-C1- 3 -alkyl, (furan-2-yl-carbonyl)-amino-C1- 3 -alkyl, (phenyl-C1- 3 -alkyl-carbonyl) amino-C 1
-
3 -alkyl, (2-(Cl-4-alkoxy)-benzoyl-carbonyl)-amino-C1- 3 -alkyl, o (pyridin-2-yl-carbonyl)-amino-C1- 3 -alkyl, (pyridin-3-yl-carbonyl)-amino
C
1
-
3 -alkyl-, (pyridin-4-yl-carbonyl)-amino-C 1
-
3 -alkyl- or C1- 3 -alkyl piperazin-1 -yl-carbonyl-C 1
.
3 -alkyl group, by a carboxy-C 2
-
3 -alkenyl, aminocarbonyl-C 2
-
3 -alkenyl, (C1- 3 -alkyl 5 amino)-carbonyl-C 2
-
3 -alkenyl, di-(C1- 3 -alkyl)-amino-carbonyl-C 2
-
3 -alkenyl or C1.4-alkoxy-carbonyl-C 2
-
3 -alkenyl group, where the substituents may be identical or different, o R 4 is a phenyl group or a phenyl group which is monosubstituted by a C1- 3 -alkyl group which is terminally substituted by an amino, guanidino, mono- or di-(C1- 2 -alkyl)-amino-, N-[o-di-(C1- 3 -alkyl)-amino-C 2 3-alkyl]-N-(C1-3-alkyl)-amino, N-methyl-(C3.4-alkyl)-amino, N-(C1-3 5 alkyl)-N-benzylamino, N-(C14-alkoxycarbonyl)-amino, N-(C 1 4 alkoxycarbonyl)-C.
4 -alkylamino, 4-(C1- 3 -alkyl)-piperazin-1-yl, imidazol 1 -yl, pyrrolidin-1 -yl, azetidin-1 -yl, morpholin-4-yl, piperazin-1 -yl, thiomorpholin-4-yl group, o by a di-(C1- 3 -alkyl)-amino-(C1- 3 -alkyl)-sulphonyl, 2-[di-(C1.
3 -alkyl)-amino] ethoxy, 4-(C1- 3 -alkyl)-piperazin-1 -yl-carbonyl, {o-[di-(C1- 3 -alkyl)-amino]
(C
2
-
3 -alkyl)}-N-(C1- 3 -alkyl)-amino-carbonyl, 1 -(C1- 3 -alkyl)imidazol-2-yl,
(CI-
3 -alkyl)-sulphonyl group, or 4 by a group of the formula /R8 -N \R7 in which 5
R
7 is a C1- 2 -alkyl, C 1
-
2 -alkyl-carbonyl, di-(C1- 2 -alkyl)-amino carbonyl-C 1
-
3 -alkyl or C1- 3 -alkylsulphonyl group and
R
8 is C1- 3 -alkyl, o-[di-(C1- 2 -alkyl)-amino]-C 2
-
3 -alkyl, Co-[mono-(C1-2 o alkyl)-amino]-C 2
-
3 -alkyl group, or a (C 1
-
3 -alkyl)-carbonyl, (C 4 .- alkyl)-carbonyl or carbonyl-(C 1
-
3 alkyl) group which is terminally substituted by a di-(C 1
-
2 -alkyl) amino, piperazin-1 -yl or 4-(CI- 3 -alkyl)-piperazin-1 -yl group, 5 where all dialkylamino groups present in the radical R 4 may also be present in quaternized form, for example as an N-methyl-(N,N-dialkyl)-ammonium group, where the counterion is preferably selected from the group consisting of 0 iodide, chloride, bromide, methylsulphonate, para-toluenesulphonate and trifluoroacetate,
R
5 is a hydrogen atom and 5 R 6 is a hydrogen atom, where the abovementioned alkyl groups include linear and branched alkyl groups in which additionally one to 3 hydrogen atoms may be replaced by fluorine atoms, where additionally a carboxyl, amino or imino group present may be substituted by an in vivo cleavable radical or may be present in the form of a prodrug radical, for example in the form of a group which can be converted in vivo into a carboxyl group or in the form of a group which can be converted in vivo into an imino or 5 amino group, their tautomers, enantiomers, diastereomers, their mixtures and their salts. In one aspect, the present invention provides compounds of general 10 formula R3 / N R6 / R5 N R2N R1 (I), in which X is an oxygen atom, 15 R is a hydrogen atom,
R
2 is a fluorine, chlorine or bromine atom or a cyano group,
R
3 is a phenyl group which is substituted 20 by a C1 2 -alkyl-carbonyl-amino group, by a carboxy-C 1
.
3 -alkyl, carboxy-Ci4-alkoxy, C1.
4 -alkoxy-carbonyl-C, 3 -alkyl, C1- 4 -alkoxy-carbonyl-C1.3-alkoxy, aminocarbonyl-C 1
.
3 -alkyl, C 1
-
2 -alkylamino) 25 carbonyl-C1-3-alkyl, di-(C 1 -2-alkyl)-aminocarbonyl-C.3-alkyl, (C1- 2 -alkyl- C &Inbl\DCAWVUb4 4 _- 'OC)-5inD LO -5A carbonyl)-amino-CIs-alkyl, (Ci 4 -alkoxy-carbonyl)-amino-Csralkyl, (phenyl carbonyl)-amino-C3-alkyl, (C 3
-
0 -cycloalkyl-carbonyl)-amino-Cs.
3 -alkyl, (Car cycloalkyl-Cr.
3 -alkyl-carbonyl)-amino-Ci s-alkyl, (thiophen-2-yl-carbonyl) amino-C 1 3 -alkyl, (furan-2-yl-oarbonyl)-amino-C-ralkyl, (phenyl-C.
3 -alkyl 5 carbonyl)-amino-Ciralkyl, 2-(C 4 -alkoxy)-benzoy-carbonyl)-amino-C-r alkyl, (pyridin-2-yl-carbonyl)-amino-Cl-3alkyl, (pyridin-3-yl-carbonyl)-amino
C
3 -alkyl, (pyridin-4-yl-carbonyl)-amino-C 3 -alkyl or C 3 -alkyl-piperazin-1 yI-carbonyl-CIs-alkyl group, 10 by an aminocarbonyl-C2-ralkenyl, (CI-3ralkylamino)-carbonyl-C 23 -alkenyl, di-(C1.
3 -alkyl)-amino-carbonyl-C 2
-
3 -aIkeny or C 1 4 -alkoxy-carbonyl-C2-r alkenyl group,
R
4 is a phenyl group or a phenyl group which is monosubstituted 15 by a C-ralkyl group which is terminally substituted by an amino, guanidino, mono- or di-(Cl 2 -alkyl)-amino-N-[o-di-(Ci-3alkyl)-amino-C 2 _ralkyl]-N-(C-s alkyl)-amino, N-methyl-(C 34 -alkyl)-amino, N-(C-3alkyl)-N-benzylamino, N
(C-
4 -alkoxycarbonyl)-amino, N-(C .
4 -alkoxycarbonyl)-Ci 4 -alkylamino, 20 4-(C-alkyl)-piperazin-1-yl, imidazol-1-yl, pyrrolidin-1-yl, azetidin-1-yl, morpholin-4-yl, piperazin-1-yl, thiomorpholin-4-yl group, by a di-(Cr.
3 -alkyl)-amino-(C 3 -alkyl)-sulphonyl, 2-[di-(C, 3 -alkyl)-amino] ethoxy, 4-(Cv-3alkyl)-piperazin-1-yl-carbonyl, {u-[di-(C 1 3 -alkyl)-amino]-(C 2
.
3
-
- 5B alkyl)}-N-(C 2 3-alkyl)-amino-carbonyl, 1-(0.
3 -alkyl)imidazol-2-yl, (C, 3 -alkyl) sulphonyl group, or by a group of the formula R8 R7 in which R is a C1.
2 -alkyi, C 1
-
2 -alkyl-carbonyl, di-(Cwralkyl)-amino-carbonyl-Cw-3 alkyl or Cw.-alkylsulphonyl group and Re is Ci-ralkyl, m-[di-(Gi.-alkyl)-amino]-C2-alkyl, ao-[mono-(C2-alkyl) amino]-C%3-alkyI group, or a (C 3 -alkyl)-carbonyl, (C,-alkyl)-carbonyl or carbonyl-(Ci.s-alkyl) group which is terminally substituted by a di(Cwzalkyl)-amino, piperazin-1-yl or 4-(C 1
.
3 -alkyl)-piperazin-1 -yl group, where all dialkylamino groups present in the radical R 4 may also be present in quaternized form, for example as an N-methyl-(NN-dialkyl)-amrmonum group, where the counterion is preferably selected from the group consisting of iodide, chloride, bromide, methylsulphonate, para-toluenesulphonate and trifluoroacetate, RS is a hydrogen atom and R5 is a hydrogen atom, where the abovementioned alkyl groups include linear and branched alkyl groups in which additionally one to 3 hydrogen atoms may be replaced by fluorine atoms, CvMkonbrnDCCmWMT 044Y4_ 1,00 60 I - C where additionally a carboxyl, amino or imino group present may be substituted by an in vivo cleavable radical or may be present in the form of a group which can be converted in vivo into a carboxyl group or in the form of a group which can be converted in vivo into an imino or amino group, 5 and its tautomers, enantiomers, diastereomers, mixtures thereof and salts thereof. II. Particularly preferred compounds of the above formula I are those compounds in which X, R 1 , R5 and R are as defined under I. and: 11J. R 2 and R 4 are as defined under 1. and R3 is a phenyl group or a phenyl group which Is monosubstituted by a fluorine, chlorine, bromine or iodine atom or by a C 1 alkoxy group, where the abovernentioned unsubstituted and the monosubstituted phenyl groups may additionally.be substituted in the 3- or 4-position by a fluorine, .chlorine or bromine atom,. by a cyano group, S.y a CI.3-alkoxy or C 1
.
2 -alkyl-carbonyl-arilno group, by a cyano-Cw.3-alkylcarboxy-Cl.
3 -alky, carboxy-Ci-w-alkoxy, carboxy Cw. 5alkylamino, carboxy-C1.-alky-N-(Cws-alkyl)-amino,
C
4 -alkoxy carbony-C-alkyl, Ci-alkoxy-carbonyl-Ci.3-alkoxy, C-alkoxy carbonyl-C 3 -alkylamino, Cl 4 -alkoxy-carbonyl-Cl.a-alkyl-N-(Cw-s-alkyl) amino, amino-CIw-alkyl, aminocarbonyl-C.aalkyl, (02-alkylamino) carbonyl-Ci3alky, di-(Ci 2 -alkyl)-aminocarbonyl-C.3alkyl, '(C.ralkyl carbonyl)-amino-C1-a-alkyl (0 4 -alkoxy-carbonyl)-amirio-C1.3-alky 1 , (C3. 6 -alkyl-carbonyl)-amino-C.ralkyl., (phenyl-carbonyl)-amino-C.
3 -alkyl, 6
(C
3 .- cycloalkyl-carbonyl)-amino-C 1
..
3 -alkyl, (C 3
-
6 -cycloalkyl-C1..
3 -alkyl carbonyl)-amino-C1- 3 -alkyl, (phenyl-carbonyl)-amino-C1- 3 -alkyl, (thiophen-2-y-carbonyl)-amino-C 1
-
3 -alkyl, (furan-2-yl-carbonyl)-amino
C
1
-
3 -alkyl, (phenyl-C 1
.
3 -alkyl-carbonyl)-amino-C 1
-
3 -alkyl, ( 2 -(C14 5 alkoxy)-benzoyl-carbonyl)-amino-C 1- 3 -alkyl, (pyridin-2-y-carbonyl) amino-C 1
-
3 -alkyl, (pyridin-3-yl-carbonyl)-amino-C 1
..
3 -alkyl, (pyridin-4-yl carbonyl)-amino-C1- 3 -alkyl or C1-3-alkyl-piperazin-1 -yl-carbonyl-C1- 3 -alkyl group, o by a carboxy-C 2
-
3 -alkenyl, aminocarbonyl-C 2
-
3 -alkenyl-, (C 1
-
3 -alkyl amino)-carbonyl-C 2
-
3 -alkenyl-, di-(C1- 3 -alkyl)-amino-carbonyl-C 2
-
3 alkenyl or C 1 .4-alkoxy-carbonyl-C 2
-
3 -alkeny group, where the substituents may be identical or different; 5 Il.ii. R 2 and R 4 are as defined under 1. and
R
3 is a phenyl group which is substituted 0 by a C- 2 -alkyl-carbonyl-amino group, by a carboxy-C 1
-
3 -alkyl, carboxy-C 14 -alkoxy, C14-alkoxy-carbonyl-C1-3 alkyl, C1.4-alkoxy-carbonyl-Cl- 3 -alkoxy, aminocarbonyl-C 1
-
3 -alkyl, (C1-2 5 alkylamino)-carbonyl-C..
3 -alkyl, di-(C 1
-
2 -alkyl)-aminocarbonyl-C 1
-
3 -alkyl,
(C
1
-
2 -alkyl-carbonyl)-amino-C1- 3 -alkyl, (C 1 .- alkoxy-carbonyl)-amino-C 1
-
3 alkyl, (phenyl-carbonyl)-amino-C1- 3 -alkyl, (C3-6-cycIoaIkyl-carbonyl) amino-C 1
-
3 -alkyl, (C 3 .- cycloalkyl-C 1
..
3 -alkyl-carbonyl)-amino-C 1
-
3 -alkyl, (thiophen-2-yl-carbonyl)-amino-C1- 3 -alkyl, (furan-2-yl-carbonyl)-amino 0 C1- 3 -alkyl, (phenyl-C 1
-
3 -alkyl-carbonyl)-amino-C 1
-
3 -alkyl, ( 2 -(C.4 alkoxy)-benzoyl-carbonyl)-amino-C 1
-
3 -alkyl, (pyridin-2-yl-carbonyl) amino-C1- 3 -alkyl, (pyridin-3-yl-carbonyl)-amino-C 1
-
3 -alkyl, (pyridin-4-yl- 7 carbonyl)-amino-C1- 3 -alkyl or C 1
-
3 -alkyl-piperazin-1 -yl-carbonyl-C1- 3 -alkyl group, by an aminocarbonyl-C 2
-
3 -alkenyl, (C1- 3 -alkylamino)-carbonyl-C2- 3 5 alkenyl, di-(C1- 3 -alkyl)-amino-carbonyl-C2- 3 -alkenyl or C 1 4-alkoxy carbonyl-C 2
-
3 -alkenyl group; ll.iii. R 2 and R 4 are as defined under 1. and 0
R
3 is a phenyl group substituted by a carboxy-C 1
-
3 -alkyl or C1 4 -alkoxy carbonyl-C1- 3 -alkyl group; 5 ll.iv. R 3 and R 4 are as defined under 1. and
R
2 is a fluorine or chlorine atom; o ll.v. R 2 and R 3 are as defined under 1. and
R
4 is a phenyl group or a phenyl group which is monosubstituted by a C1- 3 -alkyl group which is terminally substituted by an amino, 5 guanidino, mono- or di-(C 1
-
2 -alkyl)-amino-, N-[o-di-(C1- 3 -alkyl)-amino-C2 3-alkyl]-N-(C1-3-alkyl)-amino, N-methyl-(C3-4-alkyl)-amino, N-(C1-3 alkyl)-N-benzylamino, N-(C 1 .4-alkoxycarbonyl)-amino, N-(C14 alkoxycarbonyl)-C 1
.
4 -alkylamino, 4-(C1- 3 -alkyl)-piperazin-1-yl, imidazol 1 -yl, pyrrolidin-1 -yl, azetidin-1 -yl, morpholin-4-yl, piperazin-1 -yl, 0 thiomorpholin-4-yl group, by a di-(C1- 3 -alkyl)-amino-(C 1
-
3 -alkyl)-sulphonyl, 2-[di-(C1- 3 -alkyl)-amino] ethoxy, 4-(C1- 3 -alkyl)-piperazin-1-yl-carbonyl, {co-[di-(C1-3-alkyl)-amino]- 8
(C
2
-
3 -alkyl)}-N-(C 1
-
3 -alkyl)-amino-carbonyl, 1-(C1- 3 -alkyl)imidazol-2-yl, (C1- 3 -alkyl)-sulphonyl group, or by a group of the formula SR8 -N 5 R7 in which
R
7 is a C1- 2 -alkyl, C1..
2 -alkyl-carbonyl, di-(C 1
-
2 -alkyl)-amino carbonyl-C 1
-
3 -alkyl or C 1
-
3 -alkylsulphonyl group and 0
R
8 is C 1
-
3 -alkyl, o-[di-(C 1
-
2 -alkyl)-amino]-C 2
-
3 -alkyl, o-[mono-(C1- 2 alkyl)-amino]-C 2
-
3 -alkyl group, or a (C 1
-
3 -alkyl)-carbonyl, (C 4
-
6 -alkyl)-carbonyl or carbonyl-(C.
3 5 alkyl) group which is terminally substituted by a di-(C 1
-
2 -alkyl) amino, piperazin-1 -yl or 4-(C1.
3 -alkyl)-piperazin-1 -yl group, where all dialkylamino groups present in the radical R 4 may also be present in quatemized form, for example as an N-methyl 0 (N,N-dialkyl)-ammonium group, where the counterion is preferably selected from the group consisting of iodide, chloride, bromide, methylsulphonate, para-toluenesulphonate and trifluoroacetate. 5 Ill. Subgroups of particularly preferred compounds of the above formula I which are to be mentioned in particular are those in which: Ill.i. X, R 1 , R 2 , R 5 and R 6 are as defined under I., R 3 is as defined 0 under II.i. and R 4 is as defined under ll.v.; 9 Ill.ii. X, R', R 2 , R' and R are as defined under I., R 3 is as defined under lI.ii. and R 4 is as defined under II.v.; 5 Ill.iii. X, R', R 2 , R' and R 6 are as defined under I., R 3 is as defined under ll.iii. and R 4 is as defined under II.v.; Ill.iv. X, R 1 , R 5 and R 6 are as defined under I., R 2 is as defined under ll.iv., R 3 is as defined under ll.i., ll.ii. or ll.iii. and R 4 is as defined 0 under ll.v. A further preferred group of compounds of the above formula I are those in which 5 X is an oxygen atom, R' is a hydrogen atom, o R 2 is a fluorine, chlorine or bromine atom or a cyano group,
R
3 is a phenyl group or a phenyl group which is monosubstituted by a fluorine, chlorine, bromine or iodine atom or by a C1- 3 -alkoxy group, where the abovementioned unsubstituted and the monosubstituted phenyl groups may 5 additionally be substituted in the 3- or 4-position by a fluorine, chlorine or bromine atom, by a C1- 3 -alkoxy or C 1
-
2 -alkyl-carbonyl-amino group, 0 by a carboxy-C 1
-
3 -alkyl, aminocarbonyl-C1- 3 -alkyl, (C 1
-
2 -alkylamino)-carbonyl C1- 3 -alkyl, di-(C 1
-
2 -alkyl)-aminocarbonyl-C..
3 -alkyl, (C 1
..
2 -alkyl-carbonyl)-amino
C
1
-
3 -alkyl or (phenyl-carbonyl)-amino-C 1
-
3 -alky group, 10 where the substituents may be identical or different,
R
4 is a phenyl group which is substituted 5 by a C1- 3 -alkyl group terminally substituted by a di-(C1- 2 -alkyl)-amino group, or by a group of the formula /R8 -N \R7 0 in which
R
7 is a C1- 2 -alkyl, C1- 2 -alkyl-carbonyl, di-(CI- 2 -alkyl)-amino-carbonyl-C 1
-
3 alkyl or C1- 3 -alkylsulphonyl group and 5 R 8 is a CI- 3 -alkyl or o-[di-(C 1
-
2 -alkyl)-amino]-C 2
-
3 -alky group, or a C 1
-
3 -alkyl-carbonyl group terminally substituted by a di-(C1- 2 -alkyl) amino, piperazino or 4-(C1-3-alkyl)-piperazin-1-yl group, 0
R
5 is a hydrogen atom and
R
6 is a hydrogen atom, 5 where the abovementioned alkyl groups include linear and branched alkyl groups in which additionally one to 3 hydrogen atoms may be replaced by fluorine atoms, where additionally a carboxyl, amino or imino group present may be substituted by an in vivo cleavable radical, 0 11 their tautomers, enantiomers, diastereomers, their mixtures and their salts. The following compounds of the formula I are particularly preferred: 5 (a) 3-Z-[1-(4-dimethylaminomethylanilino)-1-(3-(2-carboxyethyl)phenyl)methylene]-6 chloro-2-indolinone (b) 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4-(2-carboxyethyl)phenyl)methylene]-6 fluoro-2-indolinone 0 (c) 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(2-carboxyethyl)phenyl)methylene]-6 fluoro-2-indolinone (d) 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N-methylamino)anilino)-1 -(4 5 (2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone (e) 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-methylsulphonylamino)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 0 (f) 3-Z-[1 -(4-(N-(3-dimethylaminopropyl)-N-acetylamino)aniino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone (g) 3-Z-[1 -(4-(1 -methylimidazol-2-yl)anilino)-1 -(4-(2-carboxyethyl)phenyl)methylene] 6-fluoro-2-indolinone 5 (h) 3-Z-[1 -(4-(N-(dimethylaminomethylcarbonyl)-N-methylamino)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone (i) 3-Z-[1 -(4-(N-(2-dimethylaminoethylcarbonyl)-N-methylamino)anilino)-1 -(4-(2 o carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone (j) 3-Z-[1 -(4-(pyrrolidin-1 -ylmethyl)anilino)-1 -(4-(2-carboxyethyl)phenyl)methylene]-6 fluoro-2-indolinone 5 (k) 3-Z-[1 -(4-(diethylaminomethyl)anilino)-1 -(4-(2-carboxyethyl)phenyl)methylene]-6 fluoro-2-indolinone (1) 3-Z-[1 -(4-(2-dimethylaminoethyl)anilino)-1 -(4-(2-carboxyethyl)phenyl)methylene]-6 chloro-2-indolinone 0 (m) 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4-(2-carboxyethyl)phenyl)methylene]-6 ch loro-2-indol i none (n) 3-Z-[1-(4-(pyrrolidin-1-ylmethyl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6 5 chloro-2-indolinone 12 (o) 3-Z-[1-(4-(pyrrolidin-1-ylmethyl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6 bromo-2-indolinone (p) 3-Z-[1 -(4-(dimethylaminomethyl)anilino)-1 -(4-(2-carboxyethyl)phenyl)methylene] 5 6-bromo-2-indolinone (q) 3-Z-[1 -(4-(diethylaminomethyl)anilino)-1 -(4-(2-carboxyethyl)-methylene]-6-bromo 2-indolinone 0 where additionally a carboxyl, amino or imino group present may be substituted by an in vivo cleavable radical or may be present in the form of a prodrug radical, for example in the form of a group which can be converted in vivo into a carboxyl group or in the form of a group which can be converted in vivo into an imino or amino group, 5 and their salts. A group which can be converted in vivo into a carboxyl group is to be understood as meaning, for example, a hydroxymethyl group, a carboxyl group which is esterified 0 with an alcohol in which the alcoholic moiety is preferably a C 1
.
6 -alkanol, a phenyl
C
1
-
3 -alkanol, a C3-9-cycloalkanol, where a C-8-cycloalkanol may additionally be substitituted by one or two C1- 3 -alkyl groups, a Cs..-cycloalkanol in which one methylene group in the 3- or 4-position is replaced by an oxygen atom or by an imino group optionally substituted by a C 1 -3-alkyl, phenyl-C 1
.
3 -alkyl, phenyl-C 1
-
3 -alkoxy 5 carbonyl or C1.
6 -alkyl-carbonyl group and in which the cycloalkanol moiety may additionally be substituted by one or two C1- 3 -alkyl groups, a C 4
.
7 -cycloalkenol, a C 3
.
5 alkenol, a phenyl-C 3
-
5 -alkenol, a C 3 -- alkynol or a phenyl-C 3 -s-alkynol, with the proviso that no bond to the oxygen atom originates from a carbon atom which carries a double or triple bond, a C3.-cycloalkyl-Cl- 3 -alkanol, a bicycloalkanol having a total of 0 8 to 10 carbon atoms which may additionally be substituted in the bicycloalkyl moiety by one or two C1.
3 -alkyl groups, a 1,3-dihydro-3-oxo-1 -isobenzofuranol or an alcohol of the formula Ra-CO-O-(RCRc)-OH, 5 13 in which Ra is a C1- 8 -alkyl, C5.7-cycloalkyl, phenyl or phenyl-C 1
-
3 -alkyl group, Rb is a hydrogen atom, a C1- 3 -alkyl, C 5
.
7 -cycloalkyl or phenyl group, and 5 R, is a hydrogen atom or a C1- 3 -alkyl group, and a radical cleavable in vivo from an imino or amino group is to be understood as meaning, for example, a hydroxyl group, an acyl group, such as the benzoyl or 0 pyridinoyl group, or a C1 6 -alkylcarbonyl group, such as the formyl, acetyl, propionyl, butanoyl, pentanoyl or hexanoyl group, an allyloxycarbonyl group, a C1.
16 -alkoxy carbonyl group, such as the methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert-butoxycarbonyl, pentoxycarbonyl, hexyloxycarbonyl, octyloxycarbonyl, nonyloxycarbonyl, decyloxycarbonyl, 5 undecyloxycarbonyl, dodecyloxycarbonyl or hexadecyloxycarbonyl group, a phenyl C1.
6 -alkoxy-carbonyl group, such as the benzyloxycarbonyl, phenylethoxycarbonyl or phenylpropoxycarbonyl group, a C 1
-
3 -alkylsulphonyl-C 1 .4-alkoxy-carbonyl, C 1
-
3 alkoxy-C2-4-alkoxy-C2-4-alkoxy-carbony or RaCO-0-(RbCRc)-O-CO- group, in which 0 Ra is a C1- 8 -alkyl, C 5 -7-cycloalkyl, phenyl or phenyl-C 1
-
3 -alkyl group, Rb is a hydrogen atom, a C 1
-
3 -alkyl, Cs.7-cycloalkyl or phenyl group and Re is a hydrogen atom, a C1- 3 -alkyl or RaCO-O-(RbCRe)-O- group, in which Ra 5 to R, are as defined above, and additionally, for an amino group, the phthalimido group, where the ester radicals mentioned above can also be used as a group which can be converted in vivo into a carboxyl group. 0 Preferred prodrug radicals for a carboxyl group are a C1.6-alkoxy-carbonyl group, such as the methoxycarbonyl, ethoxycarbonyl, n-propyloxycarbonyl, isopropyloxycarbonyl, n-butyloxycarbonyl, n-pentyloxycarbonyl, n-hexyloxycarbonyl 14 or cyclohexyloxycarbonyl group, or a phenyl-C1.
3 -alkoxy-carbonyl group, such as the benzyloxycarbonyl group, and, for an imino or amino group, a C 1 .- alkoxy-carbonyl group, such as the methoxy 5 carbonyl, ethoxycarbonyl, n-propyloxycarbonyl, isopropyloxycarbonyl, n-butyloxy carbonyl, n-pentyloxycarbonyl, n-hexyloxycarbonyl, cyclohexyloxycarbonyl, n-heptyloxycarbonyl, n-octyloxycarbonyl or n-nonyloxycarbonyl group, a phenyl-C 1
-
3 alkoxy-carbonyl group, such as the benzyloxycarbonyl group, a phenylcarbonyl group optionally substituted by a C 1 -3-alkyl group, such as the benzoyl or 4-ethyl-benzoyl 0 group, a pyridinoyl group, such as the nicotinoyl group, a C 1
-
3 -alkylsulphonyl-n-C 2
-
3 alkoxy-carbonyl or C1-3-alkoxy-C 2
-
3 -alkoxy-C1.
4 -alkoxy-carbony group, such as the 2 methylsulphonylethoxycarbonyl or 2-(2-ethoxy)-ethoxycarbonyl group. According to the invention, the novel compounds are obtained, for example, by the 5 following processes, which are known in principle from the literature: a. reaction of a compound of the formula zi
R
3 R6 X N R2 M R1' (V), 0 in which the radicals Z' and R 3 may, if appropriate, change their positions, X, R 2 , R 3 and R 6 are as defined at the outset, R' has the meanings mentioned at the outset for R 1 or is a protective group for the 5 nitrogen atom of the lactam group, where R 1 may also, if appropriate, represent a bond, formed via a spacer, to a solid phase, and Z' is a halogen atom, a hydroxyl, alkoxy or arylalkoxy group, for example a chlorine or bromine atom, a methoxy, ethoxy or benzyloxy group, 15 with an amine of the formula
R
4 s R 5 H (VI), 5 in which
R
4 and R 5 are defined as mentioned at the outset, and, if required, the product is subsequently cleaved from a protective group used for the nitrogen atom of the lactam group or from a solid phase. 0 Suitable protective groups for the nitrogen atom of the lactam group are, for example, an acetyl, benzoyl, ethoxycarbonyl, tert-butyloxycarbonyl or benzyloxycarbonyl group and suitable solid phases are a resin, such as a 4-(2',4'-dimethoxyphenylaminomethyl) 5 phenoxy resin, where the attachment is expediently via the amino group, or a p-benzyloxybenzyl alcohol resin, where the attachment is expediently via a spacer, such as a 2,5-dimethoxy-4-hydroxybenzyl derivative. The reaction is expediently carried out in a solvent, such as dimethylformamide, 0 toluene, acetonitrile, tetrahydrofuran, dimethyl sulphoxide, methylene chloride or a mixture thereof, if appropriate in the presence of an inert base, such as triethylamine, N-ethyldiisopropylamine or sodium bicarbonate, at temperatures between 20 and 175*C, where any protective groups used may be simultaneously removed owing to transamidation. 5 If, in a compound of the formula V, Z' is a halogen atom, the reaction is preferably carried out in the presence of an inert base at temperatures between 20 and 1200C. If, in a compound of the formula V, Z' is a hydroxyl, alkoxy or arylalkoxy group, the 0 reaction is preferably carried out at temperatures between 20 and 200*C.
16 The subsequent removal of a protective group used, which may be required, if appropriate, is expediently carried out either hydrolytically in an aqueous or alcoholic solvent, for example in methanol/water, ethanol/water, isopropanol/water, tetrahydrofuran/water, dioxane/water, dimethylformamide/water, methanol or ethanol, 5 in the presence of an alkali metal base, such as lithium hydroxide, sodium hydroxide or potassium hydroxide, at temperatures between 0 and I 00*C, preferably at temperatures between 10 and 500C, or, advantageously, by transamidation with an organic base, such as ammonia, 0 butylamine, dimethylamine or piperidine, in a solvent, such as methanol, ethanol, dimethylformamide and mixtures thereof, or in an excess of the amine used, at temperatures between 0 and 100*C, preferably at temperatures between 10 and 500C. 5 Cleavage from a solid phase employed is preferably carried out using trifluoroacetic acid and water at temperatures between 0 and 350C, preferably at room temperature. b. To prepare a compound of the formula I in which R 3 is a phenyl or naphthyl group substituted by a carboxy-C 2
-
3 -alkenyl, aminocarbonyl-C 2
-
3 -alkenyl, (C1- 3 -alkylamino) 0 carbonyl-C 2
-
3 -alkenyl, di-(C1.
3 -alkylamino)-carbonyl-C 2
-
3 -alkeny or C1- 4 -alkoxy carbonyl-C 2
-
3 -alkenyl group, reaction of a compound of the formula Z3 N R5 R6 X R N 5 R' (IX), in which 17
R
2 , R 4 , R', R 6 and X are as defined at the outset, R" has the meanings mentioned at the outset for R 1 or is a protective group for the nitrogen atom of the lactam group, where R 1 , may also, if appropriate, represent a bond, formed via a spacer, to a solid phase, and 5 Z 3 is a leaving group, for example a halogen atom or an alkyl- or arylsulphonyloxy group, such as a chlorine, bromine or iodine atom or a methylsulphonyloxy, ethylsulphonyloxy, p-toluenesulphonyloxy or trifluoromethanesulphonyloxy group, with an alkene of the formula 0 0
R
3 (X), in which
R
3 ' is an amino, (C1- 3 -alkylamino), di-(C1- 3 -alkylamino) or C1.
4 -alkoxy group and n is the number 0 or 1. 5 The reaction is expediently carried out with palladium catalysis, using, for example, palladium(ll) acetate, palladium(II) chloride, bis(triphenylphosphine)palladium(II) acetate, bis(triphenylphosphine)palladium(lI) chloride, palladium/carbon, bis-[1,2 0 bis(diphenylphosphino)ethane]palladium(0), dichloro-(1,2-bis(diphenylphosphino) ethane)palladium(II), tetrakistriphenylphosphinepalladium(0), tris(dibenzylidene acetone)dipalladium(0), 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium(ll) or tris(dibenzylideneacetone)dipalladium(0)/chloroform adduct, in the presence of a base, such as triethylamine, diisopropylethylamine, lithium carbonate, potassium 5 carbonate, sodium carbonate, caesium carbonate, and a ligand, such as triphenylphosphine, tri-ortho-tolylphosphine or tri-(tert-butyl)phosphine, in solvents such as acetonitrile, N-methylpyrrolidinone, dioxane or dimethylformamide and mixtures thereof.
18 The cleavage of a protective group used for the nitrogen atoms of the lactam group or from a solid phase, which may be required, if appropriate, is carried out as described above under process (a). 5 c. To prepare a compound of the formula I in which R 3 is a phenyl or naphthyl group substituted by a carboxy-C 1
-
3 -alkyl, C1.4-alkoxy-carbonyl-C.
3 -alkyl, aminocarbonyl-C 1
-
3 -alkyl,
(CI
3 -alkylamino)-carbonyl-C 1
.
3 -alky or di-(C1- 3 -alkyl)-aminocarbonyl-C 1
.
3 -alkyl 0 group, hydrogenation of a compound of the formula R3' 0
A
N R5 RS X N R R1' (XI), 5 in which
R
2 , R 4 , R', R 6 and X are as defined at the outset, R' has the meanings mentioned at the outset for R 1 or is a protective group for the nitrogen atom of the lactam group, where R may also, if appropriate, represent a bond, formed via a spacer, to a solid phase, O A is a C 2
-
3 -alkenyl group and
R
3 is a hydroxyl, C1.4-alkoxy, amino, (C1- 3 -alkylamino) or di-(CI- 3 -alkyl)amino group. The hydrogenation is preferably carried out using catalytic hydrogenation with 5 hydrogen in the presence of a catalyst, such as palladium/carbon or platinum, in a 19 solvent, such as methanol, ethanol, ethyl acetate, dimethylformamide, dimethylformamide/acetone or glacial acetic acid, if appropriate with addition of an acid, such as hydrochloric acid, at temperatures between 0 and 500C, but preferably at room temperature, and at a hydrogen pressure of 1 to 7 bar, but preferably 3 to 5 5 bar. The cleavage of a protective group used for the nitrogen atom of the lactam group or from a solid phase, which may be required, if appropriate, is carried out as described under process (a). 0 If, according to the invention, a compound of the formula I is obtained which contains an alkoxycarbonyl group, this can be converted by hydrolysis into a corresponding carboxyl compound, or 5 if a compound of the formula I is obtained which contains an amino or alkylamino group, this can be converted by reduction alkylation into a corresponding alkylamino or dialkylamino compound, or if a compound of the formula I is obtained which contains a dialkylamino group, this 0 can be converted by alkylation into a corresponding trialkylammonium compound, or if a compound of the formula I is obtained which contains an amino or alkylamino group, this can be converted by acylation or sulphonation into a corresponding acyl or sulphonyl compound, respectively, or 5 if a compound of the formula I is obtained which contains a carboxyl group, this can be converted by esterification or amidation into a corresponding ester or aminocarbonyl compound, respectively, or 0 if a compound of the formula I is obtained which contains a nitro group, this can be converted by reduction into a corresponding amino compound, or 20 if a compound of the formula I is obtained which contains a cyano group, this can be converted by reduction into a corresponding aminomethyl compound, or if a compound of the formula I is obtained which contains an arylalkyloxy group, this 5 can be converted with acid into a corresponding hydroxyl compound, or if a compound of the formula I is obtained which contains an alkoxycarbonyl group, this can be converted by hydrolysis into a corresponding carboxyl compound, or 0 if a compound of the formula I is obtained in which R 4 is a phenyl group substituted by an amino, alkylamino, aminoalkyl or N-alkylamino group, this can then be converted by reaction with a corresponding cyanate, isocyanate or carbamoyl halide into a corresponding urea compound of the formula 1, or 5 if a compound of the formula I is obtained in which R 4 is a phenyl group substituted by an amino, alkylamino, aminoalkyl or N-alkylamino group, this can subsequently be converted by reaction with a corresponding amidino-group-transferring compound or by reaction with a corresponding nitrile into a corresponding guanidino compound of the formula 1. 0 The subsequent hydrolysis is preferably carried out in an aqueous solvent, for example in water, methanol/water, ethanol/water, isopropanol/water, tetrahydrofuran/water or dioxane/water, in the presence of an acid, such as trifluoroacetic acid, hydrochloric acid or sulphuric acid, or in the presence of an alkali 5 metal base, such as lithium hydroxide, sodium hydroxide or potassium hydroxide, at temperatures between 0 and 100*C, preferably at temperatures between 10 and 500C. The subsequent reductive alkylation is preferably carried out in a suitable solvent, 0 such as methanol, methanol/water, methanol/water/ammonia, ethanol, ether, tetrahydrofuran, dioxane or dimethylformamide, if appropriate with addition of an acid, such as hydrochloric acid, in the presence of catalytically activated hydrogen, for example of hydrogen in the presence of Raney nickel, platinum or 21 palladium/carbon, or in the presence of a metal hydride, such as sodium borohydride, lithium borohydride, sodium cyanoborohydride or lithium aluminium hydride, at temperatures between 0 and 1 00*C, preferably at temperatures between 20 and 800C. 5 The subsequent alkylation is preferably carried out in a suitable solvent, such as ether, tetrahydrofuran, dioxane, dichloromethane, acetone or acetonitrile, in the presence of alkylating agents, such as alkyl iodides, alkyl bromides, alkyl chlorides, methanesulphonic acid alkyl esters, para-toluenesulphonic acid alkyl esters or alkyl 0 trifluoroacetates, at temperatures between 0 and 100*C, preferably at temperatures between 20 and 600C. The subsequent acylation or sulphonylation is expediently carried out using the corresponding free acid or a corresponding reactive compound, such as its 5 anhydride, ester, imidazolide or halide, preferably in a solvent, such as methylene chloride, diethyl ether, tetrahydrofuran, toluene, dioxane, acetonitrile, dimethyl sulphoxide or dimethylformamide, if appropriate in the presence of an inorganic or a tertiary organic base, at temperatures between -20 and 2000C, preferably at temperatures between 200C and the boiling point of the solvent used. The reaction 0 with the free acid can, if appropriate, be carried out in the presence of an agent which activates the acid or of a dehydrating agent, for example in the presence of isobutyl chloroformate, tetraethyl orthocarbonate, trimethyl orthoacetate, 2,2-dimethoxypropane, tetramethoxysilane, thionyl chloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide, N,N'-dicyclohexylcarbodiimide, 5 N,N'-dicyclohexylcarbodiimide/N-hydroxysuccinimide, N,N'-dicyclohexyl carbodiimide/1 -hydroxybenzotriazole, 2-(1 H-benzotriazol-1 -yl)-1, 1,3,3 tetramethyluronium tetrafluoroborate, 2-(1 H-benzotriazol-1 -yl)-1, 1,3,3 tetramethyluronium tetrafluoroborate/1 -hydroxybenzotriazole, N,N'-carbonyldiimidazole or triphenylphosphine/carbon tetrachloride, and, if 0 appropriate, with addition of a base, such as pyridine, 4-dimethylaminopyridine, N-methylmorpholine or triethylamine, expediently at temperatures between 0 and 1500C, preferably at temperatures between 0 and 100*C. The reaction with a corresponding reactive compound can, if appropriate, be carried out in the presence 22 of a tertiary organic base, such as triethylamine, N-ethyl-diisopropylamine, N-methylmorpholine or pyridine, or, if an anhydride is used, in the presence of the corresponding acids, at temperatures between 0 and 1500C, preferably at temperatures between 50 and 1000C. 5 The subsequent esterification or amidation is expediently carried out by reacting a reactive corresponding carboxylic acid derivative with an appropriate alcohol or amine, as described above. 0 The esterification or amidation is preferably carried out in a solvent, such as methylene chloride, diethyl ether, tetrahydrofuran, toluene, dioxane, acetonitrile, dimethyl sulphoxide or dimethylformamide, if appropriate in the presence of an inorganic or a tertiary organic base, preferably at temperatures between 200C and the boiling point of the solvent used. Here, the reaction with a corresponding acid is 5 preferably carried out in the presence of a dehydrating agent, for example in the presence of isobutyl chloroformate, tetraethyl orthocarbonate, trimethyl orthoacetate, 2,2-dimethoxypropane, tetramethoxysilane, thionyl chloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide, N,N'-dicyclohexylcarbodiimide, N,N'-dicyclohexylcarbodiimide/N-hydroxysuccinimide, N,N'-dicyclohexylcarbodi 0 imide/1 -hydroxybenzotriazole, 2-(1 H-benzotriazol-1 -yl)-1, 1,3,3-tetramethyluronium tetrafluoroborate, 2-(1 H-benzotriazol-1 -yl)-1, 1,3,3-tetramethyluronium tetrafluoroborate/1 -hydroxybenzotriazole, N, N'-carbonyldiimidazole or triphenyl phosphine/carbon tetrachloride, and, if appropriate, with addition of a base, such as pyridine, 4-dimethylaminopyridine, N-methylmorpholine or triethylamine, expediently 5 at temperatures between 0 and 1500C, preferably at temperatures between 0 and 100C, and the acylation with a corresponding reactive compound, such as its anhydride, ester, imidazolide or halide, is, if appropriate, carried out in the presence of a tertiary organic base, such triethylamine, N-ethyldiisopropylamine or N-methylmorpholine, at temperatures between 0 and 1500C, preferably at 0 temperatures between 50 and 100C. The subsequent reduction of a nitro group is preferably carried out hydrogenolytically, for example with hydrogen in the presence of a catalyst, such as 23 palladium/carbon or Raney nickel, in a solvent, such as methanol, ethanol, ethyl acetate, dimethylformamide, dimethylformamide/acetone or glacial acetic acid, if appropriate with addition of an acid, such as hydrochloric acid or glacial acetic acid, at temperatures between 0 and 50*C, but preferably at room temperature, and at a 5 hydrogen pressure of from 1 to 7 bar, but preferably from 3 to 5 bar. The subsequent hydrogenation of a cyano group is preferably carried out hydrogenolytically, for example using hydrogen in the presence of a catalyst, such as palladium/carbon or Raney nickel, in a solvent, such as methanol, ethanol, ethyl 0 acetate, methylene chloride, dimethylformamide, dimethylformamide/acetone or glacial acetic acid, if appropriate with addition of an acid, such as hydrochloric acid or glacial acetic acid, at temperatures between 0 and 500C, but preferably at room temperature, and at a hydrogen pressure of from 1 to 7 bar, but preferably of from 3 to 5 bar. 5 The subsequent preparation of a corresponding guanidino compound of the formula I is expediently carried out by reaction with an amidino-group-transferring compound, such as 3,5-dimethylpyrazole-1-carboxamidine, preferably in a solvent, such as dimethylformamide, and, if appropriate, in the presence of a tertiary organic base, 0 such as triethylamine, at temperatures between 0 and 50*C, preferably at room temperature. In the reactions described above, any reactive groups present, such as carboxyl, hydroxyl, amino, alkylamino or imino groups, can be protected during the reaction by 5 customary protective groups which are removed again after the reaction. A protective radical for a carboxyl group is, for example, the trimethylsilyl, methyl, ethyl, tert-butyl, benzyl or tetrahydropyranyl group, and 0 a protective group for a hydroxyl, amino, alkylamino or imino group is, for example, the acetyl, trifluoroacetyl, benzoyl, ethoxycarbonyl, tert-butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group, and, for the amino group, additionally the phthalyl group.
24 The subsequent removal of a protective radical used is, if appropriate, carried out, for example, hydrolytically in an aqueous solvent, for example in water, isopropanol/water, tetrahydrofuran/water or dioxane/water, in the presence of an 5 acid, such as trifluoroacetic acid, hydrochloric acid or sulphuric acid, or in the presence of an alkali metal base, such as lithium hydroxide, sodium hydroxide or potassium hydroxide, at temperatures between 0 and 100 C, preferably at temperatures between 10 and 500C. 0 However, a benzyl, methoxybenzyl or benzyloxycarbonyl radical is removed, for example, hydrogenolytically, for example using hydrogen in the presence of a catalyst, such as palladium/carbon, in a solvent such as methanol, ethanol, ethyl acetate, dimethylformamide, dimethylformamide/acetone or glacial acetic acid, if appropriate with addition of an acid, such as hydrochloric acid or glacial acetic acid, 5 at temperatures between 0 and 500C, but preferably at room temperature, and at a hydrogen pressure of from 1 to 7 bar, but preferably of from 3 to 5 bar. A methoxybenzyl group can also be removed in the presence of an oxidizing agent, such as cerium(IV) ammonium nitrate, in a solvent, such as methylene chloride, 0 acetonitrile or acetonitrile/water, at temperatures between 0 and 500C, but preferably at room temperature. However, a 2,4-dimethoxybenzyl radical is preferably removed in trifluoroacetic acid in the presence of anisole. 5 A tert-butyl or tert-butyloxycarbonyl radical is preferably removed by treatment with an acid, such as trifluoroacetic acid or hydrochloric acid, using, if appropriate, a solvent, such as methylene chloride, dioxane, ethyl acetate or ether. 0 A phthalyl radical is preferably removed in the presence of hydrazine or a primary amine, such as methylamine, ethylamine or n-butylamine, in a solvent, such as methanol, ethanol, isopropanol, toluene/water or dioxane, at temperatures between 20 and 500C.
25 Furthermore, chiral compounds of the formula I obtained can be separated into their enantiomers and/or diastereomers. 5 Thus, for example, compounds of the formula I obtained which occur as racemates can be separated by methods known per se (see Allinger N. L. and Eliel E. L. in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) into their enantiomers, and compounds of the formula I having at least 2 asymmetric carbon atoms can, owing to their physicochemical differences, be separated by methods known per se, 0 for example by chromatography and/or fractional crystallization, into their diastereomers, which, if they are obtained in racemic form, can then be separated into the enantiomers as mentioned above. The separation of enantiomers is preferably carried out by column separation on 5 chiral phases or by recrystallization from an optically active solvent or by reaction with an optically active substance which forms salts or derivatives, such as, for example, esters or amides, with the racemic compound, in particular acids and their activated derivatives or alcohols, and separating the mixture of diastereomeric salts or derivatives obtained in this manner, for example owing to different solubilities, 0 whereupon the free enantiomers can be released from the pure diastereomeric salts or derivatives by action of suitable agents. Particularly common optically active acids are, for example, the D and L forms of tartaric acid, dibenzoyltartaric acid, di-o tolyltartaric acid, malic acid, mandelic acid, camphorsulphonic acid, glutamic acid, N-acetylglutamic acid, aspartic acid, N-acetylaspartic acid or quinic acid. A suitable 5 optically active alcohol is, for example, (+)- or (-)-menthol, and a suitable optically active acyl radical in amides is, for example, the (+)- or (-)-menthyloxycarbonyl radical. Furthermore, the compounds of the formula I obtained can be converted into their 0 salts, in particular, for pharmaceutical use, into their physiologically acceptable salts, with inorganic or organic acids. Acids suitable for this purpose are, for example, hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, maleic acid, methanesulphonic acid, 26 ethanesulphonic acid, para-toluenesulphonic acid, phenylsulphonic acid or L-(+) mandelic acid. Moreover, the resulting novel compounds of the formula I can, if they contain a 5 carboxyl group, then, if desired, be converted into their salts with inorganic or organic bases, in particular, for pharmaceutical use, into their physiologically acceptable salts. Bases suitable for this purpose are, for example, sodium hydroxide, potassium hydroxide, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine. 0 Also suitable, for compounds of the formula I which contain 2 or more acidic or basic groups, are salts with 2 or more inorganic or organic bases or acids (disalts etc.). Some of the compounds of the general formulae V to XI used as starting materials are known from the literature or can be obtained by processes known from the 5 literature or can be obtained by the processes described above and in the examples. Compounds of the general formula IX, for example, are described in the German patent application 198 44 003. As already mentioned at the outset, the novel compounds of the formula (1) have 0 useful pharmacological properties, in particular in inhibiting action on various kinases, especially on receptor tyrosine kinases, such as VEGFR1, VEGFR2, VEGFR3, PDGFRac, PDGFRp, FGFR1, FGFR3, EGFR, HER2, c-Kit, IGF1R and HGFR, Flt-3, and on the proliferation of cultivated human cells, in particular that of endothelial cells, for example in angiogenesis, but also on the proliferation of other cells, in 5 particular of tumour cells. The biological properties of the novel compounds were examined by the following standard methods: 0 Human umbilical cord endothelial cells (HUVEC) were cultivated in IMDM (Gibco BRL), supplemented with 10% foetal bovine serum (FBS) (Sigma), 50 pM B-mercaptoethanol (Fluka), standard antibiotics, 15 pg/ml of endothelial cell growth factor (ECGS, Collaborative Biomedical Products) and 100 pg/ml of heparin (Sigma) 27 on gelatin-coated culture bottles (0.2 % gelatin, Sigma) at 37*C, 5% CO2, in an atmosphere saturated with water. To examine the inhibitory activity of the compounds according to the invention, the 5 cells were "starved" for 16 hours, i.e. kept in culture medium without growth factors (ECGS + heparin). Using trypsin/EDTA, the cells were detached from the culture bottles and washed once with serum-containing medium. 2.5 x 103 cells were then seeded in each well. 0 The proliferation of the cells was stimulated using 5 ng/ml of VEGF1 65 (vascular endothelial growth factor; H. Weich, GBF Brunswick) and 10 pg/ml of heparin. Per plate, as control value, in each case 6 wells were not stimulated. The compounds according to the invention were dissolved in 100% dimethyl 5 sulphoxide and, in triplicate, added to the cultures in different dilutions, the maximum dimethyl sulphoxide concentration being 0.3%. The cells were incubated at 37 0 C for 76 hours, and 3 H-thymidine (0.1 p Ci/well, Amersham) was then added for a further 16 hours to determine DNA synthesis. The 0 radioactively labelled cells were then immobilized on filter mats and the incorporated radioactivity was determined in a 3 counter. To determine the inhibitory activity of the compounds according to the invention, the mean value for the non-stimulated cells was subtracted from the mean value of the factor-stimulated cells (in the presence or absence of the compounds according to the invention). 5 The relative cell proliferation was calculated in percent of the control (HUVEC without inhibitor), and the concentration of active compound at which the proliferation of the cells is inhibited by 50% (IC50) was derived therefrom. 0 The compounds of the formula I according to the invention have an ICso between 50 pM and 1 nM.
28 Owing to their inhibitory action on the proliferation of cells, in particular of endothelian cells and of tumour cells, the compounds of the formula I are suitable for treating diseases in which the proliferation of cells, in particular that of endothelial cells, plays a role. 5 Thus, for example, the proliferation of endothelial cells and the related neovascularization is a decisive step in tumour progression (Folkman J. et al., Nature 339, 58-61, (1989); Hanahan D. and Folkman J., Cell 86, 353-365, (1996)). Furthermore, the proliferation of endothelial cells is also of importance in 0 haemangiomes, in metastasization, in rheumatoid arthritis, in psoriasis and in ocular neovascularization (Folkman J., Nature Med. 1, 27-31, (1995); Carmeliet P & Rakeh J., Nature 407, 249-257, (2000)). The therapeutic benefit of inhibitors of endothelial cell proliferation in the animal model was shown, for example, by O'Reilly et al. and Parangi et al. (O'Reilly M.S. et al., Cell 88, 277-285, (1997); Parangi S. et al., Proc 5 Natl Acad Sci USA 93, 2002-2007, (1996)). Thus, the compounds of the formula 1, their tautomers, their stereoisomers or their physiologically acceptable salts are suitable, for example, for treating tumours (for example squamous epithelium carcinoma, astrocytoma, Kaposi sarcoma, 0 glioblastoma, lung cancer, cancer of the bladder, neck carcinoma, oesophagus carcinoma, melanoma, ovarial carcinoma, prostate carcinoma, breast cancer, small cell lung carcinoma, glioma, colorectal carcinoma, pancreas carcinoma, urogenital cancer and gastrointestinal carcinoma, and also haematological cancers, such as, for example, multiple myeloma and acute myelotic leukaemia), psoriasis, arthritis (for 5 example rheumatoid arthritis), haemangioma, angiofibroma, disorders of the eye (for example diabetic retinopathy), neovascular glaucoma, disorders of the kidneys (for example glomerulonephritis), diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndromes, transplantation rejections and glomerulopathy, fibrotic disorders (for example cirrhosis of the liver), mesangial-cell 0 proliferative disorders, atherosclerosis, injuries of the nerve tissue and for inhibiting the reocclusion of vessels after balloon catheter treatment, in vessel prosthetics or after implantation of mechanical devices for keeping vessels open (for example stents) or other disorders in which cell proliferation or angiogenesis play a role.
29 Owing to their biological properties, the compounds according to the invention can be used alone or in combination with other pharmacologically active compounds, for example in tumour therapy in monotherapy or in combination with other antitumor 5 therapeutics, for example in combination with topoisomerase inhibitors (for example etoposide), mitosis inhibitors (for example vinblastine, Taxol), compounds which interact with nucleic acids (for example cisplatin, cyclophosphamide, adriamycin), hormone antagonists (for example tamoxifen), steroids and analogues thereof (for example dexamethasone), inhibitors of metabolic processes (for example 5-FU etc.), 0 cytokines (for example interferons), kinase inhibitors (for example EGFR kinase inhibitoren, such as, for example, Iressa; Gleevec), allosterically acting receptor tyrosine kinase inhibitors, antibodies (for example Herceptin), COX-2 inhibitors or else in combination with radiotherapy, etc. These combinations can be administered either simultaneously or sequentially. 5 30 The invention is illustrated in more detail by the examples below: Example Name 1.0 3-Z-[1 -(4-(N-methyl-N-methylsulphonylamino)anilino)-1 -(3-iodophenyl) methylene]-6-chloro-2-indolinone 1.1 3-Z-[1 -(4-(dimethylaminomethyl)anilino)-1 -(3-iodophenyl)methylene]-6 chloro-2-indolinone 1.2 3-Z-[1 -(4-(N-(dimethylaminomethylcarbonyl)-N-methylamino)anilino)-1 (4-chlorophenyl)methylene]-6-chloro-2-indolinone 1.3 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-acetylamino)anilino)-1 -(4 chlorophenyl)methylene]-6-chloro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 1.4 methylamino)anilino)-1 -(4-chlorophenyl)methylene]-6-chloro-2 indolinone 1.5 3-Z-[1 -(4-(N-(3-dimethylaminopropyl)-N-acetylamino)anilino)-1 -(4 chlorophenyl)methylene]-6-chloro-2-indolinone 1.6 3-Z-[1 -(4-(dimethylaminomethyl)anilino)-1 -(4-chlorophenyl)methylene] 6-chloro-2-indolinone 1.7 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-acetylamino)anilino)-1 -(3,4 dimethoxyphenyl)methylene]-6-chloro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 1.8 methylamino)anilino)-1 -(3,4-dimethoxyphenyl)methylene]-6-chloro-2 indolinone 1.9 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-methylsulphonylamino)anilino) 1 -(3,4-dimethoxyphenyl)methylene]-6-chloro-2-indolinone 1.10 3-Z-[1 -(4-(dimethylaminomethyl)anilino)-1 -(3,4-dimethoxyphenyl) methylene]-6-chloro-2-indolinone 31 1.11 3-Z-[1 -(4-(N -(2-dimethylaminoethyl)-N-methylcarbamoyl)anilino)-1 -(3,4 dimethoxyphenyl)methylene]-6-chloro-2-indolinone 2.0 3-Z-[1 -(4-(dimethylaminomethyl)anilino)-1 -(4-cyanophenyl)-methylene] 6-chloro-2-indolin one 3.0 3-Z-[1 -(4-(dimethylaminomethyl)anilino)-1 -(4-iodophenyl)methylene]-6 fl uoro-2-i ndol i none 3.1 3-Z-[1 -(4-(dimethylaminomethyl)anilino)-1 -(3-fluorophenyl)methylene] 6-fluoro-2-indolinone 3.2 3-Z-[1 -(4-(N-(3-dimethylaminopropyl)-N-acetylamino)anilino)-1 -(3 fluorophenyl)methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 3.3 methylamino)anilino)-1 -(3-fluorophenyl)methylene]-6-fluoro-2 indolinone 3.4 3-Z-[1 -(4-(dimethylaminomethyl)anilino)-1 -(4-(2 acetylaminoethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.5 3-Z-[1 -(4-(N-(3-dimethylaminopropyl)-N-acetylamino)anilino)-1 -(4-(2 acetylaminoethyl)phenyl)methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 3.6 methylamino)anilino)-1 -(4-(2-acetylaminoethyl)phenyl)methylene]-6 fluoro-2-indolinone 3.7 3-Z-[1 -(4-(dimethylaminomethyl)anilino)-1 -(4 methoxycarbonylmethylphenyl)methylene]-6-fluoro-2-indolinone 3.8 3-Z-[1 -(4-(dimethylaminomethyl)anilino)-1 -(3-iodophenyl)methylene]-6 fl uoro-2-i ndol i none 3.9 3-Z-[1 -(4-(dimethylaminomethyl)anilino)-1 -(3 methoxycarbonylmethylphenyl)methylene]-6-fluoro-2-indolinone 3.10 3-Z-[1 -(4-(dimethylaminomethyl)anilino)-1 -(3-(N-tert-butoxycarbonyl aminomethyl)phenyl)methylene]-6-fluoro-2-indolinone 32 3.11 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-methylsulphonylamino)anilino) 1 -(4-methoxycarbonylmethylphenyl)methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 3.12 methylamino)anilino)-1 -(4-methoxycarbonylmethylphenyl)methylene]-6 fl uoro-2-i ndol i none 3.13 3-Z-[1 -(4-(dimethylaminomethyl)anilino)-1 -(3-cyanomethylphenyl) methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 3.14 methylamino)anilino)-1 -(4-(N-tert-butoxycarbonyl aminomethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.15 3-Z-[1 -(4-(dimethylaminomethyl)anilino)-1 -(4-(N-tert-butoxycarbonyl aminomethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.16 3-Z-[1 -(4-(dimethylaminomethyl)anilino)-1 -(3-(N-tert-butoxycarbonyl-2 aminoethyl)phenyl)methylenej-6-fluoro-2-indolinone 3.17 3-Z-[1 -(4-(N-Acetyl-N-methylamino)anilino)-1 -(4-(2 methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 3.18 methylamino)anilino)-1 -(4-(2-methoxycarbonylethyl)phenyl)methylene] 6-fluoro-2-indolinone 3.19 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-methylsulphonylamino)anilino) 1 -(4-methoxycarbonylmethylphenyl)methylene]-6-fluoro-2-indolinone 3.20 3-Z-[1 -(4-(N-(3-dimethylaminopropyl)-N-acetylamino)anilino)-1 -(4-(2 methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.21 3-Z-[1 -(4-(N-tert-butoxycarbonylmethylaminomethyl)anilino)-1 -(4-(2 methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.22 3-Z-[1 -(4-(4-methylpiperazin-1 -yl-carbonyl)anilino)-1 -(4-(2 methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 33 3.23 3-Z-[1 -(4-(1 -methylimidazol-2-yl)anilino)-1 -(4-(2 methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.24 3-Z-[1 -(4-methylsulphonylanilino)-1 -(4-(2 methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 3.25 methylamino)anilino)-1 -(3-methoxycarbonylmethylphenyl)methylene]-6 fluoro-2-indolinone 3.26 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-methylsulphonylamino)anilino) 1-(3-methoxycarbonylmethylphenyl)methylene]-6-fluoro-2-indolinone 3.27 3-Z-[1 -(4-(4-methylpiperazin-1 -yl-carbonyl)anilino)-1 -(3 methoxycarbonylmethylphenyl)methylene]-6-fluoro-2-indolinone 3.28 3-Z-[1 -(4-(N-(dimethylaminomethylcarbonyl)-N-methylamino)anilino)-1 (3-methoxycarbonylmethylphenyl)methylene]-6-fluoro-2-indolinone 3.29 3-Z-[1 -(4-(N-(3-dimethylaminopropyl)-N-acetylamino)anilino)-1 -(3 methoxycarbonylmethylphenyl)methylene]-6-fluoro-2-indolinone 3.30 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-acetylamino)anilino)-1 -(3 methoxycarbonylmethylphenyl)methylene]-6-fluoro-2-indolinone 3.31 3-Z-[1 -(4-(N-(4-dimethylamino-butylcarbonyl)-N-methylamino)anilino) 1 -(3-methoxycarbonylmethylphenyl)methylene]-6-fluoro-2-indolinone 3.32 3-Z-[1 -Anilino-1 -(4-methoxycarbonylmethylphenyl)methylene]-6-fluoro 2-indolinone 3.33 3-Z-[1 -(4-(1 -methylimidazol-2-yl)anilino)-1 -(4 methoxycarbonylmethylphenyl)methylene]-6-fluoro-2-indolinone 3.34 3-Z-[1 -(4-(4-methylpiperazin-1 -ylcarbonyl)anilino)-1 -(4 methoxycarbonylmethylphenyl)methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(dimethylaminocarbonylmethyl)-N 3.35 methylsulphonylamino)anilino)-1 -(4-methoxycarbonylmethylphenyl) methylene]-6-fluoro-2-indolinone 34 3.36 3-Z-[1 -(4-(N-(dimethylaminomethylcarbonyl)-N-methylamino)anilino)-1 (4-methoxycarbonylmethylphenyl)methylene]-6-fluoro-2-indolinone 3.37 3-Z-[1 -(4-(N-methyl-N-acetylamino)anilino)-1 -(4 methoxycarbonylmethylphenyl)methylene]-6-fluoro-2-indolinone 3.38 3-Z-[1 -(4-(N-(2-dimethylaminoethylcarbonyl)-N-methylamino)anilino)- 1 (4-methoxycarbonylmethylphenyl)methylene] -6-fluoro-2-indolinone 3.39 3-Z-[1 -(4-methylsulphonylanilino)-1 -(4 methoxycarbonylmethylphenyl)methylene]-6-fluoro-2-indolinone 3.40 3-Z-[1 -(4-(N-(3-dimethylaminopropylcarbonyl)-N-methylamino)anilino) 1 -(4-methoxycarbonylmethylphenyl)methylene]-6-fluoro-2-indolinone 3.41 3-Z-[1 -(4-(N-(3-dimethylaminopropyl)-N-acetylamino)anilino)-1 -(4 methoxycarbonylmethylphenyl)methylene]-6-fluoro-2-indolinone 3.42 3-Z-[1 -Anilino-1 -(3-methoxycarbonylmethylphenyl)methylene]-6-fluoro 2-indolinone 3.43 3-Z-[1 -(4-methylsulphonylanilino)-1 -(3-methoxycarbonylmethylphenyl) methylene]-6-fluoro-2-indolinone 3.44 3-Z-[1 -(4-(1 -methylimidazol-2-yl)anilino)-1 -(3 methoxycarbonylmethylphenyl)methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(dimethylaminocarbonylmethyl)-N 3.45 methylsulphonylamino)anilino)-1 -(3-methoxycarbonylmethylphenyl) methylene]-6-fluoro-2-indolinone 3.46 3-Z-[1 -(4-(N-(3-dimethylaminopropylcarbonyl)-N-methylamino)anilino) 1 -(3-methoxycarbonylmethylphenyl)methylene]-6-fluoro-2-indolinone 3.47 3-Z-[1 -(4-(N-(2-dimethylaminoethylcarbonyl)-N-methylamino)anilino)- 1 (3-methoxycarbonylmethylphenyl)methylene] -6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 3.48 methylamino)anilino)-1 -(3-(2-methoxycarbonylethyl)phenyl)methylene] 6-fluoro-2-indolinone 35 3.49 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-methylsulphonylamino)anilino) 1 -(3-(2-methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.50 3-Z-[1 -(4-(N-(dimethylaminomethylcarbonyl)-N-methylamino)anilino)-1 (3-(2-methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.51 3-Z-[1 -(4-(N-(3-dimethylaminopropyl)-N-acetylamino)anilino)-1 -(3-(2 methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 3.52 methylamino)anilino)-1 -(3-(N-tert-butoxycarbonyl aminomethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.53 3-Z-[1 -(4-(N-methyl-N-acetylamino)anilino)-1 -(3 acetylaminomethylphenyl)methylene]-6-chloro-2-indolinone 3.54 3-Z-[1 -(4-(N-(3-dimethylaminopropyl)-N-acetylamino)anilino)-1 -(3 acetylaminomethylphenyl)methylene]-6-chloro-2-indolinone 3.55 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-methylsulphonylamino)anilino) 1 -(3-acetylaminomethylphenyl)methylene]-6-chloro-2-indolinone 3.56 3-Z-[1 -(4-(N-(dimethylaminomethylcarbonyl)-N-methylamino)anilino)-1 (3-acetylaminomethylphenyl)methylene]-6-chloro-2-indolinone 3.57 3-Z-[1 -(4-(2-dimethylaminoethyl)anilino)-1 -(4-(2 methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.58 3-Z-[1 -(4-(N-(2-dimethylaminoethylcarbonyl)-N-methylamino)anilino)- 1 (4-(2-methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.59 3-Z-[1 -(4-(N-(dimethylaminomethylcarbonyl)-N-methylamino)anilino)- 1 (4-(2-methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.60 3-Z-[1 -(4-(2-dimethylaminoethyl)anilino)-1 -(3-(2 ethoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.61 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-acetylamino)anilino)-1 -(4-(2 methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 36 3.62 3-Z-[1 -(4-(N-(3-dimethylaminopropylcarbonyl)-N-methylamino)anilino) 1-(3-(2-ethoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.63 3-Z-[1 -(4-(N-(4-dimethylaminobutylcarbonyl)-N-methylamino)anilino)-1 (3-(2-ethoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.64 3-Z-[1 -(4-(1 -methylimidazol-2-yl)anilino)-1 -(3-(2 ethoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.65 3-Z-[1 -(4-(N-(4-dimethylaminobutylcarbonyl)-N-methylamino)anilino)-1 (4-(2-methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.66 3-Z-[1 anilino-1 -(4-(2-methoxycarbonylethyl)phenyl)methylene]-6-fluoro 2-indolinone 3.67 3-Z-[1 -(4-(pyrrolidin-1 -ylmethyl)anilino)-1 -(4-(2 methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.68 3-Z-[1 -(4-(diethylaminomethyl)anilino)-1 -(4-(2 methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.69 3-Z-[1 -(4-(N-tert-butoxycarbonylaminomethyl)anilino)-1 -(4-(2 methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.70 3-Z-[1 -(4-(2-dimethylaminoethyl)anilino)-1 -(3 methoxycarbonylmethylphenyl)methylene]-6-fluoro-2-indolinone 3.71 3-Z-[1 -(4-(2-dimethylaminoethyl)anilino)-1 -(4 methoxycarbonylmethylphenyl)methylene]-6-fluoro-2-indolinone 3.72 3-Z-[1 -(4-(dimethylaminomethyl)anilino)-1 -(3-(2 ethoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.73 3-Z-[1 -(4-(2-dimethylaminoethyl)anilino)-1 -(4-(2 methoxycarbonylethyl)phenyl)methylene]-6-chloro-2-indolinone 3.74 3-Z-[1 -(4-(1 -methylimidazol-2-yl)anilino)-l -(4-(2 ethoxycarbonylethyl)phenyl)methylene]-6-chloro-2-indolinone 3.75 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4-(2 methoxycarbonylethyl)phenyl)methylene]-6-chloro-2-indolinone 37 3.76 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4-(2 ethoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.77 3-Z-[1 -(4-((4-methylpiperazin-1 -yl)methyl)anilino)-1 -(3-(2 methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.78 3-Z-[1 -(4-(imidazol-1 -ylmethyl)anilino)-1 -(3-(2 methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.79 3-Z-[1 -(4-((4-methylpiperazin-1 -yl)methyl)anilino)-1 -(4-(2 methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.80 3-Z-[1 -(4-(imidazol-1 -ylmethyl)anilino)-1 -(4-(2 methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.81 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-methylaminomethyl)anilino)-1 (4-(2-methoxycarbonylethyl)phenyl)methylenel-6-fluoro-2-indolinone 3.82 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-methylaminomethyl)anilino)-1 (3-(2-ethoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.83 3-Z-[1 -(4-(pyrrolidin-1 -ylmethyl)anilino)-1 -(4-(2 methoxycarbonylethyl)phenyl)methylene]-6-chloro-2-indolinone 3.84 3-Z-[l anilino-1 -(3-(2-ethoxycarbonylethyl)phenyl)methylene]-6-fluoro-2 indolinone 3.85 3-Z-[1 -(4-(N-tert-butoxycarbonylaminomethyl)anilino)-1 -(3-(2 ethoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.86 3-Z-[1 -(4-(N-tert-butoxycarbonylmethylaminomethyl)anilino)-1 -(3-(2 ethoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 3.87 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-methoxycarbonylmethoxy phenyl)methylene]-6-fluoro-2-indolinone 3.88 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4-methoxycarbonylmethoxy phenyl)methylene]-6-fluoro-2-indolinone 3.89 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(2-ethoxycarbonyl ethoxy)phenyl)methylene]-6-fluoro-2-indolinone 38 3.90 3-Z-[1 -(4-(pyrrolidin -1 -ylmethyl)anilino)-1 -(4-(2 methoxycarbonylethyl)phenyl)methylene]-6-bromo-2-indolinone 3.91 3-Z-[1 -(4-(dimethylaminomethyl )anilino)-1 -(4-(2 methoxycarbonylethyl)phenyl)methylene] -6-bromo-2-i ndol none 3.92 3-Z-[1 -(4-(diethylaminomethyl )anilino)-1 -(4-(2 methoxycarbonylethyl)phenyl)methylene] -6-bromo-2-i ndoli none 3.93 3-Z-[1 -(3-dimethylaminomethylanilino)-1 -(4-(2 methoxycarbonylethyl)phenyl )methyl ene]-6-fl uoro-2-i ndol none 3.94 3-Z-[1 -(3-dimethylaminomethylanilino)-1 -(3-(2 ethoxycarbonylethyl)phenyl)methylene]-6-fl uoro-2-indoli none 3.95 3-Z-[1 -(3-dimethylaminomethylanilino)-1 -(4-(2 methoxycarbonylethyl)phenyl)methylene]-6-chloro-2-indolinone 4.0 3-Z-[I1 -(4-(dimethylaminomethyl)anilino)-1 -(3,4-dimethoxyphenyl) methylene]-6-cyano-2-indolinone 5.0 3-Z-[1 -(4-(N -methyl-N-methylsulphonylamino)anilino)-1 -(3-(2 meth oxyca rbon ylvi nyl)ph enyl)m ethyl en e]-6-chlIoro-2-i ndol in one 5.1 3-Z-[1 -(4-(dimethylaminomethyl )anilino)-1 -(4-(2-methoxycarbonyl vinyl)phenyl )methylene]-6-ch loro-2-indol none 5.2 3-Z-[1 -(4-(dimethylaminomethyl)anilino)-1 -(4-(2-carbamoyl vinyl)phenyl)methylene]-6-fluoro-2-indolinone 5.3 3-Z-[1 -(4-(dimethylaminomethyl )anilino)- I -(4-(2-methoxycarbonyl vinyl)phenyl)methylene]-6-fl uoro-2-indol none 5.4 3-Z-[1 -(4-(dimethylaminomethyl )anilino)-1 -(3-(2-methoxycarbonyl vinyl)phenyl)methylene]-6-fl uoro-2-indol none 6.0 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(2 methoxycarbonylethyi)ph enyl)methylene] -6-chloro-2-i ndol none 6.1 3-Z-[1 -(4-(N-methyl-N-methylsulphonylamino)anilino)-1 -(3-(2 methoxycarbonylethyl)phenyl)methylene] -6-chloro-2-i ndol none 39 6.2 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4-(2-carbamoyl ethyl)phenyl)methylene]-6-fluoro-2-indolinone 6.3 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4-(2 methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 6.4 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(2 methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 7.0 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4-aminomethylphenyl) methylene]-6-chloro-2-indolinone 3-Z-[1 -(4-(N-((4-methylpiperazin-1 -yl)methylcarbonyl)-N 8.0 methylamino)anilino)-1 -(4-aminomethylphenyl)methylene]-6-chloro-2 indolinone 9.0 3-Z-[1 -(4-(dimethylaminomethyl)anilino)-1 -(3-aminomethylphenyl) methylene]-6-fluoro-2-indolinone 9.1 3-Z-[1 -(4-(dimethylaminomethyl)anilino)-1 -(3-(2 aminoethyl)phenyl)methylene]-6-fluoro-2-indolinone 9.2 3-Z-[1 -(4-(dimethylaminomethyl)anilino)-1 -(4-aminomethylphenyl) methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 9.3 methylamino)anilino)-1 -(4-aminomethylphenyl)methylene]-6-fluoro-2 indolinone 9.4 3-Z-[1 -(4-(methylaminomethyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 9.5 3-Z-[1 -(4-(methylaminomethyl)anilino)-1 -(4-(2-methylcarbamoyl ethyl)phenyl)methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 9.6 methylamino)anilino)-1 -(3-aminomethylphenyl)methylene]-6-fluoro-2 indolinone 40 9.7 3-Z-[1 -(4-(aminomethyl)anilino)- 1 -(4-(2 methoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 9.8 3-Z-[1 -(4-(aminomethyl)anilino)- 1 -(3-(2 ethoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 9.9 3-Z-[1 -(4-(methylaminomethyl)anilino)-1 -(3-(2 ethoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 10.0 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(2 carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone 10.1 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 10.2 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-carboxymethylphenyl) methylenel-6-fluoro-2-indolinone 10.3 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 10.4 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4-carboxymethylphenyl) methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 10.5 methylamino)anilino)-1 -(4-carboxymethylphenyl)methylene]-6-fluoro-2 indolinone 10.6 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-methylsulphonylamino)anilino) 1 -(4-carboxymethylphenyl)methylene]-6-fluoro-2-indolinone 10.7 3-Z-[1 -(4-(N-methyl-N-acetylamino)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 10.8 methylamino)anilino)-1 -(4-(2-carboxyethyl)phenyl)methylene]-6-fluoro 2-indolinone 10.9 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-methylsulphonylamino)anilino) 1 -(4-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 41 10.10 3-Z-[1 -(4-(N-(3-dimethylaminopropyl)-N-acetylamino)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 10.11 3-Z-[1 -(4-(N-tert-butoxycarbonylmethylaminomethyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 10.12 3-Z-[1 -(4-(4-methylpiperazin-1 -ylcarbonyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 10.13 3-Z-[1 -(4-(1 -methylimidazol-2-yl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 10.14 3-Z-[1 -(4-methylsulphonylanilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 10.15 3-Z-[1 -(4-(4-methylpiperazin-1 -ylcarbonyl)anilino)-1 -(3 carboxymethylphenyl)methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 10.16 methylamino)anilino)-1 -(3-carboxymethylphenyl)methylene]-6-fluoro-2 indolinone 10.17 3-Z-[1 -(4-(N-(dimethylaminomethylcarbonyl)-N-methylamino)anilino)- 1 (3-carboxymethylphenyl)methylene]-6-fluoro-2-indolinone 10.18 3-Z-[1 -(4-(N-(4-dimethylaminobutylcarbonyl)-N-methylamino)anilino)-1 (3-carboxymethylphenyl)methylene]-6-fluoro-2-indolinone 10.19 3-Z-[1 -Anilino-1 -(3-carboxymethylphenyl)-methylene]-6-fluoro-2 indolinone 10.20 3-Z-[1 -(4-methylsulphonylanilino)-1 -(3-carboxymethylphenyl) methylene]-6-fluoro-2-indolinone 10.21 3-Z-[1 -(4-(1 -methylimidazol-2-yl)anilino)-1 -(3-carboxymethylphenyl) methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(dimethylaminocarbonylmethyl)-N 10.22 methylsulphonylamino)anilino)-1 -(3-carboxymethylphenyl)-methylene] 6-fluoro-2-indolinone 42 10.23 3-Z-[1 anilino-1 -(4-carboxymethylphenyl)methylene]-6-fluoro-2 indolinone 10.24 3-Z-[1 -(4-(1 -methylimidazol-2-yl)anilino)-1 -(4-carboxymethylphenyl) methylene]-6-fluoro-2-indolinone 10.25 3-Z-[1 -(4-(N-(3-dimethylaminopropylcarbonyl)-N-methylamino)anilino) 1 -(4-carboxymethylphenyl)methylene]-6-fluoro-2-indolinone 10.26 3-Z-[1 -(4-(N-(dimethylaminomethylcarbonyl)-N-methylamino)anilino)- 1 (4-carboxymethylphenyl)methylene]-6-fluoro-2-indolinone 10.27 3-Z-[1 -(4-(4-methylpiperazin-1 -yi-carbonyl)anilino)-1 -(4 carboxymethylphenyl)methylenel-6-fluoro-2-indolinone 10.28 3-Z-[1 -(4-methylsulphonylanilino)-1 -(4-carboxymethylphenyl) methylene]-6-fluoro-2-indolinone 10.29 3-Z-[1 -(4-(N-methyl-N-acetylamino)anilino)-1 -(4-carboxymethylphenyl) methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(dimethylaminocarbonylmethyl)-N 10.30 methylsulphonylamino)anilino)-1 -(4-carboxymethylphenyl)methylene] 6-fluoro-2-indolinone 10.31 3-Z-[1 -(4-(N-(2-dimethylaminoethylcarbonyl)-N-methylamino)anilino)-1 (4-carboxymethylphenyl)methylene]-6-fluoro-2-indolinone 10.32 3-Z-[1 -(4-(N-(3-dimethylaminopropylcarbonyl)-N-methylamino)anilino) 1 -(4-carboxymethylphenyl)methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 10.33 methylamino)anilino)-1 -(3-(2-carboxyethyl)phenyl)methylene]-6-fluoro 2-indolinone 10.34 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-methylsulphonylamino)anilino) 1-(3-carboxymethylphenyl)methylene]-6-fluoro-2-indolinone 10.35 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-methylsulphonylamino)anilino) 1 -(3-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 43 10.36 3-Z-[1 -(4-(N-(dimethylaminomethylcarbonyl)-N-methylamino)anilino)-1 (3-(2-ca rboxyethyl)phenyl)methylene]-6-fl uoro-2-i ndol none 10.37 3-Z-[1 -(4-(N-(3-dimethylaminopropyl)-N-acetylamino)anlino)-1 -(3-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 10.38 3-Z-[1 -(4-(N-(dimethylaminomethylcarbonyl)-N-methylamino)anilino)-1 (4-(2-ca rboxyethyl)phenyl)methylene]-6-fl uoro-2-i ndol none 10.39 3-Z-[1 -(4-(2-dimethylaminoethyl)anilino)- I -(4-(2 carboxyethyl)ph enyl)methylene]-6-fl uoro-2-indol none 10.40 3-Z-[1 -(4-(N-(2-dimethylaminoethylcarbonyl)-N-methylamino)anlino)-1 (4-(2-ca rboxyeth yl)ph enyl)methyl en e]-6-fl uoro-2-i n dol none 10.41 3-Z-[1 -(4-(2-dimethylaminoethyl)anilino)-1 -(3-(2 ca rboxyethyl)phenyl)methylene]-6-fl uoro-2-indoli none 10.42 3-Z-[1 -(4-(N -(2-dimethylaminoethyl )-N-acetylamino)anilino)-1 -(4-(2 ca rboxyethyl)phenyl)methylene]-6-fl uoro-2-indol none 10.43 3-Z-[1 -(4-(N -(3-dimethylaminopropylcarbonyl )-N-methylamino)anilino) 1 -(3-(2-ca rboxyeth yl)phen yl)methyl en e]-6-fl uoro-2-in dol in one 10.44 3-Z-[1 -(4-(N -(4-dimethylamino-butylcarbonyl)-N-methylamino)anilino) 1 -(3-(2-ca rboxyethyl)phenyl)methylene]-6-fl uoro-2-indol none 10.45 3-Z-[1 -(4-(l1 -methylimidazol-2-y)anilino)-1 -(3-(2 carboxyethyl)ph enyl)methylene]-6-fl uoro-2-indol none 10.46 3-Z-[1 -(4-(N-(4-dimethylaminobutylcarbonyl)-N-methylamino)anilino)-1 (4-(2-carboxyethyl )phenyl)methylene]-6-fl uoro-2-i ndol none 10.47 3-Z-[1 anilino-1 -(4-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2 indolinone 10.48 3-Z-[1 -(4-(pyrrolidin -1 -ylmethyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fI uoro-2-indol none 10.49 3-Z-[1 -(4-(diethylaminomethyl )anilino)-1 -(4-(2 ca rboxyethyl)phenyl)methylene]-6-fl uoro-2-i ndol none 44 10.50 3-Z-[1 -(4-aminomethylanilino)-1 -(4-(2-carboxyethyl)phenyl)methylene] 6-fluoro-2-indolinone 10.51 3-Z-[1 -(4-(2-dimethylaminoethyl)anilino)-1 -(3-carboxymethylphenyl) methylene]-6-fluoro-2-indolinone 10.52 3-Z-[1 -(4-(2-dimethylaminoethyl)anilino)-1 -(4-carboxymethylphenyl) methylene]-6-fluoro-2-indolinone 10.53 3-Z-[1 -(4-(2-dimethylaminoethyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone 10.54 3-Z-[1 -(4-(1 -methylimidazol-2-yl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone 10.55 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone 10.56 3-Z-[1 -(4-((4-methylpiperazin-1 -yl)methyl)anilino)-1 -(3-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indoli none 10.57 3-Z-[1 -(4-(imidazol-1 -ylmethyl)anilino)-1 -(3-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 10.58 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-methylaminomethyl)anilino)-1 (3-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 10.59 3-Z-[1 -(4-((4-methylpiperazin-1 -yl)methyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 10.60 3-Z-[1 -(4-(imidazol-1 -ylmethyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 10.61 3-Z-[1 -(4-(pyrrolidin-1 -ylmethyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-chloro-2-indoli none 10.62 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-methylaminomethyl)anilino)-1 (4-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 10.63 3-Z-[1 anilino-1 -(3-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2 indolinone 45 10.64 3-Z-[1 -(4-aminomethylanilino)-1 -(3-(2-carboxyethyl)phenyl)methylene] 6-fluoro-2-indolinone 10.65 3-Z-[1 -(4-methylaminomethylanilino)- 1 -(3-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 10.66 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-carboxymethoxy-phenyl) methylene]-6-fluoro-2-indolinone 10.67 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4-carboxymethoxy phenyl)phenyl)methylene]-6-fluoro-2-indolinone 10.68 3-Z-[1 -(4-(pyrrolidin-1 -ylmethyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone 10.69 3-Z-[1-(4-(dimethylaminomethyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone 10.70 3-Z-[1 -(4-(diethylaminomethyl)anilino)-1 -(4-(2-carboxyethyl) methylene]-6-bromo-2-indolinone 10.71 3-Z-[1 -(3-dimethylaminomethylanilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 10.72 3-Z-[1 -(3-dimethylaminomethylanilino)-1 -(3-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 10.73 3-Z-[1 -(3-dimethylaminomethylanilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone 11.0 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(2-carbamoyl ethyl)phenyl)methylene]-6-chloro-2-indolinone 11.1 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(2-methylcarbamoyl ethyl)phenyl)methylene]-6-chloro-2-indolinone 11.2 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4-(2-methylcarbamoyl ethyl)phenyl)methylene]-6-fluoro-2-indolinone 11.3 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3 dimethylcarbamoylmethylphenyl)methylene] -6-fluoro-2-indolinone 46 11.4 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(2-carbamoyl ethyl)phenyl)methylene]-6-fluoro-2-indolinone 11.5 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(2-methylcarbamoyl ethyl)phenyl)methylene]-6-fluoro-2-indolinone 11.6 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(2-dimethylcarbamoyl ethyl)phenyl)methylene]-6-fluoro-2-indolinone 11.7 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-carbamoylmethylphenyl) methylene]-6-fluoro-2-indolinone 11.8 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3 methylcarbamoylmethylphenyl)methylene]-6-fluoro-2-indolinone 11.9 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4-carbamoylmethylphenyl) methylene]-6-fluoro-2-indolinone 11.10 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4-(2-dimethylcarbamoyl ethyl)phenyl)methylene]-6-fluoro-2-indolinone 11.11 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4-(2-(4-methylpiperazin-1 -yl carbonyl)ethyl)phenyl)methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 11.12 methylamino)anilino)-1 -(4-carbamoylmethylphenyl)methylene]-6-fluoro 2-indolinone 11.13 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-methylsulphonylamino)anilino) 1 -(4-carbamoylmethylphenyl)methylene]-6-fluoro-2-indolinone 11.14 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4 dimethylcarbamoylmethylphenyl)methylene]-6-fluoro-2-indolinone 11.15 3-Z-[1-(4-dimethylaminomethylanilino)-1-(4 methylcarbamoylmethylphenyl)methylene] -6-fluoro-2-indolinone 11.16 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-methylsulphonylamino)anilino) 1 -(4-methylcarbamoylmethylphenyl)methylene]-6-fluoro-2-indolinone 47 11.17 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-methylsulphonylamino)anilino) 1-(4-dimethylcarbamoylmethylphenyl)methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 11.18 methylamino)anilino)-1 -(4-methylcarbamoylmethylphenyl)methylenel-6 fl uoro-2-i ndol i none 11.19 3-Z-[1 -(4-(N-methyl-N-acetylamino)anilino)-1 -(4-(2-methylcarbamoyl ethyl)phenyl)methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 11.20 methylamino)anilino)-1 -(4-(2-methylcarbamoyl ethyl)phenyl)methylene]-6-fluoro-2-indolinone 11.21 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-methylsulphonylamino)anilino) 1-(4-(2-methylcarbamoylethyl)phenyl)methylene]-6-fluoro-2-indolinone 11.22 3-Z-[1 -(4-(N-tert-butoxycarbonylmethylaminomethyl)anilino)-1 -(4-(2 methylcarbamoylethyl)phenyl)methylene] -6-fluoro-2-indolinone 11.23 3-Z-[1 -(4-(1 -methylimidazol-2-yl)anilino)-1 -(4-(2-methylcarbamoyl ethyl)phenyl)methylene]-6-fluoro-2-indolinone 11.24 3-Z-[1 -(4-methylsulphonylanilino)-1 -(4-(2-methylcarbamoyl ethyl)phenyl)methylene]-6-fluoro-2-indolinone 11.25 3-Z-[1 -(4-(4-methylpiperazin-1 -ylcarbonyl)anilino)-1 -(4-(2 methylcarbamoylethyl)phenyl)methylene] -6-fluoro-2-indolinone 11.26 3-Z-[1 -(4-(4-methylpiperazin-1 -ylcarbonyl)anilino)-1 -(3 methylcarbamoylmethylphenyl)methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 11.27 methylamino)anilino)-1 -(3-methylcarbamoylmethylphenyl)methylene]-6 fl uoro-2-i ndol i none 12.0 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4-acetylaminomethylphenyl) methylene]-6-chloro-2-indolinone 48 3-Z-[1 -(4-(N -(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.1 methylamino)anilino)-1 -(4-acetylaminomethylphenyl)methylene]-6 ch Ioro-2-i ndol i none 12.2 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4-benzoylamin ophenyl) methylene]-6-ch loro-2-i ndol in one 3-Z-[1 -(4-(N -(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.3 methylamino)anilino)-1 -(4-benzoylaminomethylphenyl )methylene]-6 ch Ioro-2-i ndol i none 12.4 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-acetylaminomethyiphenyl) methyl ene]-6-fluoro-2-i ndol in one 12.5 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3 propionylani nomethyl phenyl)methylene] -6-fl uoro-2-indol none 12.6 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3 benzoyla minomethyl phenyl )methylene]-6-fl uoro-2-i ndol none 12.7 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3 phenylacetylaminomethylphenyl)methylene]-6-fluoro-2-indolinone 12.8 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(2 acetyla mi noethyl)phenyl)methylene]-6-fl uoro-2-i ndoli none 12.9 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(2 benzoylaminoethyl )phenyl)methylene]-6-fluoro-2-indolinone 12.10 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(2 propionylaminoethyl)phenyl)methylene]-6-fluoro-2-indolinone 12.11 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(2 phenylacetylaminoethyl)phenyl)methylene]-6-fluoro-2-i ndol none 12.12 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4-acetylaminomethyiphenyl) methylene]-6-fluoro-2-indol none 12.13 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4 propionylaminomethylphenyl)methylene]-6-fluoro-2-indolinone 49 12.14 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4 phenylacetylaminomethylphenyl)methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.15 methylamino)anilino)-1 -(4-acetylaminomethylphenyl)methylene]-6 fl uoro-2-i ndol i none 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.16 methylamino)anilino)-1 -(4-propionylaminomethylphenyl)methylene]-6 fl uoro-2-i ndol i none 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.17 methylamino)anilino)-1 -(4-phenylacetylaminomethylphenyl) methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.18 methylamino)anilino)-1 -(3-cyclopropylcarbonylaminomethylphenyl) methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.19 methylamino)anilino)-1 -(3-cyclobutylcarbonylaminomethylphenyl) methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.20 methylamino)anilino)-1 -(3-(pyridin-2-yl carbonylaminomethyl)phenyl)methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.21 methylamino)anilino)-1 -(3-cyclohexylcarbonylaminomethylphenyl) methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.22 methylamino)anilino)-1 -(3-(pyridin-3-yl carbonylaminomethyl)phenyl)methylene] -6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.23 methylamino)anilino)-1 -(3-isobutyrylaminomethylphenyl)methylene]-6 flu oro-2-i ndol i none 50 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.24 methylamino)anilino)-1 -(3-(3-methylbutyrylaminomethylphenyl) methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.25 methylamino)anilino)-1 -(3 cyclohexylmethylcarbonylaminomethylphenyl)methylene]-6-fluoro-2 indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.26 methylamino)anilino)-1 -(3-methoxyacetylaminomethylphenyl) methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.27 methylamino)anilino)-1 -(3-(2-methoxybenzoyl aminomethyl)phenyl)methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.28 methylamino)anilino)-1 -(3-tert-butylacetylaminomethylphenyl) methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.29 methylamino)anilino)-1 -(3-(2-thiophen carbonylaminomethyl)phenyl)methylene] -6-fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.30 methylamino)anilino)-1 -(3-pivaloylaminomethylphenyl)methylene]-6 fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.31 methylamino)anilino)-1 -(3-(2-furoylaminomethyl)phenyl)methylene]-6 fl uoro-2-i ndol i none 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.32 methylamino)anilino)-1 -(3-acetylaminomethylphenyl)methylene]-6 fluoro-2-i ndol i none 51 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.33 methylamino)anilino)-1 -(3-propionylaminomethylphenyl)methylene]-6 fluoro-2-indolinone 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.34 methylamino)anilino)-1 -(3-benzoylaminomethylphenyl)methylene]-6 fl uoro-2-i ndol i none 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N 12.35 methylamino)anilino)-1 -(3-phenylacetylaminomethylphenyl) methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3 12.36 cyclopropylcarbonylaminomethylphenyl)methylene]-6-fluoro-2 indolinone 12.37 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3 cyclobutylcarbonylaminomethylphenyl)methylene]-6-fluoro-2-indolinone 12.38 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(pyridin-2-yl carbonylaminomethyl)phenyl)methylene] -6-fluoro-2-indolinone 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3 12.39 cyclohexylcarbonylaminomethylphenyl)methylene]-6-fluoro-2 indolinone 12.40 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(pyridin-3-yl carbonylaminomethyl)phenyl)methylene] -6-fluoro-2-indolinone 12.41 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3 isobutyrylaminomethylphenyl)methylene]-6-fluoro-2-indolinone 12.42 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(3-methylbutyryl aminomethylphenyl)methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3 12.43 cyclohexylmethylcarbonylaminomethylphenyl)methylene]-6-fluoro-2 indolinone 52 12.44 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3 methoxyacetylaminomethylphenyl)methylene]-6-fluoro-2-indolinone 12.45 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(2-methoxybenzoyl aminomethyl)pheny)methylene]-6-fluoro-2-indolinone 12.46 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-tert butylacetylaminomethylphenyl)methylene]-6-fluoro-2-indolinone 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(2 12.47 thiophenecarbonylaminomethyl)phenyl)methylene]-6-fluoro-2 indolinone 12.48 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3 pivaloylaminomethylphenyl)methylene]-6-fluoro-2-indolinone 12.49 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(2 furoylaminomethyl)phenyl)methylene]-6-fluoro-2-indolinone 12.50 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(pyridin-4-yl carbonylaminomethyl)phenyl)methylene] -6-fluoro-2-indolinone 13.0 3-Z-[1 -(4-trimethylammoniummethylanilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone iodide 13.1 3-Z-[1-(4-trimethylammoniummethylanilino)-1-(3-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone iodide 14.0 3-Z-[1 -(4-guanidinomethylanilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 14.1 3-Z-[1 -(4-guanidinomethylanilino)-1 -(3-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 53 Abbreviations used: HOBt = 1-hydroxy-1 H-benzotriazole 5 TBTU = O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium tetrafluoroborate Preparation of the starting materials: 0 Example I: Dimethyl 2-(4-fluoro-2-nitrophenyl)malonate With ice-cooling, 185 g of potassium tert-butoxide are added to a solution of 188 ml of dimethyl malonate in 970 ml of N-methylpyrrolidone, and the mixture is stirred for 5 2 hours. Over a period of 30 minutes, 150 ml of 2,5-difluoronitrobenzene are added dropwise to the resulting slurry, and the mixture is then stirred at 85 0 C for 6 hours. The mixture is poured into 4 liters of ice-water and 250 ml of concentrated hydrochloric acid and extracted with 2 liters of ethyl acatate. The organic phase is dried with sodium sulphate and concentrated. The oily residue is triturated twice with 0 water and then taken up in 600 ml of ethyl acetate. The solution is dried with sodium sulphate and concentrated to dryness. The resulting crude product is recrystallized from 600 ml of ethyl acetate/hexane = 2:8 and dried. Yield: 222 g (59% of theory) Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate = 5:1) 5 C1 1
H
10 FN0 6 Mass spectrum: m/z = 270 [M-H]~ The following compounds are prepared analogously to Example 1: 0 (1.1) Diethyl 2-(4-bromo-2-nitrophenyl)malonate from 2,5-dibromonitrobenzene and diethyl malonate Rf value: 0.40 (silica gel, petroleum ether/ethyl acetate = 5:1)
C
1 3
H
1 4 BrNO 6 54 Mass spectrum: m/z = 359/361 [M]* (1.2) Dimethyl 2-(4-cyano-2-nitrophenyl)malonate from 4-chloro-3-nitrobenzonitrile and dimethyl malonate 5 Rf value: 0.50 (silica gel, methylene chloride/methanol = 50:1)
C
12
H
10
N
2 0 6 Mass spectrum: m/z = 277 [M-H] Example 11: 0 Methyl 4-cyano-2-nitrophenylacetate 14.2 g of dimethyl 2-(4-cyano-2-nitrophenyl)malonate (starting material 1.2) are dissolved in 200 ml of dimethyl sulphoxide, and 4.5 g of lithium chloride and 1.0 ml of water are added. The solution is stirred at 100*C for 3.5 hours, 300 ml of ice-water 5 are then added and the mixture is allowed to stand for 12 hours. The resulting precipitate is filtered off with suction, taken up in methylene chloride and washed with water. The organic phase is dried over sodium sulphate, concentrated using a rotary evaporator and dried. Yield: 7.7 g (68% of theory) 0 Rf value: 0.40 (silica gel, methylene chloride/methanol) = 50:1
C
10
H
8
N
2 0 4 Mass spectrum: m/z = 219 [M-H]~ Example Ill: 5 4-Fluoro-2-nitrophenylacetic acid At 100C, 50.0 g of dimethyl 2-(4-fluoro-2-nitrophenyl)malonate (starting material 1) are stirred in 400 ml of 6 molar hydrochloric acid for 20 hours, 400 ml of water are then added and the mixture is cooled to 00C. The resulting precipitate is filtered off 0 with suction, washed with water and 100 ml of petroleum ether and dried. Yield: 34.5 g (94% of theory) Rf value: 0.30 (silica gel, cyclohexane/ethyl acetate) = 5:2
C
8
H
6
FNO
4 55 Mass spectrum: m/z = 154 [M-COO-H] Example IV: 5 6-Fluoro-2-indolinone With addition of 20 g of palladium on activated carbon (10%), 119 g of 4-fluoro-2 nitrophenylacetic acid (starting material 111) are hydrogenated in 600 ml of acetic acid under a hydrogen pressure of 50 psi. The catalyst is filtered off with suction and the 0 solvent is distilled off. The crude product is triturated with 500 ml of petroleum ether, filtered off with suction, washed with water and dried. Yield: 82.5 g (91 % of theory) Rf value: 0.30 (silica gel, petroleum ether/ethyl acetate = 1:1)
C
8
H
6 FNO 5 Mass spectrum: m/z = 150 [M-H] The following compounds are prepared analogously to Example IV: (IV.1) 6-Bromo-2-indolinone 0 from diethyl 2-(4-bromo-2-nitrophenyl)malonate (starting material 1.1) using Raney nickel as hydrogenation catalyst Rf value: 0.45 (silica gel, petroleum ether/ethyl acetate = 1:1)
C
8
H
6 BrNO Mass spectrum: m/z = 210/212 [M-H] 5 (IV.2) 6-Cyano-2-indolinone from methyl 4-cyano-2-nitrophenylacetate (starting material 11) using palladium/calcium carbonate as hydrogenation catalyst Rf value: 0.45 (silica gel, methylene chloride/methanol = 9:1) 0 C 9
H
6
N
2 0 Mass spectrum: m/z = 157 [M-H]- 56 Example V: 1 -acetyl-6-fluoro-2-indolinone At 1300C, 82.5 g of 6-fluoro-2-indolinone (starting material IV) are stirred in 180 ml 5 acetic anhydride for 3 hours. After cooling to room temperature, the precipitate is filtered off with suction, washed with 100 ml of petroleum ether and dried. Yield: 64.8 g (61 % of theory) Rf value: 0.75 (silica gel, petroleum ether/ethyl acetate = 1:1)
C
10
H
8 FN0 2 0 Mass spectrum: m/z = 192 [M-H]~ The following compounds are prepared analogously to Example V: (V.1) 1 -acetyl-6-chloro-2-indolinone 5 from 6-chloro-2-indolinone and acetic anhydride Rf value: 0.55 (silica gel, petroleum ether/ethyl acetate = 2:3)
C
11
H
1 0 CIN0 6 Mass spectrum: m/z = 208/210 [M-H] 0 (V.2) 1-acetyl-6-bromo-2-indolinone from 6-bromo-2-indolinone (starting material IV.1) and acetic anhydride Rf value: 0.60 (silica gel, petroleum ether/ethyl acetate = 2:1) C1oH8BrNO 2 Mass spectrum: m/z = 253/255 [M]* 5 (V.3) 1-acetyl-6-cyano-2-indolinone from 6-cyano-2-indolinone (starting material IV.2) and acetic anhydride Rf value: 0.60 (silica gel, methylene chloride/methanol = 50:1) C11H 8
N
2 0 2 0 Mass spectrum: m/z = 199 [M-H]- 57 Example VI: 1 -acetyl-3-1 -hydroxy-1 -(3-iodophenvl)methylenel-6-chloro-2-indolinone 10.5 g of 1-acetyl-6-chloro-2-indolinone (starting material V.1), 13.6 g of 5 3-iodobenzoic acid and 17.7 g of TBTU are initially charged in 100 ml of dimethylformamide, 35 ml of triethylamine are added and the mixture is stirred at room temperature for 12 hours. After this time, the solvent is removed under reduced pressure, water is added to the residue and the residue is filtered off with suction, washed with a little water, methanol and ether and dried at 100*C under reduced 0 pressure. Yield: 12.9 g (59 % of theory) Rf value: 0.80 (silica gel, methylene chloride/methanol = 9:1)
C
1 7 HiiCllN0 3 Mass spectrum: m/z = 438/440 [M-H] 5 The following compounds are prepared analogously to Example VI: (VI.1) 1-acetyl-3-[1-hydroxy-1-(4-methoxycarbonylmethylphenyl)methylene]-6-fluoro 2-indolinone 0 from 1 -acetyl-6-fluoro-2-indolinone (starting material V) and methyl (4-carboxyphenyl)acetate (preparation according to Tetrahedron 1997, 53, 7335 7340) (VI.2) 1 -acetyl-3-[1 -hydroxy-1 -(4-chlorophenyl)methylene]-6-chloro-2-indolinone 5 from 1-acetyl-6-chloro-2-indolinone (starting material V.1) and 4-chlorobenzoic acid (VI.3) 1-acetyl-3-[1-hydroxy-1-(3,4-dimethoxyphenyl)methylene]-6-chloro-2 indolinone from 1-acetyl-6-chloro-2-indolinone (starting material V.1) and 3,4-dimethoxybenzoic 0 acid (VI.4) 1-acetyl-3-[1-hydroxy-1-(3,4-dimethoxyphenyl)methylene]-6-cyano-2 indolinone 58 from 1 -acetyl-6-cyano-2-indolinone (starting material V.3) and 3,4-dimethoxybenzoic acid (VI.5) 1-acetyl-3-[1-hydroxy-1-(3-fluorophenyl)methylene]-6-fluoro-2-indolinone 5 from 1-acetyl-6-fluoro-2-indolinone (starting material V) and 3-fluorobenzoic acid (VI.6) 1-acetyl-3-[1-hydroxy-1-(4-(2-acetylaminoethyl)phenyl)methylene]-6-fluoro-2 indolinone from 1 -acetyl-6-fluoro-2-indolinone (starting material V) and 4-(2-acetylaminoethyl) o benzoic acid (preparation according to J. Am. Chem. Soc. 1943, 65, 2377) (VI.7) 1-acetyl-3-[1-hydroxy-1-(3-methoxycarbonylmethylphenyl)methylene]-6-fluoro 2-indolinone from 1 -acetyl-6-fluoro-2-indolinone (starting material V) and methyl 5 (3-carboxyphenyl)acetate (preparation analogously to Tetrahedron 1997, 53, 7335 7340) (VI.8) 1-acetyl-3-[1-hydroxy-1-(3-(N-tert-butoxycarbonylaminomethyl)phenyl) methylene]-6-fluoro-2-indolinone 0 from 1 -acetyl-6-fluoro-2-indolinone (starting material V) and 3-(N-tert-butoxycarbonyl aminomethyl)benzoic acid (preparation according to Tetrahedron 1997, 53, 7335 7340) (VI.9) 1-acetyl-3-[1-hydroxy-1-(3-cyanomethylphenyl)methylene]-6-fluoro-2 5 indolinone from 1 -acetyl-6-fluoro-2-indolinone (starting material V) and (3-carboxyphenyl) acetonitrile (preparation according to J. Prakt. Chem. 1998, 340, 367-374) (VI.10) 1-acetyl-3-[1-hydroxy-1-(4-(N-tert-butoxycarbonylaminomethyl)phenyl) 0 methylene]-6-fluoro-2-indolinone from 1 -acetyl-6-fluoro-2-indolinone (starting material V) and 4-(N-tert-butoxycarbonyl aminomethyl)benzoic acid (preparation according to Bioorg. Med. Chem. Lett 2000, 10, 553-557) 59 (VI. 11) 1 -acetyl-3-[1 -hydroxy-1 -(4-iodophenyl)methylene]-6-fluoro-2-indolinone from 1 -acetyl-6-fluoro-2-indolinone (starting material V) and 4-iodobenzoic acid 5 (VI.12) 1 -acetyl-3-[1 -hydroxy-1 -(4-iodophenyl)methylene]-6-chloro-2-indolinone from 1-acetyl-6-chloro-2-indolinone (starting material V.1) and 4-iodobenzoic acid (VI.13) 1 -acetyl-3-[1 -hydroxy-1 -(3-iodophenyl)methylene]-6-fluoro-2-indolinone from 1-acetyl-6-fluoro-2-indolinone (starting material V) and 3-iodobenzoic acid 0 (VI.14) 1-acetyl-3-[1-hydroxy-1-(4-(2-methoxycarbonylethyl)phenyl)methylene]-6 fluoro-2-indolinone from 1-acetyl-6-fluoro-2-indolinone (starting material V) and 4-(2 methoxycarbonylethyl)benzoic acid (preparation analogously to Tetrahedron 1997, 5 53, 7335-7340) (VI.15) 1-acetyl-3-[1-hydroxy-1-(3-(2-methoxycarbonylethyl)phenyl)methylene]-6 fluoro-2-indolinone from 1 -acetyl-6-fluoro-2-indolinone (starting material V) and 3-(2 0 methoxycarbonylethyl)benzoic acid (preparation analogously to Tetrahedron 1997, 53, 7335-7340) (VI.16) 1-acetyl-3-[1-hydroxy-1-(3-(N-tert-butoxycarbonyl-2 aminoethyl)phenyl)methylene]-6-fluoro-2-indolinone 5 from 1 -acetyl-6-fluoro-2-indolinone (starting material V) and 3-(N-tert-butoxycarbonyl 2-aminoethyl)benzoic acid (preparation analogously to Bioorg. Med. Chem. Lett 2000, 10, 553-557) (VI.17) 1-acetyl-3-[1-hydroxy-1-(4-(N-tert-butoxycarbonyl-2 0 aminoethyl)phenyl)methylene]-6-fluoro-2-indolinone from 1 -acetyl-6-fluoro-2-indolinone (starting material V) and 4-(N-tert-butoxycarbonyl 2-aminoethyl)benzoic acid (preparation analogously to Bioorg. Med. Chem. Lett 2000, 10, 553-557) 60 (VI. 18) 1 -acetyl-3-[1 -hydroxy-1 -(4-cyanophenyl)methylene]-6-chloro-2 indolinone from 1-acetyl-6-chloro-2-indolinone (starting material V.1) and 4-cyanobenzoic acid 5 (VI. 19) 1 -acetyl-3-[1 -hydroxy-1 -(3-acetylaminomethylphenyl)methylenel-6 fluoro-2-indolinone from 1 -acetyl-6-fluoro-2-indolinone (starting material V) and 3-acetylaminomethyl benzoic acid (prepared according to J. Med. Chem. 1997, 40, 4030-4052) 0 (VI.20) 1-acetyl-3-[1-hydroxy-1-(3-(2-ethoxycarbonylethyl)phenyl)methylene]-6-fluoro 2-indolinone from 1 -acetyl-6-fluoro-2-indolinone (starting material V) and 3-(2 ethoxycarbonylethyl)benzoic acid (preparation analogously to Tetrahedron 1997, 53, 5 7335-7340) (VI.21) 1-acetyl-3-[1-hydroxy-1-(4-(2-methoxycarbonylethyl)phenyl)methylene]-6 chloro-2-indolinone from 1-acetyl-6-chloro-2-indolinone (starting material V.1) and 4-(2 0 methoxycarbonylethyl)benzoic acid (preparation analogously to Tetrahedron 1997, 53, 7335-7340) (VI.22) 1-acetyl-3-[1-hydroxy-1-(4-(2-ethoxycarbonylethyl)phenyl)methylene]-6-fluoro 2-indolinone 5 from 1 -acetyl-6-fluoro-2-indolinone (starting material V) and 4-(2 ethoxycarbonylethyl)benzoic acid (preparation analogously to Tetrahedron 1997, 53, 7335-7340) (VI.23) 1-acetyl-3-[1-hydroxy-1-(3-methoxycarbonylmethyloxy-phenyl)methylene]-6 0 fluoro-2-indolinone from 1 -acetyl-6-fluoro-2-indolinone (starting material V) and 3-methoxycarbonylmethyloxybenzoic acid (preparation see Tetrahedron Letters 1998, 39, 8563-8566) 61 (VI.24) 1-acetyl-3-[1-hydroxy-1-(4-methoxycarbonylmethyloxyphenyl)methylene]-6 fluoro-2-indolinone from 1 -acetyl-6-fluoro-2-indolinone (starting material V) and 5 4-methoxycarbonylmethyloxybenzoic acid (preparation analogously to Tetrahedron Letters 1998, 39, 8563-8566) (VI.25) 1-acetyl-3-[1-hydroxy-1-(3-(2-ethoxycarbonylethyloxy)phenyl)methylene]-6 fluoro-2-indolinone 0 from 1 -acetyl-6-fluoro-2-indolinone (starting material V) and 3-(2 ethoxycarbonylethyloxy)benzoic acid (preparation see PCT Int. Apple. W09620173, 60) (VI.26) 1-acetyl-3-[1-hydroxy-1-(4-(2-ethoxycarbonylethyloxy)phenyl)methylene]-6 5 fluoro-2-indolinone from 1 -acetyl-6-fluoro-2-indolinone (starting material V) and 4-(2 ethoxycarbonylethyloxy)benzoic acid (preparation see PCT Int. Apple. W09620173, 58) 0 (VI.27) 1-acetyl-3-[1-hydroxy-1-(4-(2-methoxycarbonylethyl)phenyl)methylene]-6 bromo-2-indolinone from 1 -acetyl-6-bromo-2-indolinone (starting material V.2) and 4-(2 methoxycarbonylethyl)-benzoic acid (preparation analogously to Tetrahedron 1997, 53, 7335-7340) 5 Example VII: 1 -acetyl-3-[1 -methoxy-1 -(3-iodophenyl)methylenel-6-chloro-2-indolinone 0 A little at a time, 2.36 g of trimethyloxonium tetrafluoroborate are added to a solution of 3.52 g of 1-acetyl-3-[1-hydroxy-1-(3-iodophenyl)methylene]-6-chloro-2-indolinone (starting material VI) and 2.72 ml of ethyldiisopropylamine in 80 ml of dichloromethane, and the mixture is stirred at room temperature for one hour.
62 Another 1.4 ml of ethyldiisopropylamine and 1.2 g of trimethyloxonium tetrafluoroborate are added, and the mixture is stirred at room temperature for another two hours. The mixture is then extracted with water and the organic phase is dried over magnesium sulphate and evaporated to dryness. The residue is 5 recrystallized from ether and dried at 800C under reduced pressure. Yield: 2.40 g (66 % of theory) Rf value: 0.60 (silica gel, petroleum ether/dichloromethane/ethyl acetate = 5:4:1)
C
1 8
H
1 3 ClNO 3 Mass spectrum: m/z = 438/440 [M-H] 0 m.p. 185 - 187 *C The following compounds are prepared analogously to Example VII: (VII.1) 1-acetyl-3-[1-methoxy-1-(4-methoxycarbonylmethylphenyl)methylene]-6 5 fluoro-2-indolinone from 1-acetyl-3-[1-hydroxy-1-(4-methoxycarbonylmethylphenyl)methylene]-6-fluoro-2 indolinone (starting material VI.1) (VII .2) 1 -acetyl-3-[1 -methoxy-1 -(4-chlorophenyl)methylene]-6-chloro-2-indolinone 0 from 1-acetyl-3-[1-hydroxy-1-(4-chlorophenyl)methylene]-6-chloro-2-indolinone (starting material VI.2) (VII .3) 1 -acetyl-3-[1 -methoxy-1 -(3,4-dimethoxyphenyl)methylene]-6-chloro-2 indolinone 5 from 1 -acetyl-3-[1 -hydroxy-1 -(3,4-dimethoxyphenyl)methylene]-6-chloro-2-indolinone (starting material VI.3) (VII .4) 1 -acetyl-3-[1 -methoxy-1 -(3,4-dimethoxyphenyl)methylene]-6-cyano-2 indolinone 0 from 1-acetyl-3-[1-hydroxy-1-(3,4-dimethoxyphenyl)-methylene]-6-cyano-2-indolinone (starting material VI.4) (VII.5) 1-acetyl-3-[1-methoxy-1-(3-fluorophenyl)methylene]-6-fluoro-2-indolinone 63 from 1-acetyl-3-[1-hydroxy-1-(3-fluorophenyl)methylene]-6-fluoro-2-indolinone (starting material VI.5) (VII .6) 1 -acetyl-3-[1 -methoxy-1 -(4-(2-acetylaminoethyl)phenyl)methylene]-6-fluoro-2 5 indolinone from 1-acetyl-3-[1-hydroxy-1-(4-(2-acetylaminoethyl)phenyl)methylene]-6-fluoro-2 indolinone (starting material VI.6) (VI l.7) 1 -acetyl-3-[1 -methoxy-1 -(3-methoxycarbonylmethylphenyl)methylene]-6 0 fluoro-2-indolinone from 1-acetyl-3-[1-hydroxy-1-(3-methoxycarbonylmethylphenyl)methylene]-6-fluoro-2 indolinone (starting material VI.7) (VI l.8) 1 -acetyl-3-[1 -methoxy-1 -(3-(N-tert-butoxycarbonylaminomethyl)phenyl) 5 methylene]-6-fluoro-2-indolinone from 1-acetyl-3-[1-hydroxy-1-(3-(N-tert-butoxycarbonyl aminomethyl)phenyl)methylene]-6-fluoro-2-indolinone (starting material VI.8) (VII.9) 1-acetyl-3-[1-methoxy-1-(3-cyanomethylphenyl)methylene]-6-fluoro-2 0 indolinone from 1-acetyl-3-[1-hydroxy-1-(3-cyanomethylphenyl)methylene]-6-fluoro-2-indolinone (starting material VI.9) (VII.10) 1 -acetyl-3-[1 -methoxy-1 -(4-(N-tert-butoxycarbonyl 5 aminomethyl)phenyl)methylene]-6-fluoro-2-indolinone from 1-acetyl-3-[1-hydroxy-1-(4-(N-tert-butoxycarbonyl aminomethyl)phenyl)methylene]-6-fluoro-2-indolinone (starting material VI. 10) (VII.11) 1 -acetyl-3-[1 -methoxy-1 -(4-iodophenyl)methylene]-6-fluoro-2-indolinone 0 from 1-acetyl-3-[1-hydroxy-1-(4-iodophenyl)methylene]-6-fluoro-2-indolinone (starting material VI.11) 64 (VII.12) 1 -acetyl-3-[1 -methoxy-1 -(4-iodophenyl)methylene]-6-chloro-2 indolinone from 1-acetyl-3-[1-hydroxy-1-(4-iodophenyl)methylene]-6-chloro-2-indolinone (starting material VI.12) 5 (VII. 13) 1 -acetyl-3-[1 -methoxy-1 -(3-iodophenyl)methylene]-6-fluoro-2-indolinone from 1-acetyl-3-[1-hydroxy-1-(3-iodophenyl)methylene]-6-fluoro-2-indolinone (starting material VI.13) 0 (VII. 14) 1 -acetyl-3-[1 -methoxy-1 -(3-(2-methoxycarbonylethyl)phenyl)methylenel 6-fluoro-2-indolinone from 1-acetyl-3-[1-hydroxy-1-(3-(2-methoxycarbonylethyl)phenyl)methylene]-6-fluoro 2-indolinone (starting material VI.14) 5 (VII.15) 1 -acetyl-3-[1 -methoxy-1 -(4-(2-methoxycarbonylethyl)phenyl)methylene] 6-fluoro-2-indolinone from 1-acetyl-3-[1-hydroxy-1-(4-(2-methoxycarbonylethyl)phenyl)methylene]-6-fluoro 2-indolinone (starting material VI.15) 0 (VII.16) 1 -acetyl-3-[1 -methoxy-1 -(4-(N-tert-butoxycarbonyl-2 aminoethyl)phenyl)methylene]-6-fluoro-2-indolinone from 1-acetyl-3-[1-hydroxy-1-(4-(N-tert-butoxycarbonyl-2 aminoethyl)phenyl)methylene]-6-fluoro-2-indolinone (starting material VI.117) 5 (VII.17) 1 -acetyl-3-[1 -methoxy-1 -(3-(N-tert-butoxycarbonyl-2 aminoethyl)phenyl)methylene]-6-fluoro-2-indolinone from 1-acetyl-3-[1-hydroxy-1-(3-(N-tert-butoxycarbonyl-2 aminoethyl)phenyl)methylene]-6-fluoro-2-indolinone (starting material VI.16) 0 (VII.18) 1 -acetyl-3-[1 -methoxy-1 -(3-acetylaminomethylphenyl)methylene]-6 fluoro-2-indolinone from 1-acetyl-3-[1-hydroxy-1-(3-acetylaminomethylphenyl)methylene]-6-fluoro-2 indolinone (starting material VI.19) 65 (VII.19) 1 -acetyl-3-[1 -methoxy-1 -(3-(2-ethoxycarbonylethyl)phenyl)methylene] 6-fluoro-2-indolinone from 1-acetyl-3-[1-hydroxy-1-(3-(2-ethoxycarbonylethyl)phenyl)methylene]-6-fluoro-2 5 indolinone (starting material VI.20) (VII.20) 1 -acetyl-3-[1 -methoxy-1 -(4-(2-methoxycarbonylethyl)phenyl)methylene] 6-chloro-2-indolinone from 1-acetyl-3-[1-hydroxy-1-(4-(2-methoxycarbonylethyl)phenyl)methylenej-6-chloro 0 2-indolinone (starting material VI.21) (VII.21) 1 -acetyl-3-[1 -methoxy-1 -(4-(2-ethoxycarbonylethyl)phenyl)methylene] 6-fluoro-2-indolinone from 1-acetyl-3-[1-hydroxy-1-(4-(2-ethoxycarbonylethyl)phenyl)methylene]-6-fluoro-2 5 indolinone (starting material VI.22) (VII.22) 1 -acetyl-3-[1 -methoxy-1 -(4-methoxycarbonylmethyloxyphenyl) methylene]-6-fluoro-2-indolinone from 1-acetyl-3-[1-hydroxy-1-(4-methoxycarbonylmethyloxyphenyl)methylene]-6 0 fluoro-2-indolinone (starting material VI.23) (VII.23) 1 -acetyl-3-[1 -methoxy-1 -(3-methoxycarbonylmethyloxyphenyl) methylene]-6-fluoro-2-indolinone from 1-acetyl-3-[1-hydroxy-1-(3-methoxycarbonylmethyloxyphenyl)methylene]-6 5 fluoro-2-indolinone (starting material VI.24) (VII.24) 1 -acetyl-3-[1 -methoxy-1 -(3-(2 ethoxycarbonylethyloxy)phenyl)methylene]-6-fluoro-2-indolinone from 1-acetyl-3-[1-hydroxy-1-(3-(2-ethoxycarbonylethyloxy)phenyl)methylene]-6 0 fluoro-2-indolinone (starting material VI.25) (VII.25) 1 -acetyl-3-[1 -methoxy-1 -(4-(2 ethoxycarbonylethyloxy)phenyl)methylene]-6-fluoro-2-indolinone 66 from 1-acetyl-3-[1-hydroxy-1-(4-(2-ethoxycarbonylethyloxy)phenyl)methylene]-6 fluoro-2-indolinone (starting material VI.26) (VII.26) 1 -acetyl-3-[1 -methoxy-1 -(4-(2-methoxycarbonylethyl)phenyl)methylene] 5 6-bromo-2-indolinone from 1-acetyl-3-[1-hydroxy-1-(4-(2-methoxycarbonylethyl)phenyl)methylene]-6 bromo-2-indolinone (starting material VI.27) Example VIII: 0 1 -Acetyl-3-[1 -chloro-1 -(4-cyanophenyl)methylenel-6-chloro-2-indolinone A suspension of 7.0 g of 1-acetyl-3-[1-hydroxy-1-(4-cyanophenyl)methylene]-6 chloro-2-indolinone (starting material VI.18) and 6.39 g of phosphorus pentachloride in 150 ml of dioxane is stirred at 100*C for 6 hours. After addition of a further 1.0 g of 5 phosphorus pentachloride, the mixture is stirred at 1 10*C for another 4 hours. The solvent is then distilled off and the residue is washed with ethyl acetate. Yield: 4.5 g (61 % of theory) Rf value: 0.70 (silica gel, methylene chloride/methanol = 50:1)
C
18
H
1 0 Cl 2
N
2 0 2 0 Example IX: The syntheses of the following compounds have already been described in the international application WO 01/27081: 5 (IX.1) 4-(diethylaminomethyl)aniline (IX.2) N-(2-dimethylaminoethyl)-N-methylsulphonyl-p-phenylenediamine 0 (IX.3) 3-(dimethylaminomethyl)aniline (IX.4) 4-(dimethylaminomethyl)aniline 67 (IX.5) 4-(2-dimethylaminoethyl)aniline (IX.6) 4-[N-(2-dimethylaminoethyl)-N-acetylamino]aniline 5 (IX.7) 4-[N-(3-dimethylaminopropyl)-N-acetylamino]aniline (IX.8) 4-[(N-dimethylaminocarbonylmethyl-N-methylsulphonyl)amino]aniline (IX.9) N-(4-aminophenyl)-N-methylmethanesulphonamide 0 (IX.10) N-(dimethylaminomethylcarbonyl)-N-methyl-p-phenylenediamine (IX. 11) N-[(2-dimethylaminoethyl)carbonyl]-N-methyl-p-phenylenediamine 5 (IX.12) 4-(N-tert-butoxycarbonylaminomethyl)aniline (IX. 13) 4-(N-ethyl-N-tert-butoxycarbonylaminomethyl)aniline (IX.14) 4-[(4-methylpiperazin-1 -yl)methyl]aniline 0 (IX.15) 4-(imidazol-1 -ylmethyl)aniline (IX.16) 4-(1 -methylimidazol-2-yl)aniline 5 (IX.17) 4-[(N-(2-dimethylaminoethyl)-N-methylamino)methyl]aniline (IX.1 8) 4-(N-methyl-N-tert-butoxycarbonylaminomethyl)aniline (IX.19) N-[(4-methylpiperazin-1-yl)methylcarbonyl]-N-methyl-p-phenylenediamine 0 (IX.20) 4-(4-tert-butoxycarbonylpiperazin-1 -ylmethyl)aniline (IX.21) 4-(thiomorpholin-4-ylmethyl)aniline 68 (IX.22) 4-(pyrrolidin-1 -ylmethyl)aniline (IX.23) 4-(morpholin-4-yl-methyl)aniline 5 (IX.24) 4-(N-benzyl-N-methylaminomethyl)aniline (IX.25) 4-(N-ethyl-N-methylaminomethyl)aniline 0 (IX.26) 4-[N-(2-dimethylaminoethyl)-N-methylamino]aniline (IX.27) 4-[(N-propyl-N-methylamino)methyl]aniline The following compounds are prepared analogously to Example IX: 5 (IX.28) 4-[N-(2-(N-benzyl-N-methylamino)ethyl)-N-acetylamino]aniline (IX.29) 4-amino-N-(2-dimethylaminoethyl)-N-methylbenzamide 0 (IX.30) 4-(4-methylpiperazin-1 -ylcarbonyl)aniline (IX.31) 4-(2-dimethylaminoethoxy)aniline (IX.32) N-(4-dimethylaminobutylcarbonyl)-N-methyl-p-phenylenediamine 5 (IX.33) N-[(3-dimethylaminopropyl)carbonyl]-N-methyl-p-phenylenediamine 69 Preparation of the end products: Example 1.0 5 3-Z-[1 -(4-(N-Methyl-N-methylsulphonylamino)anilino)-1 -(3-iodophenyl)methylenel-6 ch loro-2-indol i none 0.9 g of 1-acetyl-3-(1-methoxy-1-(3-iodophenyl)methylene)-6 -chloro-2-indolinone (starting material VII) and 0.5 g of N-methyl-N-methylsulphonyl-p-phenylenediamine (starting material IX.9) are dissolved in 10 ml of dimethylformamide and stirred at 0 120*C for 3 hours. After cooling, 1.5 ml of piperidine are added and the mixture is stirred at room temperature for another hour. Water is added and the resulting precipitate is filtered off with suction, washed with a little water, methanol and ether and finally dried under reduced pressure at 100C. Yield: 0.9 g (74% of theory), 5 Rf value: 0.6 (silica gel, methylene chloride/methanol = 9:1) m.p. 292-294 0C
C
2 3
H
19 CllN 3 0 3 S Mass spectrum: m/z = 578/580 [M-H] 0 The following compounds of the formula 1-1 are prepared analogously to Example 1.0: 4' R 3 N /H 0 Cl II-N 70 Ex- Starting Emp mSatin Empirical Mass m.p. Rf formula spectrum [0C] value* e als VII 529/531 238- 0.30 1.1 / -CH 2 -NMe 2
C
24
H
21 ClN 3 0 - - IX.4 [M+H]* 240 (A) ci -N(Me)-(CO)- VII.2 495/497 277- 0.20 1.2
C
26
H
24 Cl 2
N
4 0 2
CH
2 -NMe 2 IX.10 [M+H]* 279 (B) ci -(Oe- V.2507/509 241- 0.10 1.3 /\ -N(COMe)- VII.2 C 27
H
26 Cl 2
N
4 0 2
(CH
2
)
2 -NMe 2 IX.6 [M-H]- 243 (B) ci N N-Me VII.2 548/550 266- 0.10 1.4 Me. C 29
H
29 Cl 2
N
5 0 2 N 0 IX.19 [M-H]- 268 (B) c1. -N(COMe)- VIl.2 521/523 241- 0.10 1.5 C281H2802N\402
(CH
2
)
3 -NMe 2 IX.7 [M-H]- 242 (B) ci VIl.2 438/440 243- 0.10 1.6 I n/ -CH 2 -NMe 2
C
24
H
2 1 Cl 2
N
3 0 [M8/44 244 (B) IX.4 [M+H]* 244 (B) MeO OMe N(COMe)- VII.3 533/535 128- 0.75 1.7 C 29
H
31 CI N 4
(CH
2
)
2 -NMe 2 IX.6 [M-H]- 130 (C) MeO OMe rN-Me VII.3 574/576 208- 0.65 1.8 MeN ,-J C31H34CIN 5
O
4 N0 IX.19 [M-H]- 210 (C) MeO OMe -N(SO 2 Me)- VII.3 569/571 198- 0.75 1.9 C 28
H
31 CI N 4 0 5 S -. - (CH 2
)
2 -NMe 2 IX.2 [M-H]~ 200 (C) MeO OMe VII.3 462/464 239- 0.70 1.10 -CH 2 -NMe 2
C
26
H
26
CIN
3 0 3 IX.4 [M-H]- 240 (C) 71 MeO OMe O Me Vll.3 533/535 147- 0.70 1.11 NaC29H31CIN404 1.11NMe2 IX.29 [M-H] 149 (C) *Eluent mixtures: (A): silica gel, methylene chloride/methanol 9:1 (B): silica gel, methylene chloride/ethanol 10:1 5 (C): silica gel, methylene chloride/methanol 4:1 Example 2.0 0 3-Z-[1 -(4-(Dimethylaminomethyl)anilino)-1 -(4-cyanophenyl)methylenel-6-chloro-2 indolinone 1.07 g of 1-acetyl-3-[1-chloro-1-(4-cyanophenyl)methylene]-6-chloro-2-indolinone (starting material VII) and 0.54 g of 4-(dimethylaminomethyl)aniline (starting material IX.4) are dissolved in 10 ml of dimethylformamide and stirred at 800C for 3 hours. 5 After cooling, 1 ml of 6N aqueous sodium hydroxide is added, and the mixture is stirred at room temperature for 30 minutes. Water is added and the mixture is extracted three times with methylene chloride. The combined organic phases are washed twice with water, dried over sodium sulphate and concentrated using a rotary evaporator, and the product is recrystallized from diethyl ether. !0 Yield: 0.92 g (72% of theory), Rf value: 0.1 (silica gel, methylene chloride/methanol = 9:1)
C
2 5
H
21
CIN
4 0 Mass spectrum: m/z = 427/429 [M-H] !5 Example 3.0 3-Z-[1 -(4-(dimethylaminomethyl)anilino)-1 -(4-iodophenyl)methylenel-6-fluoro-2 indolinone 3.5 g of 1-acetyl-3-(1-methoxy-1-(4-iodophenyl)methylene)-6-fluoro-2-indolinone 0 (starting material V11.1 1) and 1.6 g of 4-(dimethylaminomethyl)aniline (starting 72 material IX.4) are dissolved in 30 ml of dimethylformamide and stirred at 120 0 C for 2 hours. After cooling, the solvent is removed under reduced pressure, the residue is taken up in 30 ml of methanol and 2 spatula tips of sodium methoxide are added. Once a yellow precipitate has formed, this is filtered off with suction from the solvent 5 and the residue is washed with a little methanol and ether and finally dried under reduced pressure at 100*C. Yield: 1.9 g (46% of theory), Rf value: 0.3 (silica gel, methylene chloride/methanol = 9:1) m.p. 243-246 *C 0 C 24
H
21
FIN
3 0 Mass spectrum: m/z = 514 [M+H]* The following compounds of the formula l-3a are prepared analogously to Example 3.0: 5 R4'
R
3 N /H 0 R2 N (1-3a) Ex- Starting Empirical Mass m.p. Rf amp R R3R 4 ' materi formula spectrum [*C] value* le als F VII.5 404 225- 0.20 3.1 -F / -CH 2 -NMe 2
C
24
H
21
F
2
N
3 0 - IX.4 [M-H]~ 227 (A) 3.2 -F F -N(COMe)- VIl.5 491 160- 0.20
(CH
2
)
3 -NMe 2 IX.7 [M+H]* 163 (A) 73 F Me. NMe V.5 518 218- 0.40 3.3 -F 'N C 29
H
29
F
2
N
5 0 2 0 IX.19 [M+H]* 220 (A) H3C r N VII.6 471 106- 0.25 3.4 -F -CH 2 -NMe 2
C
28
H
29
FN
4 0 2 lux, IX.4 [M-H]~ 110 (A)
H
3 C -. O N -N(COMe)- VII.6 558 194- 0.25 3.5 -F C 32
H
36
FN
5
O
3
(CH
2
)
3 -NMe 2 IX.7 [M+H]* 196 (A)
H
3 Cr 0 f-N-Me 3.6 -F N Me, N - VII.6 583 238- 0.25 3.6 - ,'NC 33
H
37
FN
6
O
3 0 IX.19 [M-H]- 240 (A) 0OMe VIl.1 460 173- 0.30 3.7 -F 0 e -CH 2 -NMe 2
C
27
H
26
FN
3 0 3 [M+ 176 (A) IX.4 [M+H]* 176 (A) VII.13 514 198- 0.30 3.8 -F / -CH 2 -NMe 2
C
24
H
21
FIN
3 0 514 203B ~IX.4 [M+H]* 200 (B) O~eVl.7458 195- 0.25 3.9 -F OMe -CH 2 -NMe 2 VII.7 C 27
H
26
FN
3 0 3 IX.4 [M-H]- 198 (A) tBuO.O NH VII.8 517 230- 0.30 3.10 -F -CH 2 -NMe 2
C
3 oH 3 3
FN
4 0 3 IX.4 [M+H]* 240 (A) 74 3.11 -F 0OMe -N(SO 2 Me)- VII.1 567 188- 0.40
(CH
2
)
2 -NMe 2 IX.2 [M+H]* 189 (A) O OMe <"N-Me Me. NN 'j Vll.1 572 200- 0.35 0 IX.19 [M+H]* 203 (C) CN VIl.9 427 130- 0.25 3.13 -F -CH 2 -NMe 2
C
26
H
23
FN
4 0 .' IX.4 [M+H]* 135 (A) OtBu <'N-Me HN40 Me, ./N Vll.10 629 215- 0.35 3.14 -F 0N C 35
H
41
FN
6 0 4 o IX.19 [M+H]* 220 (A) OtBu HN4 0 Vll.10 517 186- 0.35 3.15 -F -CH 2 -NMe 2
C
30
H
33
FN
4 0 3 IX.4 [M+H]* 190 (A) OtBu 0 NH VII.17 531 0.40 3.16 -F -CH 2 -NMe 2
C
31
H
35
FN
4 0 3 n.d. IX.4 [M+H]* (A) OMe 0 Vll.15 488 166- 0.40 3.17 -F -NMe-(COMe)
C
28
H
26
FN
3 0 4 I "' [M+H]* 170 (A) OMe N-Me oMe. rN,_ Vll.15 586 176- 0.30 3.18 -F ,.N 0 C 33
H
36
FN
5 0 4 ' IX.19 [M+H]* 180 (A) 75 OMe 3.19 -F
-N(SO
2 Me)- VII.15 581 195- 0.45
(CH
2
)
2 -NMe 2 IX.2 [M+H]* 198 (A) OMe 3.20 -F -N(COMe)- VII.15 559 100- 0.50
(CH
2
)
3 -NMe 2 IX.7 [M+H]* 104 (A) OMe o Me VII.15 558 132- 0.80 3.21 -F ,N-NOtBu C 32 H34FN 3 0 5 0 IX.18 [M-H]- 137 (D) OMe 0 0 N-Me Vll.15 543 234- 0.60 3.22 -F NV C31H31FN404 IX.30 [M+H]* 236 (A) OMe O N3 Vl.15 497 110- 0.40 3.23 -F ':/N C 29
H
25
FN
4 0 3 lyle IX.16 [M+H]* 115 (A) OMe O VII.15 495 130- 0.60 3.24 -F
-SO
2 Me
C
26
H
23
FN
2 0 5 S [M+H] 137 (A) O rN-Me 3.25 -F OMe Me N_ Vll.7 572 0.60 0 IX.19 [M+H]* (B) 0 3.26 -F OMe -N(SO 2 Me)- V1l.7 567 0.60 3.26 -F C 2 9
H
31
FN
4 0 5 S n.d. - - (CHr2)2-N'~ve2 IX.2 [M+H]* (B) 76 0 OMe 0 'N-Me VII.7 529 201- 0.60 3.27 -F NX C 30
H
29
FN
4 0 4 IX.30 [M+H]* 203 (B) 0 OMe -N(Me)-(CO)- VII.7 517 0.60 3.28 -F C92F44126
CH
2 -NMe 2 IX.10 [M+H]* (B) 0 OMe -N(COMe)- VII.7 531 0.50 3.29 -F CH1F44179
(CH
2
)
2 -NMe 2 IX.6 [M+H]* (B) 0 OMe -N(COMe)- VIl.7 545 0.20 3.30 -F C~ 31
H
33
FN
4 0 4 123
(CH
2
)
3 -NMe 2 IX.7 [M+H]* (B) 0 OMe -N(Me)-(CO)- Vll.7 559 0.20 3.31 -F C,~ 32
H
35
FN
4 0 4 201 - , (CH 2
)
4 -NMe 2 IX.32 [M+H]* (B) 0 OMe VIl.1 403 198- 0.80 3.32 -F -H C 2 4
H
19
FN
2 0 3 [M+H]+ 206 (A) O Oe N Vll.1 483 223- 0.75 3.33 -F 'N C 2 8
H
23
FN
4 0 3 -e IX.16 [M+H]* 226 (A) OMe O N-Me VII.1 529 215- 0.30 3.34 -F N C 3 0
H
29
FN
4 0 4 IX.30 [M+H]* 220 (A) 0,e
-N(SV
2 Me)- Vl.1 581 227- 0.65 3.35 -F (CH 2 )-(CO)- C 2 9
H
2 9
FN
4 0 6 S [M+H]+ 230 (A) NMe 2 77 3.36 -F 0OMe -N(Me)-(CO)- VII.1 517 128- 0.45
CH
2 -NMe 2 IX.10 [M+H]* 130 (A) O - 0 e -N(COMe)- Vll1 474 218- 0.40 3.37 -F -H 3 - C 27
H
24
FN
3 0 4 [+] 2 A CH3 .[M+H]* 223 (A) - - 0 e N(Me)-(CO)- VII.1 531 192- 0.40 3.38 -F CaoH 31
FN
4 0 4 19 (A (CH2)2-NMe2 IX.1 1 [M+H]* 194 (A) o oMe VIl.1 481 205- 0.65 3.39 -F -SO 2 Me C2 5
H
21
FN
2 0 5 S - - [M+-H]* 214 (A) o - 0 e -N(Me)-(CO)- VII.1 545 190- 0.15 3.40 -F 031 H 33
FN
4 0 4
(CH
2
)
3 -NMe 2 IX.33 [M+H]* 193 (A) - e N(COMe)- VII.1 545 184- 0.50 3.41 -F C 31
H
33
FN
4 0 4
(CH
2
)
3 -NMe 2 IX.7 [M+H]* 188 (A) 0 O~e ll.74030.70 3.42 -F OMe -H V.7 C24HFN203 403 114 [M+H]* (B) 0 OeV.7481 0.60 3.43 -F OMe -SO 2 Me V.7C2H21 FN20S 129 [M+H]* (B) 0 OMe N VI1.7 483 0.60 3.44 -F ' N 0 28
H
23
FN
4 0 3 125 -e IX.16 [M+H]* (B) 78 o
-N(SO
2 Me)- VII.7 581 0.60 3.45 -F OMe (CH 2 )-(CO)- C 29
H
29
FN
4 0 6 S 163
.
NMe 2 IX.8 [M+H]* (B) 0 OMe -N(Me)-(CO)- Vll.7 545 0.10 3.46 -F ,,~C 31
H
33
FN
4 0 4 101 - (CH 2
)
3 -NMe 2 IX.33 [M+H]* (B) 0 3.47 OMe -N(Me)-(CO)- VII.7 531 0.20 -F47 -F C 30
H
31
FN
4 0 4 161
(CH
2
)
2 -NMe 2 IX.1 1 [M+H]* (B) MeO 0'N-Me Me NVIl.14 586 181- 0.20 3.48 -F Me.N C 30
H
31
FN
4 0 4 O IX.19 [M+H]* 183 (B) MeO 0 3.49 -F
-N(SO
2 Me)- VII.14 581 158- 0.35
(CH
2
)
2 -NMe 2 IX.2 [M+H]* 160 (B) MeO 0 3.50 -F -N(Me)-(CO)- VII.14 531 0.40 3.50 -F CaoH 31
FN
4 0 4 nd
CH
2 -NMe 2 IX.10 [M+H]* (B) MeO 0 -N(COe)- ll.1 5590.50 3.51 -F -N(COMe)- VII.14 n.d.
(CH
2
)
3 -NMe 2 IX.7 [M+H]* (E) tBuOy-o fN-Me NH MeNa VIl.8 629 0.35 3.52 -F Me N C 35
H
41
FN
6 0 4 n.d. 0 IX.19 [M+H]* (A) 79 OrCH 3 HN -NMe-(CO)- VII.26 473 122- 0.50 3.53 -FC2HFN0
CH
3 . [M+H]* 126 (F) OrCH 3 HN -N(COMe)- VII.26 544 80- 0.25 3.54 -FC3H4sO
(CH
2
)
3 -NMe 2 IX7 [M+H]* 83 (A) OyCH3 HN -N(SO 2 Me)- VII.18 566 190- 0.30 3.55 -F C 2 9
H
32 FNsO 4 S
(CH
2
)
2 -NMe 2 IX.2 [M+H]* 195 (A) OtCH 3 HN -N(Me)-(CO)- VII.18 516 238- 0.30 3.56 -F C 29
H
30 FNsO 3
CH
2 -NMe 2 IX.10 [M+H]* 241 (G) OMe 0 VII.15 488 205- 0.55 3.57 -F -(CH 2
)
2 -NMe 2
C
29
H
30
FN
3 0 3 IX.5 [M+H]* 208 (G) OMe 3.58 -F -N(Me)-(CO)- Vl.15 543 196- 0.20 3.58-F031 H 31
FN
4 0 4
(CH
2
)
2 -NMe 2 IX.1 1 [M-H]- 202 (A) OMe 3.59 -F -N(Me)-(CO)- VII.15 531 177- 0.30
CH
2 -NMe 2 IX.10 [M+H]* 182 (A) EtO VIl.19 500 100- 0.35 3.60 -F -(CH 2
)
2 -NMe 2
C
30
H
32
FN
3 0 3 IX.5 [M-H]- 105 (B) 80 OMe 3.61 -F -N(COMe)- VII.15 545 167- 0.40
(CH
2
)
2 -NMe 2 IX.6 [M+H]* 169 (A) EtO 3.62 -F -N(Me)-(CO)- VII.19 571 0.35
(CH
2
)
3 -NMe 2 IX.33 [M-H]- (A) EtO O -N(Me)-(CO)- VII.19 585 0.40 3.63 -F C 34
H
39
FN
4 0 4 n.d.
(CH
2
)
4 -NMe 2 IX.32 [M-H]- (A) EtO N VII.19 511 95- 0.25 3.64 -F - C 30
H
27
FN
4 0 3 Me IX.16 [M+H]* 105 (B) OMe 3.65 -F -N(Me)-(CO)- VII.15 573 173- 0.20
(CH
2
)
4 -NMe 2 IX.32 [M+H]* 175 (A) OMe o VII.15 417 168- 0.65 3.66 -F -H C 25
H
21
FN
2 0 3 [M+Hf 174 (A) OMe O VII.15 500 168- 0.40 3.67 -F /N I.2 C30H30FN303 [+] 7 B 'IX.22 [M+H]* 173 (B) OMe O VII.15 502 0.45 3.68 -F -CH2-NEt2 . C3H32FN303 +n.d. IX.1 H 2
F
3 0 [M+H]* (B) 81 OMe 0 H VII.15 544 0.30 3.69 -F -yOtBu C 31
H
32
FN
3 0 5 n.d. 0 IX.12 [M-H]~ (G) 0 O~eVl.7472 165- 0.25 3.70 -F OMe -(CH 2
)
2 -NMe 2 VII.7 C 28
H
28
FN
3 0 3 170.(B IX.5 [M-H]- 170 (B) 0 OMe VIl.1 472 193- 0.25 3.71 -F -(CH 2
)
2 -NMe 2
C
28
H
2 8
FN
3 0 3 - IX.5 [M-H]- 197 (B) EtO Vll.19 488 48- 0.45 3.72 -F -CH 2 -NMe 2
C
29
H
3 0
FN
3 0 3 / -1' -IX.4 [M+H]* 52 (B) OMe o VII.20 504/506 156- 0.30 3.73 -CI -(CH 2
)
2 -NMe 2
C
29
H
30
CIN
3 0 3 16- 0.3 ~' IX.5 [M+H]* 160 (H) OMe O N4 V-.20 513/515 0.40 3.74 -CI
C
29
H
25
CIN
4 0 3 + 110 Mye IX.16 [M+H] (H) OMe 3 CVll.20 490/492 173- 0.70 3.75 -C-CH2-NMe2 IX.4 C 28
H
28
CIN
3 0 3 [M+H]+ 175 (1) OEt O VII.21 488 158- 0.35 3.76 -F -CH 2 -NMe 2
C
29
H
30
FN
3 0 3 91' -IX.4 [M+H]* 161 (B) 82 MeO O N-Me VII.14 529 147- 0.50 3.77 -F N C 31
H
33
FN
4 0 3 [M+H]+ 150 (1) IX.14 MeO O N VII.14 497 182- 0.60 3.78 -F NC29H2FN403 IX.15 [M+H]* 185 (K) OMe O -N-Me Vll.15 529 0.35 3.79 -F NN eC 31
H
33
FN
4 0 3 59 184 03 IX.14 [M+H]* (B) OMe O N VII.15 497 0.45 3.80 -F N. C 29
H
25
FN
4 0 3 233 X.5[M+H]* (B) OMe 0 -CH 2 -NMe- VII.15 531 0.40 3.81 -F C 3 1 HasFN 4 0 3 120
(CH
2
)
2 -NMe 2 IX.17 [M+H]* (B) EtO
-CH
2 -NMe- VI.19 545 0.40 3.82 -F C 32
H
3 7
FN
4 0 3 n .d.
(CH
2
)
2 -NMe 2 IX.17 [M+Hj (K) OMe o VIl.20 516/518 195- 0.30 3.83 -CI .
1 -N2I C 30
H
30
CIN
3 0 3 38 IX.22 [M+H]* 197 (H) EtO VIl.19 431 156- 0.80 3.84 -F -H C 26
H
23
FN
2 0 3 [M+H]+ 160 (M) 83 EtO 0 H Vll.19 560 0.50 3.85 -F -(NyOtBu C 32 H34FN 3 0 5 [M+H]s n.d. O IX.12 (L) EtO O Me Vll.19 574 0.60 3.86 -F (NyrOtBu C 33
H
3 6
FN
3 0 5 + n.d. O IX.18 [M+H] (L) MeO O VI1.22 476 0.25 3.87 -F -CH 2 -NMe 2
C
27
H
2 6
FN
3 0 4 129 - IX.4 [M+H]* (B) OMe O0- VII.23 476 0.25 3.88 -F O -CH2-NMe2 C 27
H
26
FN
3 0 4 155 ~2<. IX.4 [M+H]* (B) OEt VIl.24 504 0.20 3.89 -F O -CH 2 -NMe 2
C
29
H
30
FN
3 0 4 n.d. IX.4 [M+H]* (B) OMe 0 VI1.26 560/562 230- 0.45 3.90 -Br .{N' C 30
H
30 BrN 3 0 3 9 -r IX.22 [M+H]* 235 (B) OMe o VII.26 534/536 178- 0.35 3.91 -Br -CH 2 -NMe 2
C
28
H
28 BrN 3 03 IX.4 [M+H]* 180 (B) OMe O VII.26 562/564 173- 0.40 3.92 -Br -CH 2 -NEt 2
C
3 oH 32 BrN 3 03 [M+HJ+ 176 (B) 84 *Eluent mixtures: (A): silica gel, methylene chloride/methanol/ammonia 9:1:0.1 (B): silica gel, methylene chloride/methanol 9:1 (C): silica gel, methylene chloride/methanol/ammonia 8:1:0.1 5 (D): silica gel, methylene chloride/methanol/ammonia 10:1:0.1 (E): silica gel, methylene chloride/methanol/ammonia 5:1:0.01 (F): silica gel, ethyl acetate/methanol/ammonia = 9:1:0,1 (G): alumina, methylene chloride/methanol = 19:1 (H): silica gel, methylene chloride/methanol/ammonia 9:1:0.01 0 (1): silica gel, methylene chloride/methanol 5:1 (K): alumina, methylene chloride/ethanol = 20:1 (L): silica gel, petroleum ether/ethyl acetate 1:1 (M): silica gel, petroleum ether/ethyl acetate 1:2 5 The following compounds of the formula 1-3b are prepared analogously to Example 3.0: R4' R3' N / H 0 R2 N (1-3b) Ex- Starting Empirical Mass m.p. Rf amp R R R 4 ' materi formula spectrum [*C] value* le als OMe 0 VII.15 474 176- 0.40 3.93 -F -CH 2 -NMe 2 C2 8
H
28
FN
3 0 3 / ii' -IX.3 [M+H]* 179 (A) 85 EtO O VIl.19 486 0.45 3.94 -F -CH 2 -NMe 2
C
29
H
3 0
FN
3 0 3 n.d. IX.3 [M-H]- (B) OMe O VII.20 490/492 163- 0.40 3.95 -Cl -CH 2 -NMe 2
C
28
H
28
CIN
3 0 3 [M+H]+ 165 (A) IX.3 [+] 6 A *Eluent mixtures: (A): silica gel, methylene chloride/methanol 9:1 (B): silica gel, methylene chloride/methanol/ammonia 9:1:0.1 5 Example 4.0 3-Z-[1 -(4-(Dimethylaminomethyl)anilino)-1 -(3,4-dimethoxyphenyl)methylene]-6 0 cyano-2-indolinone 130 mg of 1 -acetyl-3-(1 -methoxy-1 -(3,4-dimethoxyphenyl)methylene)-6-cyano-2 indolinone (starting material VII.4) and 58 mg of 4-(dimethylaminomethyl)aniline (starting material IX.4) are dissolved in 5 ml of dimethylformamide and stirred at 80 0 C for 2 hours. After cooling, the solvent is removed under reduced pressure and the 5 residue is purified on a silica gel column using the mobile phase methylene chloride/methanol 9:1. Yield: 21 mg (12% of theory), Rf value: 0.35 (silica gel, methylene chloride/methanol = 9:1) m.p. 265 *C 0 C 2 7
H
26
N
4 0 3 86 Example 5.0 3-Z-[1 -(4-(N-Methyl-N-methylsulphonylamino)anilino)-1 -(3-(2-methoxycarbonyl vinyl)phenyl)methylenel-6-chloro-2-indolinone 5 580 mg of 3-Z-[1 -(4-(N-methyl-N-methylsulphonylamino)anilino)-1 -(3-iodophenyl) methylene]-6-chloro-2-indolinone (starting material 1.0) and 140 ml of methyl acrylate are dissolved in 20 ml of acetonitrile and 11 ml of dimethylformamide, and 11 mg of palladium(II) acetate, 2 ml of triethylamine and 30 mg of tri-ortho-tolylphosphine are added. Under nitrogen as protective gas, the solution is stirred at 90 0 C for 10 hours. 0 After cooling, the solution is filtered through Celite, the solvent is removed under reduced pressure and the residue is purified on a silica gel column using the mobile phase methylene chloride/methanol 20:1. Yield: 450 mg (84% of theory), Rf value: 0.30 (silica gel, toluene/ethyl acetate = 1:1) 5 m.p. 228-232 *C
C
27
H
2 4
CIN
3 0 5 S Mass spectrum: m/z = 537/539 [M]* The following compounds of the formula 1-5 are prepared analogously to Example .0 5.0: R4'
R
3 N / H 0 R N (1-5) H(-5 87 Start Ex ampi R 2 Ring Empirical Mass m.p. Rr mate- formula spectrum [*C] value* e rials O OMe 486/488 150- 0.50 5.1 -CI -CH 2 -NMe 2 1.1 C 28
H
26
CIN
3 0 3 [M-H]- 155 (A)
NH
2 455 269- 0.20 5.2 -F -CH 2 -NMe 2 3.0 C 27
H
2 5
FN
4 0 2 [M-H]~ 270 (B) OMe 0 470 205- 0.65 5.3 -F -CH 2 -NMe 2 3.0 C 28
H
2 6
FN
3 0 3 [M-H)~ 208 (A) 0 OMe 472 138- 0.45 5.4 -F -CH 2 -NMe 2 1.1 C 2 8
H
2 6
FN
3 0 3 + 140 (A) *Eluent mixtures: (A): silica gel, methylene chloride/methanol 5:1 (B): silica gel, methylene chloride/methanol/ammonia 9:1:0.01 5 Example 6.0 3-Z-[1 -(4-Dimethylaminomethylanilino)-1 -(3-(2 methoxycarbonylethyl)phenyl)methylenel-6-chloro-2-indolinone 0 1.0 g of 3-Z-[1-(4-(dimethylaminomethyl)anilino)-1-(3-(2-methoxycarbonyl vinyl)phenyl)methylene]-6-chloro-2-indolinone (starting material 5.1) is dissolved in 100 ml of methanol, and 200 mg of 10 per cent palladium/carbon as catalyst are added. The mixture is then hydrogenated at room temperature and a hydrogen 88 pressure of 50 psi for 6 hours. After the reaction has ended, the catalyst is filtered off, the solvent is removed under reduced pressure and the residue is dried under reduced pressure at 100*C. Yield: 900 mg (90% of theory), 5 Rf value: 0.40 (silica gel, methylene chloride/methanol = 9:1) m.p. 160 *C
C
2 8
H
2 8
CIN
3 0 3 Mass spectrum: m/z = 490/492 [M+H]* 0 The following compounds of the formula 1-6 are prepared analogously to Example 6.0: R4' R3 N H i N R2H (1-6) Start Ex am- 2 3 4 ing Empirical Mass m.p. Rf am- R R R' mate- formula spectrum [ C] value* rials O OMe -N(e)-538/540 148- 0.50 6.1 -Cl -N(Me)- 5.0 C 27
H
26
CIN
3 0 5 S / N SO 2 Me [M-H]- 150 (A) 89
NH
2 0 459 0.70 6.2 -F -CH 2 -NMe 2 5.2 C 27
H
27
FN
4 0 2 150 / [M+H]* (B) OMe 0 474 0.35 6.3 -F -CH 2 -NMe 2 5.3 C 28
H
28
FN
3 0 3 140 / [M+H]* (A) 0 OMe 474 140- 0.30 6.4 -F -CH 2 -NMe 2 5.4 C 28
H
28
FN
3 0 3 [M+H]+ 142 (A) *Eluent mixtures: (A): silica gel, methylene chloride/methanol 9:1 (B): silica gel, methylene chloride/methanol/ammonia 5:1:0.01 5 Example 7.0 3-Z-[1 -(4-Dimethylaminomethylanilino)-1 -(4-aminomethylphenyl)methylenel-6-chloro 0 2-indolinone 900 mg of 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4-cyanophenyl)methylene]-6 chloro-2-indolinone (starting material 2.0) are dissolved in 20 ml of methylene chloride and 30 ml of methanolic ammonia and, as catalyst, 200 mg of Raney nickel are added. The mixture is then hydrogenated at room temperature and a hydrogen 5 pressure of 50 psi for 2 hours and 15 minutes. After the reaction has ended, the catalyst is filtered off, the solvent is removed under reduced pressure and the residue is washed with a little methanol and diethyl ether. To liberate the base, the residue is taken up in 1 N aqueous sodium hydroxide solution and extracted four times with methylene chloride/methanol 9:1. The combined organic phases are washed with 0 water and dried over sodium sulphate. The product is washed with a little diethyl ether and dried under reduced pressure.
90 Yield: 680 mg (75% of theory), Rf value: 0.60 (silica gel, methylene chloride/methanol/ammonia = 9:1:0.1) m.p. 211-214 *C
C
2 5
H
2 5
CIN
4 0 5 Mass spectrum: m/z = 433/435 [M+H]* Example 8.0 0 3-Z-f -(4-(N-((4-Methylpiperazin-1 -yl)methylcarbonyl)-N-methylamino)anilino)-1 -(4 aminomethylphenyl)methylenel-6-chloro-2-indolinone 1.39 g of 1 -acetyl-3-Z-[1 -(4-(N-((4-methylpiperazin-1 -yl)methylcarbonyl)-N methylamino)anilino)-1 -(4-cyanophenyl)methylene]-6-chloro-2-indolinone are dissolved in 20 ml of methylene chloride and 30 ml of methanolic ammonia and, as 5 catalyst, 200 mg of Raney nickel are added. The mixture is then hydrogenated at room temperature at a hydrogen pressure of 50 psi for 2 hours. After the reaction has ended, the catalyst is filtered, the solvent is removed under reduced pressure and the residue is washed with a little methanol and diethyl ether. To liberate the base, the residue is taken up in 1 N aqueous sodium hydroxide solution and extracted four 0 times with methylene chloride/methanol 9:1. The combined organic phases are washed with water and dried over sodium sulphate. The product is purified on a silica gel column using, as mobile phase, a gradient of methylene chloride and methylene chloride/methanol/ammonia 8:1:0.1. The product is washed with a little diethyl ether and dried under reduced pressure. 5 Yield: 700 mg (54% of theory), Rf value: 0.15 (silica gel, methylene chloride/methanol/ammonia = 9:1:0.1) m.p. 232-235 *C
C
3 0
H
3 3
CIN
6 0 2 Mass spectrum: m/z = 544/546 [M]* 0 91 Example 9.0 3-Z-[1 -(4-(Dimethylaminomethyl)anilino)-1 -(3-aminomethylphenvl)methylenel-6 fluoro-2-indolinone 5 2.72 g of 3-Z-[1-(4-(dimethylaminomethyl)anilino)-1-(3-(N-tert-butoxycarbonyl aminomethyl)phenyl)methylene]-6-fluoro-2-indolinone (starting material 3.10) are dissolved in 50 ml of methylene chloride, and 10 ml of trifluoroacetic acid are added. The mixture is stirred at room temperature for 3 hours. After this time, most of the solvent is removed under reduced pressure and the residue is taken up in ethyl 0 acetate and washed twice with 1 N aqueous sodium hydroxide solution. The organic phase is dried over sodium sulphate, the solvent is removed using a rotary evaporator and the residue is purified on a silica gel column using the mobile phase methylene chloride/methanol/ammonia 9:1:0.1. The product is washed with a little diethyl ether and dried under reduced pressure. 5 Yield: 1.77 g (81 % of theory), Rf value: 0.25 (silica gel, methylene chloride/methanol/ammonia 9:1:0.1) m.p. 168-175 *C C2 5
H
25
FN
4 0 Mass spectrum: m/z = 415 [M-H]~ !0 The following compounds of the formula 1-9 are prepared analogously to Example 9.0: R4' R3 N /H I 0 R2 N (1-9) 92 Start Ex am- 2 3 ing Empirical Mass m.p. Rf am- R R R mate- formula spectrum [OCI value* pie rials
NH
2 431 155- 0.45 9.1 -F -CH 2 -NMe 2 3.16 C 2 6
H
27
FN
4 0 [31 160.(C [M+H]* 160 (C)
N
2 417 203- 0.25 9.2 -F -CH 2 -NMe 2 3.15 C 2 5
H
25
FN
4 0 [17 207 (A) [M+H]* 207 (A)
NH
2 N NMe 529 170- 0.15 9.3 -F H 3 C ,N 3.14 C 30
H
33
FN
6 0 2 0 -[M+H]* 175 (A) OH 0 ; 446 245- 0.20 9.4 -F -CH 2 -NHMe 10.11 C 26
H
24
FN
3 0 3 [46 25 (D) [M+H]* 251 (D)
NHCH
3 0 A 459 239- 0.30 9.5 -F -CH 2 -NHMe 11.22 C 2 6
H
24
FN
3 0 3 [59 23 (A) [M+H]* 243 (A)
NH
2 N NMe 529 9.6 -F Ha 3 C, , 3.52 C 3 oH 33
FN
6 0 2 . n.d. n.d. - -0, [M+H]~ OMe 0 444 158- 0.25 9.7 -F -CH 2
-NH
2 3.69 C 26
H
24
FN
3 0 3 [M-H]- 163 (A) 93 EtO O 460 205- 0.30 9.8 -F -CH 2
-NH
2 3.85 C 27
H
26
FN
3 0 3 [M+H]+ 210 (B) EtO O 474 148- 0.30 9.9 -F -CH 2 -NHMe 3.86 C 28
H
28
FN
3 0 3 / "" [M+H]* 150 (B) *Eluent mixtures: (A): silica gel, methylene chloride/methanol/ammonia 9:1:0.1 (B): silica gel, methylene chloride/methanol/ammonia 9:1:0.01 5 (C): silica gel, methylene chloride/methanol/ammonia 8:2:0.2 (D): Reversed phase RP8, methanol/sodium chloride solution(5%) = 3:2 Example 10.0 0 3-Z-[1 -(4-Dimethylaminomethylanilino)-1 -(3-(2-carboxyethyl)phenyl)methylenel-6 chloro-2-indolinone 900 mg of 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(2 methoxycarbonylethyl)phenyl)methylene]-6-chloro-2-indolinone (starting material 6.0) are dissolved in 10 ml of ethanol, and 5 ml of 1 N aqueous sodium hydroxide solution 5 are added. The mixture is stirred at room temperature for 5 hours. After cooling, 5 ml of 1 N hydrochloric acid are added. The resulting precipitate is filtered off with suction and washed with water. Yield: 830 mg (95% of theory), Rf value: 0.50 (reversed phase RP8, methanol/sodium chloride solution (5%) = 4:1) 0 m.p. 210-215 *C
C
27
H
2 6
CIN
3 0 3 Mass spectrum: m/z = 476/478 [M+H]* 94 The following compounds of the formula 1-10a are prepared analogously to Example 10.0: 4' R3 N /H I N R2 H (1-10a) 5 H Start Ex am- 2R 4 ' ing Empirical Mass m.p. Rf mate- formula spectrum [0C] value* pie rials OH O 460 0.65 10.1 -F -CH 2 -NMe 2 6.3 C 27
H
26
FN
3 0 3 250 I [M+H]* (A) OH 0 444 278- 0.10 10.2 -F -CH 2 -NMe 2 3.9 C 26
H
24
FN
3 0 3 [M-H]~ 282 (B) O OH 458 198- 0.20 10.3 -F -CH 2 -NMe 2 6.4 C 27
H
26
FN
3 0 3 [M-H]- 200 (C) 0 OH 10.4 -F -CH 2 -NMe 2 3.7 C 26
H
24
FN
3 0 3 [M-H]- 216 (D) 95 0OH rNMe O OH4H N N e558 260- 0.20 10.5 -F 3.12 C 31
H
32
FN
5 0 4 / [M+H]* 263 (D) O H -N(SO 2 Me)- 553 246- 0.30 10.6 -F (S 2 Me) 3.11 C 28
H
29
FN
4 0 5 S (CH2)2-NMe2 [M+H]* 249 (D) OH O-NMe-(CO)- 474 286- 0.60 10.7 -F 3.17 C 27
H
24
FN
3 0 4
CH
3 [M+H]* 290 (E) O OH rNMe HO ~N J 570 215- 0.20 10.8 -F 3 'N, 3.18 C 32 H34FN 5
O
4 0 [M-H]- 222 (D) OH 0 -N(SO 2 Me)- 567 160- 0.20 10.9 -F 3.19 C 29
H
31
FN
4 0 5 S
(CH
2
)
2 -NMe 2 [M+H]* 165 (D) OH O-N(COMe)- 545 153- 0.15 10.10 -F 3.20 C 31
H
33
FN
4 0 4
(CH
2
)
3 -NMe 2 [M+H]* 158 (D) OH O Me 546 215- 0.60 10.11 -F N OtBu 3.21 C 31
H
32
FN
3 0 5 0 [M+H]* 219 (E) OH 0 O N-Me 529 179- 0.25 10.12 -F 0N 3.22 C 30
H
29
FN
4 0 4 [ [M+H]* 186 (E) 96 OH 0O- 483 264- 0.65 10.13 -F N 3.23 C 28
H
23
FN
4 0 3 483 267 (E) Me [M+H]* 267 (E) OH 0481 146- 0.70 10.14 -F -SO 2 Me 3.24 C 25
H
21
FN
2 0 5 S 481 146 (.7 / "' [M+H]* 155 (E) OH O 'NM 515 0.70 10.15 -F 0 N 3.27 C 29
H
27
FN
4 0 4 251 - -[M+H]+ (E) OH /NMe 10.16 -F 0 H N 3.25 C 31
H
32
FN
5 0 4 558 234 0.10 0 [M+H]+ (E) OH 10.17 -F -N(Me) CO)- 3.28 C 28
H
27
FN
4 0 4 203 0.60 I-- CH 2 -N Me 2 [M+Hf+ (E) OH 10.18 -F -N(Me)-(CO)- 3.31 C 31
H
33
FN
4 0 4 251 n.d. I-- (CH 2
)
4 -N Me 2 MH OH 0 387 0.60 10.19 -F -H 3.42 C 23
H
17
FN
2 0 3 130 [M-H] (E) OH 0 467 0.55 10.20 -F -SO 2 Me 3.43 C 24
H
19
FN
2 0 5 S 467 139 0.5 - - [M+H]* (E) 97 OH O Ni 469 0.35 10.21 -F N 3.44 C 27
H
21
FN
4 0 3 157 n~e [M+H]* (E) O OH -N(SO2Me)- 567 0.55 10.22 -F (CH 2 )-(CO)- 3.45 C 28
H
27
FN
4 0 6 S 183 -. - N~e 2 [M+H]* (E) NMe2 OH389 237- 0.10 10.23 -F -H 3.32 C 23
H
17
FN
2 0 3 [M+H]* 240 (D) 0HN 469 259- 0.15 10.24 -F e 3.33 (27H21FN403 He [M+H]* 265 (D) 10.25 -F OH -N(COMe)- 3.41 C30H31FN404 531 274- 0.15 (CH2)3-NMe23[M+H]* 278 (D) 0 O O H -N(Me)-(CO)- 503 258- 0.20 10.26 -F CH 2 -NMe 2 3.36 C 28
H
27
FN
4 0 4 [ +] 2 64 (D) -H-Ne [M+H]+ 264 (D) 0 O O 'N-Me 515 279- 0.15 10.27 -F N N-Me 3.34 0 29
H
27
FN
4 0 4 - -[M+H]+ 282 (D) 0 O 467 260- 0.35 10.28 -F -SO 2 Me 3.39 C 24
H
1 9
FN
2 0 5 S [M+H 266 (F) 01OH 10.29 -F / COe) 3.37 C 26
H
22
FN
3 0 4 46 29-03 - H 3 [M+H]+ 294 (F) 98 OH
-N(SO
2 Me)- 567 238- 0.30 10.30 -F CH 2 -(CO)- 3.35 C 28
H
27
FN
4 0 6 S [M+H]+ 242 (F) -. NMe 2 0 O O H -N(Me)-(CO)- 517 250- 0.35 10.31 -F 3.38 C 29
H
29
FN
4 0 4
(CH
2
)
2 -NMe 2 [M+H]* 255 (F) 0 O 10.32 -F -N(Me)-(CO)- 3.40 C 3 oH 31
FN
4 0 4 531 184- 0.25
(CH
2
)
3 -NMe 2 [M+H]* 190 (F) 0 OH fNMe 10.33 -F H3C N 3.48 C 32 H34FN 5 O4 572 170- 0.40 O [M-H]- 175 (C) OH 10.34 -F 0 -N(SO2Me)- 3.26 C 2 8
H
29
FN
4 0 5 S 553 180 0.60
(CH
2
)
2 -NMe 2 [M+H]* (C) O OH -N(O2M)-567 196- 0.30 10.35 -F -N(SO 2 Me)- 3.49 C 2 9
H
3 1
FN
4 0 5 S
(CH
2
)
2 -NMe 2 [M+H]* 199 (C) O OH 10.36 -F -N(Me)-(CO)- 3.50 C29H29FN404 517 150 0.20
CH
2 -NMe 2 [M+H]* (C) 0 OH -N(O~)-545 206- 0.30 10.37 -F -N(COMe)- 3.51 C 31
H
3 3
FN
4 0 4 545 20 (A)
(CH
2
)
3 -NMe 2 [M+H]* 210 (A) 99 OH O-N(Me)-(CO)- 517 231- 0.60 10.38 -F H-N Me 2 3.59 C 29
H
29
FN
4 0 4 [ + ] 23 6 (A) / " CH 2 -NMe 2 [M+H]+ 236 (A) OH 474 218- 0.50 10.39 -F
-(CH
2
)
2 -NMe 2 3.57 C 28
H
28
FN
3 0 3 [M+H]* 222 (A) OH 10.40 -F 0 -N(Me)-(CO) 3.58 C 3 oH 31
FN
4 0 4 531 215- 0.50
(CH
2
)
2 -NMe 2 [M+H]* 218 (A) O OH 474 172- 0.15 10.41 -F
-(CH
2
)
2 -NMe 2 3.60 C 28
H
28
FN
3 0 3 [M+H]* 177 (G) OH 10.42 -F 0 -N(COMe)- 3.61 C30H31FN404 531 230- 0.50
(CH
2
)
2 -NMe 2 [M+H]* 234 (A) 0 OH 10.43 -F -N(Me)-(CO)- 3.62 C 31
H
33
FN
4 0 4 545 170- 0.30
(CH
2
)
3 -NMe 2 [M+H]* 175 (E) 0 OH 10.44 -F -N(Me)-(CO)- 3.63 C 32
H
35
FN
4 0 4 559 142- 0.10
(CH
2
)
4 -NMe 2 [M+H]* 146 (G) 0 OH N3 483 262- 0.20 10.45 -F N 3.64 C 28
H
23
FN
4 0 3 Mle [M+H]* 269 (E) 100 OH 0 -N(Me)-(CO)- 559 234- 0.30 10.46 -F 3.65 C 32
H
35
FN
4 0 4
(CH
2
)
4 -NMe2 [M+H]* 236 (A) OH O 403 231- 0.20 10.47 -F -H 3.66 C 24
H
19
FN
2 0 3 [M+H]+ 233 (A) OH 486 205- 0.10 10.48 -F N 3.67 C 2 9
H
2 8
FN
3 0 3 I [M+H]* 210 (E) OH 0 488 145- 0.15 10.49 -F -CH 2 -NEt 2 3.68 C 2 9
H
3 0
FN
3 0 3 [M+H]* 150 (E) OH 0 430 280- 0.05 10.50 -F -CH 2
-NH
2 9.7 C 2 5 H22FN 3 03 [M-H]- 285 (H) OH O 460 273- 0.15 10.51 -F
-(CH
2
)
2 -NMe 2 3.70 C 27
H
26
FN
3 0 3 [M+H]* 276 (E) 0 OH 460 230- 0.05 10.52 -F -(CH 2
)
2 -NMe 2 3.71 C 2 7
H
26
FN
3 0 3 [M+H]+ 235 (E) OH 0 490/492 255- 0.50 10.53 -CI -(CH 2
)
2 -NMe 2 3.73 C2 8
H
28
CIN
3 0 3 / "' [M+H]* 258 (A) 101 OH 1054 -CIN 499/501 296- 0.50 1.4-l/N 3.74 C 28
H
23 C1N 4 0 3 [+] 0 A Mye [M+H]* 300 (A) OH O 476/478 228- 0.50 10.55 -Cl -CH 2 -NMe 2 3.75 C 27
H
26
CIN
3 0 3 [M6/47 230.(A [M+H]* 230 (A) O OH '--N-Me 515 210- 0.40 10.56 -F N 3.77 C 30
H
31
FN
4 0 3 515 210 (.4 [M+H]* 215 (A) O OH N 483 240- 0.50 10.57 -F 3.78 C 28
H
23
FN
4 0 3 I ~ [M+H]* 245 (A) 0 OH -H-e-517 0.30 10.58 -F -CH 2 -NMe- 3.82 C 30
H
33
FN
4 0 3 n.d.
(CH
2
)
2 -NMe 2 [M+H]* (1) OH 010.59 -F N N-Me 515 0.35 10.59 -F N 3.79 C 3
H
31
FN
4 0 3 275 [M+H]* (A) OH 0 -IN 483 0.55 10.60 -F rN: 3.80 C 28
H
23
FN
4 0 3 280 [M+H]+ (A) OH 1060C N7 3.83 C2H8I33502/504 260- 0.50 10.61 28LCI' /-N [M+H]+ 266 (A) 102 OH
O-CH
2 -NMe- 517 0.05 10.62 -F 3.81 C 3 oH 33
FN
4 0 3 n.d.
(CH
2
)
2 -NMe 2 [M+H] (E) HO O 403 110- 0.60 10.63 -F -H 3.84 C 24
H
19
FN
2 0 3 [M+H]+ 112 (K) HO O 432 260- 0.60 10.64 -F -CH 2
-NH
2 9.8 C 25
H
22
FN
3 0 3 I [M+H]* 263 (A) HO 0 446 265- 0.60 10.65 -F -CH 2 -NHMe 9.9 C 26
H
24
FN
3 0 3 [M+-H]* 270 (A) HO OJ 462 0.10 10.66 -F -CH 2 -NMe 2 3.87 C 26
H
24
FN
3 0 4 250 [M+H]* (M) OH 0 462 0.15 10.67 -F O -CH2-NMe2 3.88 C2 6
H
24
FN
3 0 4 [M+H], 247 (M) OH 10.68 -Br 3.90 C 29
H
28 BrN 3 0 3 546/548 290- 0.30 [M+H]* 293 (E) OH 0 520/522 243- 0.25 10.69 -Br -CH 2 -NMe 2 3.91 C 27
H
26 BrN 3 03 / "' [M+H]* 246 (E) 103 OH 548/550 252- 0.35 10.70 -Br -CH 2 -NEt 2 3.92 C 29
H
30 BrN 3 03 [M+H]* 255 (E) *Eluent mixtures: (A): reversed phase RP8, methanol/sodium chloride solution (5%) = 4:1 (B): silica gel, methylene chloride/methanol = 8:2 5 (C): silica gel, methylene chloride/methanol = 5:1 (D): reversed phase RP8, methanol/sodium chloride solution (5%) = 3:2 (E): silica gel, methylene chloride/methanol = 9:1 (F): reversed phase RP8, methanol/sodium chloride solution (5%) = 7:3 (G): silica gel, methylene chloride/methanol/ammonia = 9:1:0.1 0 (H): alumina, methylene chloride/methanol = 19:1 (1): reversed phase RP8, methanol/sodium chloride solution (5%) = 4:2 (K): silica gel, petroleum ether/ethyl acetate = 1:1 (M): silica gel, methylene chloride/methanol = 4:1 5 The following compounds of the formula 1-10b are prepared analogously to Example 10.0: R4'
R
3 N / H R2 N (1-1Ob)
H
104 Start Ex am- R2 R3 R4' ing Empirical Mass m.p. Rr mate- formula spectrum [*C] value* pl e rials OH O460 0.20 10.71 -F -CH 2 -NMe 2 3.93 C 27
H
26
FN
3 0 3 150 [M+H]* (A) O OH 460 105- 0.30 10.72 -F -CH 2 -NMe 2 3.94 C 27
H
26
FN
3 0 3 [60 109 (B) }/ [M+H]* 109 (B) OH 476/478 230- 0.50 10.73 -Cl -CH 2 -NMe 2 3.95 C 27
H
26
CIN
3 0 3 [M+H]* 235 (C) *Eluent mixtures: (A): silica gel, methylene chloride/methanol = 5:1 (B): silica gel, methylene chloride/methanol = 9:1 5 (C): reversed phase RP8, methanol/sodium chloride solution (5%) = 4:1 Example 11.0 0 3-Z-[1 -(4-Dimethylaminomethylanilino)-1 -(3-(2-carbamoylethyl)phenyl)methylenel-6 chloro-2-indolinone 480 mg of 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(3-(2 carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone (starting material 10.0), 350 mg of TBTU, 150 mg of HOBt and 420 ml of triethylamine are dissolved in 10 ml 5 of dimethylformamide, and 620 mg of N-hydroxysuccinimide ammonium salt are added. The mixture is stirred at room temperature for 20 hours. After removal of the solvent under reduced pressure, the residue is suspended in a little ethyl acetate and 105 water, filtered off and washed with water. The residue is purified on an alumina column (activity 2-3) using the mobile phase methylene chloride/ethanol 20:1. The product is recrystallized from diethyl ether and dried under reduced pressure at 100 C. 5 Yield: 370 mg (78% of theory), Rf value: 0.40 (alumina, methylene chloride/ethanol = 20:1) m.p. 222-225 *C
C
27
H
27
CIN
4 0 2 Mass spectrum: m/z = 475/477 [M+H]* 0 The following compounds of the formula 1-11 are prepared analogously to Example 11.0: R4' 3 N /H I o R2jC N 0 (1-11) 5 Start Ex am- 2 3 4 ing Empirical Mass m.p. Rf am- R R R' mate- formula spectrum [CC] value* rials 0
NHCH
3 10.0 489/491 223- 0.50 11.1 -Cl -CH 2 -NMe 2
C
28
H
29
CIN
4 0 2 [M+H]- 225 (A) 106
NHCH
3 10.1 473 148- 0.40 11.2 -F 0-CH2-NMe2 ,,. C28H29FN402 47 18-00 [M+H]* 150 (B) NMe 2 o 10.2 473 98- 0.30 11.3 -F 0 -CH 2 -NMe 2
C
28
H
29
FN
4 0 2 [M3H 98-103 30 **[M+H]* 103 (C) O
NH
2 459 223- 0.50 11.4 -F -CH 2 -NMe 2 10.3 C 27
H
27
FN
4 0 2 [59 225 (A) / [M+H]* 225 (A) O NHMe 10.3 473 210- 0.70 11.5 -F -CH 2 -NMe 2 1. C2 8
H
29
FN
4 0 2 473 213 (A) / *[M+H]* 213 (A) ONMe 2 10.3 487 213- 0.80 11.6 -F -CH 2 -NMe 2
C
29
H
31
FN
4 0 2 487 215 (A) / **[M+H]* 215 (A)
NH
2 o 443 115- 0.25 11.7 -F -CH 2 -NMe 2 10.2 C 2 6
H
2 5
FN
4 0 2 [M-H]- 120 (C) NHMe o 10.2 457 222- 0.25 11.8 -F -CH 2 -NMe 2 1. C 27
H
27
FN
4 0 2 [M7 225 (C) **[M-H]- 225 (C) O NH 2 44 14-00 11.9 -F -CH 2 -NMe 2 10.4 C 2 6
H
2 5
FN
4 0 2 [M-H]- 146 (D) 107 NMe 2 10.1 487 198- 0.60 11.10 -F
-CH
2 -NMe 2 . C 29
H
31
FN
4 0 2 [M+H]* 200 (B) Me N
N
9 10.1 542 0.60 11.11 -F 0 -CH 2 -NMe 2
C
32
H
36
FN
5 0 2 175 [M+H]* (B) 1 NH 2 HNMe 557 150- 0.40
H
3 C~ N 55 10 04 11.12 -F 10.5 C 3 1
H
33
FN
6 0 3 [M+H]* 156 (E) oN2 -N(SO 2 Me)- 552 197- 0.50 11.13 -F 10.6 C 2 8
H
3 0
FN
5 0 4 S [52 199 (D)
(CH
2
)
2 -NMe 2 [M+H]* 199 (D) 0 NMe 2 10.4 473 147- 0.35 11.14 -F 0 e -CH 2 -NMe 2 1 C 28
H
29
FN
4 0 2 [73 152 (D) [M+H]* 152 (D) 0 NHe o He10.4 459 208- 0.35 11.15 -F -CH 2 -NMe 2 1. C 2 7
H
27
FN
4 0 2 459 214 (D) [M+H]* 214 (D) 11.16 -F N -N(SO 2 Me)- 10.6 C29H32FN5O4S 566 218- 0.70
(CH
2
)
2 -NMe 2 [M+H]* 222 (F) O N0e2 -N(SO 2 Me)- 10.6 580 199- 0.40
(CH
2
)
2 -NMe 2 ***S[M+H]* 205 (C) 108 0NHMe r--NMe OHeH 3 %N N~e 10.5 571 155- 0.20 11.18 -F s, H c*N C 32
H
35
FN
6 0 3 * [M+H]* 160 (C)
NHCH
3 11.19 -F -N(Me)-(CO)- 10.7 C 28
H
27
FN
4 0 3 487 137- 0.50
CH
3 ** [M+H]* 145 (C) O NHCH 3 rNMe o HCPN- 10.8 585 211- 0.40 11.20 -F 3C C 33
H
37
FN
6 0 3 /'- 0 ** [M+H]* 219 (C)
NHCH
3 11.21 -F
-N(SO
2 Me)- 10.9 C 3
HFN
5 4 S 578 192- 0.50
(CH
2
)
2 -NMe 2 ** [M-H]- 200 (C)
NHCH
3 0 Me 10.11 559 180- 0.50 11.22 -F -N-NyOtBu C 32
H
35
FN
4 0 4 o0* [M+H]* 187 (C)
NHCH
3 o N3 10.13 496 262- 0.40 11.23 -F e N C 29
H
26
FN
5 0 2 ule **[M+H]* 266 (C)
NHCH
3 0 10.14 494 180- 0.60 11.24 -F
-SO
2 Me ,, C 26
H
24
FN
3 0 4 S [M+H]* 188 (C)
NHCH
3 o O N-Me 10.12 542 226- 0.50 11.25 -F . 'N C31H2F.12 **
C
31
H
32
FN
5 0 3 [M+H]* 230
(C)
109 NHMe r--NMe NH e ~ NJ 10.16 571 0.10 11.26 -F 0cH 3 Ns, C 32
H
35
FN
6 0 3 213 ' ** [M+H]* (G) NHMe 0 0 'N-Me 10.15 528 0.40 11.27 -F N N C 30
H
30
FN
5 0 3 245 I - ** [M+H]* (G) *Eluent mixtures: (A): silica gel, methylene chloride/methanol/ammonia = 5:1:0.01 (B): alumina, methylene chloride/ethanol = 20:1 5 (C): silica gel, methylene chloride/methanol/ammonia = 9:1:0.1 (D): silica gel, methylene chloride/methanol/ammonia = 6:1:0.1 (E): silica gel, methylene chloride/methanol/ammonia = 5:1:0.1 (F): silica gel, methylene chloride/methanol/ammonia = 7:1:0.1 (G): silica gel, methylene chloride/methanol = 9:1 0 ** using methylammonium chloride as base equivalent using dimethylammonium chloride as base equivalent **** using piperidine hydrochloride as base equivalent 5 Example 12.0 3-Z-[1 -(4-Dimethylaminomethylanilino)-1 -(4-acetylaminomethylphenyl)methylenel-6 chloro-2-indolinone 100 mg of 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4-aminomethylphenyl) 0 methylene}-6-chloro-2-indolinone (starting material 7.0) are dissolved in 5 ml of methylene chloride and 5 ml of pyridine, and 20 pl of acetyl chloride are added at 00C. The mixture is stirred at 00C for 10 minutes and at room temperature for a further 4 hours. Another 20 pl of acetyl chloride are then added, and the mixture is stirred at room temperature for 12 hours. After this time, the solvent is removed 110 under reduced pressure and the residue is taken up in methylene chloride and washed with water. The aqueous phase is extracted twice with methylene chloride and the combined organic phases are dried over sodium sulphate. The solvent is removed using a rotary evaporator and the residue is washed with ether. 5 Yield: 51 mg (47% of theory), Rf value: 0.30 (silica gel, methylene chloride/methanol/ammonia = 9:1:0.01) m.p. 219-220 *C
C
27
H
2 7
CIN
4 0 2 Mass spectrum: m/z = 473/475 [M-H] 0 The following compounds of the formula 1-12 are prepared analogously to Example 12.0: R4' 3 N /H 0 I N R2 N (1-12) 5 Start Ex am- R2 R3 R4' ing Empirical Mass m.p. Rr mate- formula spectrum [*C] value* pie rials
CH
3 fNCH HN O H N 3 585/587 252- 0.25 12.1 -Cl / N 8.0 C 32
H
35
CN
6 0 3 [M-H]~ 255 (B) 111 1 CI H 535/537 238 0.45 12.2o
-CH
2 -NMe 2 7.0 C 32
H
29
CIN
4 0 2 [M-HF (de- (B) comp.) NNCH H -N, 364/4 28-00 12.3 -CI HN O H3CN4 8.0 C 37
H
37
CIN
6
O
3 0 [M-HI- 284 (B) Oy-CH3 HN 457 245- 0.40 12.4 -F -CH 2 -NMe 2 9.0 C 27
H
27
FN
4 0 2 [M-H]- 250 (C) DyEt HN 471 212- 0.35 12.5 -F -CH 2 -NMe 2 9.0 C 28
H
29
FN
4 0 2 [M-H]- 214 (D) HN 519 237- 0.40 12.6 -F -CH 2 -NMe 2 9.0 C 32
H
29
FN
4 0 2 [M-H] 240 (D) tp533 187- 0.30 12.7 -F HN -CH 2 -NMe 2 9.0 C 33
H
31
FN
4 0 2 533 187 (.3 [M-H]~ 190 (0)
CH
3 0 NH 471 234- 0.30 12.8 -F -CH 2 -NMe 2 9.1 C 28
H
29
FN
4 0 2 471 234 (.3 [M-H]- 237 (D) 112 O H533 144- 0.45 12.9 -F NH -CH 2 -NMe 2 9.1 C 33
H
3 1FN 4 0 2 [M-H]- 150 (C) Et ~NH 485 235- 0.25 12.10 -F -CH 2 -NMe 2 9.1 C 29
H
31
FN
4 0 2 [M-H]- 237 (D) 01 NH 547 217- 0.30 12.11 -F -CH 2 -NMe 2 9.1 C 34
H
33
FN
4 0 2 [M-H]- 220 (D) CH HN O 457 112- 0.25 12.12 -F -CH 2 -NMe 2 9.2 C 27
H
27
FN
4 0 2 - j[M-H]~ 120 (D) Et HN4O 586 176- 0.30 12.13 -F -CH 2 -NMe 2 9.2 C 28
H
29
FN
4 0 2 [M+H]+ 180 (D) 535 80- 0.35 12.14 -F HN O -CH 2 -NMe 2 9.2 C 33
H
3 1FN 4 0 2 [M+H]' 85 (D) CH
CH
3 f--NCH HN O H N 3 569 230- 0.35 12.15 -F 0 9.3 C 32
H
35
FN
6 0 3 O [M-H]- 235 (D) 113 Et f \NCH
HN
4 0 H 3 C N JNH 3 583 205- 0.30 12.16 -F C 9.3 0 33
H
37
FN
6 0 3 - - [M-H]- 210 (D) rNCH HCN 3 645 217- 0.35 12.17 -F HN O 3 N_93 C8H9 O 0 9.3 C 38
H
39
FN
6 0 3 [-l 2 D ~-1. ~[M-H]- 220 (D) rNCH HN H 3 C /N"J 3 597 209- 0.30 12.18 -F CN9.6 C 34
H
37
FN
6
O
3 [+] 1 D 0 [M+H]* 212 (D) rNCH HN H N~ 3 611 190-.0.30 12.19 -F 3 N 9.6 C 35
H
39
FN
6 0 3 0 \[M+H]* 193 (D) 0N to I NCH HNH 3634 160- 0.30 12.20 -F 3 N 9.6 C 36
H
36
FN
7 0 3 [M+H]* 163 (D) 0NCH HN HN 3 639 223- 0.30 12.21 -F H N 9.6 C 37
H
43
FN
6 0 3 0 ~[M+H]* 227 (D) 0NCH 12.22 -F HN H 3 CN 3 9 634 170- 0.25 0 9[M+H]* 175 (D) 114 O CH3 o C 3 NCH HN CH3 H N 3599 194- 0.20 12.23 -F H 3 C N 9.6 C 34
H
39
FN
6 0 3 0 [M+H]* 196 (D)
H
3 C
CH
3 HN N \jN 3 613 197- 0.70 12.24 -F H3C N 9.6 C 3 5
H
41
FN
6 0 3 0 [M+H]* 200 (E) otr NCH oH N ~C 3 653 130- 0.75 12.25 -F HN H 3 C 9.6 C 3 8
H
4 5
FN
6 0 3 0 [M+H]* 135 (E) OMe O NCH HN H 3 601 155- 0.60 12.26 -F H3% N 9.6 C 33
H
37
FN
6 0 4 0 a[M+H]* 159 (E) MeO O a-N\NCH HN0 H N \_j3 663 168- 0.35 12.27 -F HN H 3 CN 9.6 C 38
H
39
FN
6 0 4 } [M+H]* 172 (C)
C(CH
3 3 O NCH HN H 3 C N 3 627 85- 0.35 12.8 -9.6
C
36
H
43
FN
6 0 3 12.28 -F 0[M +H]* 90 (C) tNCH HN H 3 CN N - 3 639 170- 0.25 12.29 -F N 9.6 C 35
H
35
FN
6 0 3 S [M+HI+ 175 (C) [MH*17-C 115
(CH
3
)
3 Cr 0 HN H 3 Cr N~ 3 613 242- 0.30 12.30 -F HN 9.6 C 35
H
41
FN
6 0 3 r NCH 12.31 -F HN
H
3 C ,N 3 9.6 C35HasFN6O4 623 155- 0.65 0 9[M+H]* 160 (F)
O-CH
3 rNCH 12.32 -F HN H 3 C N 3 9.6 532H71FNO3 . 190- 0.60 '-.096
C
3
H
5 N0 [M+H]+ 195 (F) yEt /'NCH HN HCN-- N 585 203- 0.65 12.33 -F H 9.6 C 33
H
37
FN
6 03 585 203 (.6 ~'* [M+H]* 209 (E) 0 \NCH
-
633 145- 0.60 12.34 -F HN H N 3 9.6 C 37
H
37
FN
6 0 3 633 15 (F) 0 [M+H]* 150 (F) 12.35 -F HN O H N NC 9.6 38H39FN3 647 148- 0.65 * ~[M+H]* 151 (F) HN 485 216- 0.35 12.36 -F -CH 2 -NMe 2 9.0 C 29
H
29
FN
4 0 2 485 220 (D) [M+H]* 220 (D) 116 HN 499 214- 0.35 12.37 -F -CH 2 -NMe 2 9.0 C 3 oH 31
FN
4 0 2 [M+H]* 217 (D) HN 522 205- 0.35 12.38 -F -CH 2 -NMe 2 9.0 C 31
H
28
FN
5 0 2 [M+H]* 210 (D) HN 527 235- 0.35 12.39 -F -CH 2 -NMe 2 9.0 C 32
H
35
FN
4 0 2 [M+H]* 237 (D) 0 D, HN 520 135- 0.20 12.40 -F -CH 2 -NMe 2 9.0 C 31
H
28
FN
5 0 2 [M-H] 140 (D) 0 CH 3 CH HN CH3 487 210- 0.20 12.41 -F -CH 2 -NMe 2 9.0 C 29
H
31
FN
4 0 2 [M+H]* 215 (D)
H
3 C
CH
3 HN 501 202- 0.25 12.42 -F -CH 2 -NMe 2 9.0 C 3 oH 33
FN
4 0 2 if" [M+H]* 206 (D) 541 198- 0.35 12.43 -F HN -CH 2 -NMe 2 9.0 C 33
H
37
FN
4 0 2 [M+H]+ 203 (D) 117 OMe HN 489 173- 0.35 12.44 -F -CH 2 -NMe 2 9.0 C 28
H
29
FN
4 0 3 [M+H]* 177 (D) MeO 549 202- 0.50 12.45 -F HN -CH 2 -NMe 2 9.0 C 3 3
H
31
FN
4 0 3 [M-H]- 207 (C)
C(CH
3
)
3 513 203- 0.45 12.46 -F HN -CH 2 -NMe 2 9.0 C 3 1
H
35
FN
4 0 2 [M-H]- 209 (C) HN 527 245- 0.35 12.47 -F -CH 2 -NMe 2 9.0 C 3 oH 27
FN
4 0 2 S [M+H]* 250 (C)
(CH
3
)
3 Cy-O HN 501 248- 0.45 12.48 -F -CH 2 -NMe 2 9.0 C 30
H
33
FN
4 0 2 [M+H]+ 252 (C) HN 511 216- 0.30 12.49 -F -CH 2 -NMe 2 9.0 C 30
H
27
FN
4 0 3 [M+H]* 219 (C) o N HN 522 167- 0.20 12.50 -F -CH 2 -NMe 2 9.0 C 31
H
28
FN
5 0 2 [M+H]* 170 (D) *Eluent mixtures: 118 (A): silica gel, methylene chloride/ethanol/ammonia = 20:1:0.01 (B): silica gel, methylene chloride/methanol/ammonia = 9:1:0.01 (C): alumina, methylene chloride/methanol = 19:1 (D): silica gel, methylene chloride/methanol/ammonia = 9:1:0.1 5 (E): silica gel, methylene chloride/methanol/ammonia = 8:2:0.2 (F): alumina, methylene chloride/methanol = 9:1 Alternatively, the following acylating agents were used: benzoyl chloride, propionyl chloride, phenylacetyl chloride, cyclopropanecarbonyl 0 chloride, cyclobutanecarbonyl chloride, pyridin-2-ylcarbonyl chloride, pyridin-3 ylcarbonyl chloride, pyridin-4-ylcarbonyl chloride, cyclohexylcarbonyl chloride, isobutyryl chloride, 3-methylbutyryl chloride, cyclohexylmethylcarbonyl chloride, methoxyacetyl chloride, 2-methoxybenzoyl chloride, tert-butylacetyl chloride, thiophene-2-carbonyl chloride, pivaloyl chloride, 2-furoyl chloride 5 Example 13.0 3-Z-[1 -(4-Trimethylammoniumm ethylanilino)-1 -(4-(2-carboxyethyl)phenyl)methylenel 0 6-fluoro-2-indolinone iodide 200 mg of 3-Z-[1 -(4-dimethylaminomethylanilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone (starting material 10.1) are dissolved in 40 ml of acetone, and 250 ml of methyl iodide are added. The mixture is stirred at room temperature for 20 hours. After this time, the resulting residue is 5 filtered off with suction. The product is dried at 800C under reduced pressure. Yield: 200 mg (83% of theory), Rf value: 0.50 (reversed phase RP8, methanol/sodium chloride solution (5%) = 4:1) m.p. 210 0C
C
2 8
H
2 9
FN
3 0 3 1 0 Mass spectrum: m/z = 474 [M+H]* 119 The following compound of the formula 1-13 is prepared analogously to Example 13.0: R4' 3 N /H 0 R N (1-13) }5 Start Ex am- R2ing Empirical Mass m.p. Rf mate- formula spectrum [*C] value* rials 0 OH Me 474 0.50 13.1 -F N-Me - 10.3 C 28
H
29
FN
3 0 3 1 150 /Me [M+H]* (A) *Eluent mixture: (A): reversed phase RP8, methanol/sodium chloride solution (5%) = 4:1 0 Example 14.0 3-Z-[1 -(4-Guanidinomethylanilino)-1 -(4-(2-carboxyethyl)phenyl)methylenel-6-fluoro-2 indolinone iodide 5 170 mg of 3-Z-[1-(4-aminomethylanilino)-I-(4-(2-carboxyethyl)phenyl)methylene]-6 fluoro-2-indolinone (starting material 10.50) are dissolved in 20 ml of tetrahydrofuran, and 390 mg of 3,5-dimethylpyrazole-1 -carboxamidine nitrate and 330 ml of diethylisopropylamine are added. The mixture is stirred under reflux for 10 hours.
120 After this time, the solvent is concentrated, water is added and the resulting residue is filtered off with suction. The product is dried at 80 0 C. Yield: 150 mg (81% of theory), Rf value: 0.40 (silica gel, methylene chloride/methanol/acetic acid = 5:1:0.1) 5 m.p. 290 C
C
2 6
H
2 4
FN
5 0 3 Mass spectrum: m/z = 474 (M+H]* The following compound of the formula 1-14 is prepared analogously to Example 0 14.0: R4' 3 N /H II o 0 R N (1-14) Start Ex am- 2 3 ing Empirical Mass m.p. Rf am- R R R pie mate- formula spectrum [C] value* rials 0 OH H 474 0.70 14.1 -F N rNH 2 10.64 C 26
H
24
FN
5 0 3 305 HN [M+H]* (A) 5 *Eluent mixture: (A): reversed phase RP8, methanol/sodium chloride solution (5%) = 4:1 121 Example 15 Dry vial with 75 mg of active compound per 10 ml 5 Composition: Active compound 75.0 mg Mannitol 50.0 mg Water for injection ad 10.0 ml 0 Preparation: Active compound and mannitol were dissolved in water. After filling, the product is freeze-dried. The ready-to-use solution is obtained by dissolving the product in water for injection. 5 Example 16 Dry vial with 35 mg of active compound per 2 ml 0 Composition: Active compound 35,0 mg Mannitol 100,0 mg 5 Water for injection ad 2.0 ml Preparation: Active compound and mannitol were dissolved in water. After filling, the product is freeze-dried. The ready-to-use solution is obtained by dissolving the product in water 0 for injection.
122 Example 17 Tablet with 50 mg of active compound 5 Composition: (1) Active compound 50.0 mg (2) Lactose 98.0 mg (3) Maize starch 50.0 mg 0 (4) Polyvinylpyrrolidone 15.0 mg (5) Magnesium stearate 2.0 mg 215.0 mg Preparation: 5 (1), (2) and (3) are mixed and granulated using an aqueous solution of (4). (5) is added to the dried granules. From this mixture, biplanar tablets having a facet on both sides and being partially scored on one side are pressed. Diameter of the tablets: 9 mm. 0 Example 18 Tablet with 350 mg of active compound Composition: 5 (1) Active compound 350.0 mg (2) Lactose 136.0 mg (3) Maize starch 80.0 mg (4) Polyvinylpyrrolidone 30.0 mg 0 (5) Magnesium stearate 4,0 mq 600.0 mg 123 Preparation: (1), (2) and (3) are mixed and granulated using an aqueous solution of (4). (5) is added to the dried granules. From this mixture, biplanar tablets having a facet on both sides and being partially scored on one side are pressed. 5 Diameter of the tablets: 12 mm. Example 19 Capsules with 50 mg of active compound 0 Composition: (1) Active compound 50.0 mg (2) Maize starch, dried 58.0 mg 5 (3) Lactose, powdered 50.0 mg (4) Magnesium stearate 2.0 mg 160.0 mg Preparation: 0 (1) is ground with (3). This ground material is, with vigorous mixing, added to the mixture of (2) and (4). This powder mixture is, in a capsule filling machine, filled into hard gelatin capsules size 3. 5 Example 20 Capsules with 350 mg of active compound Composition: (1) Active compound 350.0 mg 0 (2) Maize starch, dried 46.0 mg (3) Lactose, powdered 30.0 mg (4) Magnesium stearate 4.0 mg 430.0 mg 124 Preparation: (1) is ground with (3). This ground material is, with vigorous mixing, added to the mixture of (2) and (4). 5 This powder mixture is, in a capsule filling machine, filled into hard gelatin capsules size 0. Example 21 0 Suppositories with 100 mg of active compound 1 suppository contains: Active compound 100.0 mg 5 Polyethylene glycol (MW 1500) 600.0 mg Polyethylene glycol (MW 6000) 460.0 mg Polyethylene sorbitan monostearate 840.0 mg 2 000.0 mg 0 Preparation: The polyethylene glycol is melted together with polyethylene sorbitan monostearate. At 40 0 C, the ground active substance is homogeneously dispersed in the melt. The melt is cooled to 38 0 C and poured into slightly pre-cooled suppository moulds. 5 Analogously to the examples above, it is possible to prepare the following compounds: (1) 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-methylsulphonylamino)anilino)-1 -(4-(2 0 carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone (2) 3-Z-[1 -(4-(N-(dimethylaminomethylcarbonyl)-N-methylamino)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone 125 (3) 3-Z-[1 -(4-(N -(2-dimethylaminoethyl)-N-acetylamino)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-ch loro-2-i ndol none (4) 3-Z-[1 -(4-(N -(2-methylaminoethyl)-N-acetylamino)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone 5 (5) 3-Z-[1 -(4-(N-(3-dimethylaminopropyl)-N-acetylamino)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylenel-6-ch loro-2-i ndol none (6) 3-Z-[1 -(4-(N -(3-methylaminopropyl )-N-acetylamino)anilino)-1 -(4-(2 ca rboxyethyl)phenyl)methylenel-6-ch loro-2-i ndol none (7) 3-Z-[1 -(4-(3-dimethylaminopropyl )anilino)-1 -(4-(2-carboxyethyl)phenyl)methylene] 0 6-chloro-2-i nd oli none (8) 3-Z-[1 -(4-ethylaminomethylanilino )-1 -(4-(2-carboxyethyl)phenyl)methylene]-6 ch loro -2-i ndol i none (9) 3-Z-[1 -(4-methylaminomethylanilino)- 1 -(4-(2-carboxyethyl)phenyl)methylenel-6 chloro-2-indolinone 5 (10) 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N-methylamino)anilino)-1 (4-(2-ca rboxyethyl )phenyl)methylene]-6-ch loro-2-i ndol none (11) 3-Z-[1 -(4-(4-methylpiperazin-1 -ylcarbonyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-ch loro-2-i ndol none (12) 3-Z-[1 -(4-(N-(3-dimethylaminopropyl)-N-methylsulphonylamino)aniino)-1 -(4 0 (2-ca rboxyethyl )ph enyl)methylene]-6-chloro-2-i n doli none (13) 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-propylsulphonylamino)anilino)-1 -(4-(2 ca rboxyeth yl)ph enyl)methyl en e]-6-ch Ioro-2 -i ndol none (14) 3-Z-[1 -(4-aminomethylanilino)-1 -(4-(2-carboxyethyl )phenyl)methylene] -6 chloro-2-i nd oli none 5 (15) 3-Z-[1 -(3-(methylaminomethyl)anilino)-1 -(4-(2 ca rboxyethyl)phenyl)methylen e]-6-ch loro-2-i ndol none (16) 3-Z-[1 -(3-(2-dimethylaminoethyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone (17) 3-Z-[1 -(3-(3-dimethylaminopropyl)anilino)-1 -(4-(2 0 ca rboxyethyl)phenyl)methylene]-6-chloro-2-i ndol none (18) 3-Z-[1 -(4-(N-(dimethylamino-carbonylmethyl)-N methylsulphonylamino)anilino)-1 -(4-(2-carboxyethyl)phenyl)methylene]-6-chloro 2-indolinone 126 (19) 3-Z-[1 -(4-(N-methyl-N-methylsulphonylamino)anilino)-1 -(4-(2 ca rboxyethyl)phenyl)methylene]-6-ch loro-2-indol none (20) 3-Z-[1 -(4-(N -methyl-N-acetylamino)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-ch loro-2-i ndol none 5 (21) 3-Z-[1 -(4-(N -(N-(2-dimethylaminoethyl)-N-methylaminomethylcarbonyl)-N methylamino)anilino)-1 -(4-(2-carboxyethyl)phenyl)methylene]-6-chloro-2 indolinone (22) 3-Z-[1 -(4-(2-diethylaminoethylsulphonyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylen e] -6-ch loro-2-i ndol none 0 (23) 3-Z-[1 -(4-(N -(2-dimethylaminoethyl-carbonyl )-N-methylamino)anilino)-lI-(4-(2 carboxyethyl)phenyl)methylene]-6-ch loro-2-i ndol none (24) 3-Z-[1 -(4-(N -(2-dimethylaminoethyl)-N-methylaminomethyl )anilino)-1 -(4-(2 ca rboxyethyl)phenyl)methylene]-6-chloro-2-ind oli none (25) 3-Z-[1 -(4-(2-dimethylaminoethoxy)anilino)-1 -(4-(2 5 ca rboxyethyl)phenyl)methylene]-6-ch loro-2-indoli none (26) 3-Z-[1 -(4-(N -(4-dimethylaminobutylcarbonyl)-N-methylamino)anilino)- 1-(4-(2 carboxyethyl)phenyl)methylene]-6-ch loro-2-i ndol none (27) 3-Z-[1 -(4-(N -(3-dimethylaminopropylcarbonyl)-N-methylamino)anilino)-lI-(4-(2 carboxyethyl)ph enyl)methylene]-6-ch loro-2-i ndol none 0 (28) 3-Z-[1 -(4-(methylethylaminomethyl)anilino)-1 -(4-(2 carboxyeth yl)phenyl)methylen el-6-ch loro-2-i ndol none (29) 3-Z-[1 -(4-(methylpropylaminomethyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-ch loro-2-i ndol none (30) 3-Z-[1 -(4-(methylbenzylaminomethyl)anilino)-1 -(4-(2 5 carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone (31) 3-Z-[1 -(4-(N -(2-dimethylaminoethyl)-N-methylaminomethyl )anilino)-1 -(4-(2 carboxyethyl)phenylmethylene]-6-chloro-2-indolinone (32) 3-Z-[1 -(4-(azetidin-1I-ylmethyl)anilino)-1 -(4-(2-carboxyethyl)phenyl)methylene] 6-ch loro-2-i ndol none 0 (33) 3-Z-[1 -(4-((4- methylpiperazin-1 -yI)methyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone (34) 3-Z-[1 -(4-(piperazin -1 -ylmethyl)anilino)-l1-(4-(2 ca rboxyethyl)phenyl)methylene]-6-ch loro-2-i ndoli none 127 (35) 3-Z-[1 -(4-(morpholin-4 -ylmethyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-ch loro-2-i ndol none (36) 3-Z-[1 -(4-(thiomorpholin -4-ylmethyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-ch loro-2-i ndol none 5 (37) 3-Z-[1 -(4-(imidazol-1 -ylmethyl)anilino)-1 -(4-(2-carboxyethyl)phenyl)methylene] 6-chloro-2-indolinone (38) 3-Z-I1-(4-(N -(2-dimethylaminoethyl)-N-methytsulphonylamino)anilino)-1 -(3-(2 carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone (39) 3-Z-[1 -(4-(N -(dimethylaminomethylcarbonyl)- N-methylamino)anilino)-lI-(3-(2 0 ca rboxyethyl)phenyl)methylen e]-6-ch loro-2-i ndol none (40) 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-acetylamino)anilino)-1 -(3-(2 ca rboxyethyl)phenyl)methyl ene]-6-ch loro-2-i ndol none (41) 3-Z-[1 -(4-(N -(2-methylaminoethyl)-N-acetylamino)anilino)-1 -(3-(2 ca rboxyethyl)phenyl)methylene]-6-ch loro-2-i ndol none 5 (42) 3-Z-[1 -(4-(N -(3-dimethylaminopropyl)-N-acetylamino)anilino)-lI-(3-(2 carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone (43) 3-Z-[l1-(4-(N -(3-methylaminopropyl)-N-acetylamino)anilino)-1 -(3-(2 ca rboxyethyl)phenyl)methylene]-6-ch loro-2-i ndol none (44) 3-Z-[1 -(4-(3-dimethylaminopropyl )an ilino)-1 -(3-(2 0 ca rboxyethyl)phenyl)methylene]-6-ch loro-2-i ndol none (45) 3-Z-[1 -(4-ethyla min omethylan ilino )-1 -(3-(2-ca rboxyethyl)phenyl )methylene]-6 chloro-2-indolinone (46) 3-Z-[1 -(4-methylaminomethylanilino)-lI-(3-(2-carboxyethyl )phenyl)methylene] 6-chloro-2-indolinone 5 (47) 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N-methylamino)anilino)-1 (3-(2-ca rboxyethyl)phenyl)methylene]-6-chloro-2-in dol none (48) 3-Z-[1 -(4-(4-methylpiperazin-1 -ylcarbonyl )anilino)-1 -(3-(2 ca rboxyethyl)phenyl)methylen e]-6-ch loro-2-i ndol none (49) 3-Z-[1 -(4-(N -(3-dimethylaminopropyl )-N-methylsulphonylamino)anilino)-1 -(3 0 (2-ca rboxyethyl)phenyl)methylene]-6-ch Ioro-2-i ndol none (50) 3-Z-[1 -(4-(N -(2-dimethylaminoethyl)-N-propylsulphonylamino)anilino)-1 -(3-(2 ca rboxyethyl)ph enyl)methylene]-6-chloro-2 -indol none 128 (51) 3-Z-[1 -(4-aminomethylanilino)-1 -(3-(2-carboxyethyl)phenyl)methylene] -6 ch loro-2-i ndol none (52) 3-Z-[1 -(3-(dimethylaminomethyl)anilino)-1 -(3-(2 carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone 5 (53) 3-Z-[1 -(3-(methylaminomethyl )anilino)-1 -(3-(2 carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone (54) 3-Z-[1 -(3-(2-dimethylaminoethyl)anilino)-lI-(3-(2 carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone (55) 3-Z-[1 -(3-(3-dimethylaminopropyl )anilino)-1 -(3-(2 0 ca rboxyethyl)phenyl)methylene]-6-ch loro-2-i ndol none (56) 3-Z-[1 -(4-(2-dimethylaminoethyl)anilino)-1 -(3-(2 ca rboxyethyl)phenyl)methyl en e]-6-ch loro-2-i ndol none (57) 3-Z-[1 -(4-(N-(dimethylaminocarbonylmethyl)-N-methylsulphonylamino)anilino) 1 -(3-(2-ca rboxyethyl )phenyl )methylene]-6-ch loro-2 -i ndol in one 5 (58) 3-Z-[1 -(4-(N-methyl-N-methylsulphonylamino)anilino)-1 -(3-(2 ca rboxyethyl)ph enyl)methylene]-6-ch loro-2-i ndoli none (59) 3-Z-[1 -(4-(N -methyl-N-acetylamino)anilino)-lI-(3-(2 carboxyethyl)phenyl)methylene]-6-ch loro-2-indoli none (60) 3-Z-[1 -(4-(1 -methylimidazol-2-y)anilino)-1 -(3-(2 0 ca rboxyethyl)phenyl)methylene]-6-chloro-2-indoli none (61) 3-Z-[1 -(4-(N -(N-(2-dimethylaminoethyl)-N-methylaminomethylcarbonyl )-N methylamino)anilino)-1 -(3-(2-carboxyethyl )phenyl )methylene]-6-chloro-2 indolinone (62) 3-Z-[1 -(4-(2 -diethylaminoethylsulphonyl)anilino)-1 -(3-(2 5 ca rboxyethyl)phenyl)methylene]-6-ch loro-2-i ndol none (63) 3-Z-[1 -(4-(N -(2-dimethylaminoethylcarbonyl)-N-methylamino)anilino)-l1-(3-(2 ca rboxyethyl)phenyl)methylene]-6-ch loro-2-i ndol none (64) 3-Z-[1 -(4-(N -(2-dimethylaminoethyl)-N-methylaminomethyl)anlino)-1 -(3-(2 ca rboxyethyl)phenyl)methylene]-6-chloro-2-i ndol none 0 (65) 3-Z-[1 -(4-(2-dimethylaminoethoxy)anilino)-1 -(3-(2 ca rboxyethyl)phenyl)methylene]-6-ch loro-2-indol none (66) 3-Z-[1 -(4-(N -(4-dimethylaminobutylcarbonyl)-N-methylamino)anilino)-l1-(3-(2 carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone 129 (67) 3-Z-[1 -(4-(N -(3-dimethylaminopropylcarbonyl)-N-methylamino)anilino)-lI-(3-(2 ca rboxyethyl)phenyl)methylene]-6-chloro-2-indo i none (68) 3-Z-[1 -(4-(methylethylaminomethyl)anilino)-1 -(3-(2 ca rboxyethyl)phenyl)methylene]-6-ch loro-2-i ndol none 5 (69) 3-Z-[1 -(4-(methylpropylaminomethyl)anilino)-1 -(3-(2 ca rboxyethyl)phenyl)methylen e]-6-ch loro-2-i ndol none (70) 3-Z-[1 -(4-(methylbenzylaminomethyl)anilino)-1 -(3-(2 carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone (71) 3-Z-[1 -(4-(diethylaminomethyl )anilino)-1 -(3-(2-carboxyethyl)phenyl)methylene] 0 6-chloro-2-indolinone (72) 3-Z-[1 -(4-(N -(2-dimethylaminoethyl )-N-methylaminomethyl)anilino)-1 -(3-(2 ca rboxyethyl)phenylmethylene]-6-ch loro-2-indol none (73) 3-Z-[1 -(4-(pyrrolidin-1 -ylmethyl)anilino)-1 -(3-(2 5 carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone (74) 3-Z-[1 -(4-(azetidin- 1-ylmethyl )anilino)-1 -(3-(2-carboxyethyl)phenyl)methylene] 6-ch loro-2-i ndoli none (75) 3-Z-[1 -(4-((4- methylpiperazin-1 -yI)methyl)anilino)-1 -(3-(2 ca rboxyethyl)ph enyl)methylene]-6-ch loro-2-i ndol none 0 (76) 3-Z-[1 -(4-(piperazin -1 -ylmethyl)anilino)-lI-(3-(2 ca rboxyethyl)phenyl)methylene-6-ch loro-2-i ndol none (77) 3-Z-[1 -(4-(morpholin-4 -ylmethyl )anilino)-1 -(3-(2 carboxyethyl)phenyl)methylene]-6-ch loro-2-i ndol none (78) 3-Z-[1 -(4-(thiomorpholin -4-ylmethyl)anilino)-1 -(3-(2 5 ca rboxyethyl)ph enyl)methylene]-6-chloro-2-ind olin one (79) 3-Z-[1 -(4-(imidazol- 1-ylmethyl)anilino)-1 -(3-(2-carboxyethyl)phenyl)methylene] 6-ch loro-2-indol none (80) 3-Z-[1 -(4-(N -(2-methylaminoethyl )-N-acetylamino)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fl uoro-2-i ndol none 0 (81) 3-Z-[1 -(4-(N -(3-methylaminopropyl)-N-acetylamino)anilino)-1 -(4-(2 ca rboxyethyl)phenyl)methylene]-6-fluoro-2-i ndol none (82) 3-Z-[1 -(4-(3-dimethylaminopropyl )anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 130 (83) 3-Z-[1 -(4-ethylaminomethylanilino )-1 -(4-(2-carboxyethyl )phenyl)methylenel-6 fi uoro-2-i ndol i none (84) 3-Z-[l1-(4-(N-(3-dimethylaminopropyl)-N-methylsulphonylamino)anilino)-1 -(4 (2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 5 (85) 3-Z-[1 -(4-(N -(2-dimethylaminoethyl )-N-propylsulphonylamino)anilino)-1 -(4-(2 ca rboxyethyl)phenyl)methylene]-6-fl uoro-2-indoli none (86) 3-Z-[1 -(3-( methylaminomethyl)anilino)-1 -(4-(2 ca rboxyethyl)ph en yl)m ethyl en ej-6-fl uoro-2-i ndol in one (87) 3-Z-[1 -(3-(2 -dimethylaminoethyl)anilino)-lI-(4-(2 0 carboxyethyl)phenyl)methylene]-6-fI uoro-2-i ndol none (88) 3-Z-[1 -(3-(3-dimethylaminopropyl )anilino)-1 -(4-(2 ca rboxyethyl)ph enyl)methylene]-6-fl uoro-2-i ndol none (89) 3-Z-[1 -(4-(N -(dimethylaminocarbonylmethyl)- N-methylsulphonylamino)anilino) 1 -(4-(2-carboxyethyl )phenyl )methylene]-6-fl uoro-2-indol in one 5 (90) 3-Z-[1 -(4-(N-methyl-N-methylsulphonylamino)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fl uoro-2-i ndol none (91) 3-Z-[1 -(4-(N-(N-(2-dimethylaminoethyl)-N-methylaminomethylcarbonyl)-N methylamino)anilino)-1 -(4-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2 indolinone 0 (92) 3-Z-[1 -(4-(2-diethylaminoethylsulphonyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone (93) 3-Z-[1 -(4-(2-dimethylaminoethoxy)anilino)-1 -(4-(2 ca rboxyethyl)ph en yl)m ethyl en ej-6-fl uoro-2-i ndol in one (94) 3-Z-[1 -(4-(N -(3-dimethylaminopropylcarbonyl)-N-methylamino)anilino)-l1-(4-(2 5 ca rboxyethyl)phenyl)methylene]-6-fl uoro-2-i ndol none (95) 3-Z-[1 -(4-(methylethylaminomethyl)anilino)-lI-(4-(2 ca rboxyethyl)ph enyl)methylene]-6-fl uoro-2-i ndol none (96) 3-Z-[1 -(4-(methylpropylaminomethyl)anilino)-1 -(4-(2 ca rboxyethyl)phenyl)methylene]-6-fI uoro-2-indolin one 0 (97) 3-Z-[1 -(4-(methylbenzylaminomethyl)anilino)-1 -(4-(2 ca rboxyethyl)phenyl)methylene]-6-fl uoro-2-i ndol none 131 (98) 3-Z-[1 -(4-(azetidin- 1-ylmethyl )anilino)-1 -(4-(2-carboxyethyl)phenyl)methylene] 6-fluoro-2-indolinone (99) 3-Z-[1 -(4-(piperazin -1 -ylmethyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 5 (100) 3-Z-[1 -(4-(morpholin-4-ylmethyl)anilino)-1 -(4-(2 ca rboxyethyl)phenyl)methylene]-6-fluoro-2-indo in one (101) 3-Z-[1 -(4-(thiomorpholin -4-ylmethyl )anilino)-1 -(4-(2 ca rboxyethyl)phenyl)methylene]-6-fl uoro-2-i ndol none (102) 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-acetylamino)anlino)-1 -(3-(2 0 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone (103) 3-Z-[l1-(4-(N -(2-methylaminoethyl)-N-acetylamino)anilino)-1 -(3-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone (104) 3-Z-[1 -(4-(N -(3-methylaminopropyl)-N-acetylamino)anilino)-1 -(3-(2 carboxyethyI)phenyl)methylene]-6-fl uoro-2-i ndol none 5 (105) 3-Z-[1 -(4-(3-dimethylaminopropyl)anilino)-1 -(3-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone (106) 3-Z-j1 -(4-ethylaminomethylanilino )-1 -(3-(2-carboxyethyl )phenyl)methylene]-6 fl uoro-2-indol none (107) 3-Z-[1 -(4-(4-methylpiperazin-1 -ylcarbonyl)anilino)-1 -(3-(2 0 carboxyethyl)phenyl)methylene]-6-fl uoro-2-i ndol none (108) 3-Z-[1 -(4-(N-(3-dimethylaminopropyl)-N-methylsulphonylamino)anilino)-1 -(3 (2-ca rboxyethyl)phenyl)methylene]-6-fl uoro-2-indoli none (109) 3-Z-[1 -(4-(N -(2-dimethylaminoethyl)-N-propylsulphonylamino)anilino)-1 -(3-(2 ca rboxyethyl)phenyl)methylene]-6-fl uoro-2-i ndol none 5 (110) 3-Z-[1 -(3-(methylaminomethyl)anilino)-1 -(3-(2 ca rboxyethyl)phenyl)methylene]-6-fI uoro-2-i ndol none (111) 3-Z-[1 -(3-(2-dimethylaminoethyl)anilino)-1 -(3-(2 ca rboxyethyl)phenyl)methylene]-6-fI uoro-2-i ndol none (112) 3-Z-[l1-(3-(3-dimethylaminopropyl )anilino)-1 -(3-(2 0 ca rboxyethyl)ph en yl)m ethyl en ej-6-fl uoro-2-i ndol in one (113) 3-Z-[1 -(4-(N-(dimethylaminocarbonylmethyl)-N-methylsulphonylamino)anilino) 1 -(3-(2-ca rboxyeth yl)phenyl)methyl en el-6-fl uoro-2-in dol in one 132 (114) 3-Z-[1 -(4-(N-methyl-N-methylsulphonylamino)anilino)-1 -(3-(2 ca rboxyethyl)phenyl)methylene]-6-fl uoro-2-i ndol none (115) 3-Z-[1 -(4-(N-methyl-N-acetylamino)anilino)-1 -(3-(2 carboxyethyl)ph enyl)methylene]-6-fl uoro-2-i ndol none 5 (116) 3-Z-[1 -(4-(N -(N-(2-dimethylaminoethyl)-N-methylaminomethylcarbonyl)-N methylamino)anilino)-1 -(3-(2-carboxyethyl)phenyl)methylenej-6-fluoro-2 indolinone (117) 3-Z-[1 -(4-(2-diethylaminoethylsulphonyl)anilino)-1 -(3-(2 ca rboxyethyl)phenyl)methyl ene]-6-fl uoro-2-i ndol none 0 (118) 3-Z-[1 -(4-(N-(2-dimethylaminoethylcarbonyl)-N-methylamino)anilino)-1 -(3-(2 ca rboxyethyl)phenyl)methylene-6-fl uoro-2-i ndol none (119) 3-Z-[1 -(4-(N-(2-dimethylaminoethyl )-N-methylaminomethyl)anilino)-1 -(3-(2 carboxyethyl)phenyl)methylene]-6-fl uoro-2-indol none (120) 3-Z-[1 -(4-(2-dimethylaminoethoxy)anilino)-1 -(3-(2 5 ca rboxyethyl)phenyl)methylene]-6-fluoro-2-i ndol none (121) 3-Z-[1 -(4-(methylethylaminomethyl)anilino)-1 -(3-(2 ca rboxyethyl)phenyl)methyl en e]-6-fl uoro-2-i ndol none (122) 3-Z-[1 -(4-(methylpropylaminomethyl)anilino)-1 -(3-(2 carboxyethyl)phenyl)methylene]-6-fl uoro-2-i ndol none 0 (123) 3-Z-[1 -(4-(methylbenzylaminomethyl)anilino)-1 -(3-(2 ca rboxyethyl)ph en yl)methyl en e]-6-fl uoro-2-i ndol none (124) 3-Z-[l1-(4-(diethylaminomethyl )anilino)-1 -(3-(2-carboxyethyl)phenyl)methylene] 6-fl uoro-2-i ndol none 5 (125) 3-Z-[l1-(4-(pyrrolidin -1 -ylmethyl)anilino)-1 -(3-(2 ca rboxyethyl)phenyl)methylene]-6-fl uoro-2-i ndol none (126) 3-Z-[1 -(4-(azetidin- 1-ylmethyl )anilino)-1 -(3-(2-carboxyethyl)phenyl)methylene] 6-fl uoro-2-i ndol none (127) 3-Z-[1 -(4-(piperazin -1 -ylmethyl)anilino)-l1-(3-(2 0 carboxyethyl)phenyl)methylene]-6-fI uoro-2-i ndol none (128) 3-Z-[1 -(4-(morpholin-4 -ylmethyl)anilino)-1 -(3-(2 carboxyethyl)phenyl)methylene]-6-fl uoro-2-i ndoli none 133 (129) 3-Z-[l1-(4-(thiomorpholin -4-ylmethyl)anilino)-1 -(3-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone (130) 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-methylsulphonylamino)anlino)-1 -(4-(2 ca rboxyethyl)phenyl)methylene]-6-bromo-2-i ndol none 5 (131) 3-Z-[1 -(4-(N-(dimethylaminomethylcarbonyl)-N-methylamino)anilino)-1 -(4-(2 ca rboxyethyl)phenyl)methyl ene]-6-bromo-2-i ndol none (132) 3-Z-[1 -(4-(N -(2-dimethylaminoethyl )-N-acetylamino)anilino)-1 -(4-(2 ca rboxyethyl)phenyl)methylene]-6-bromo-2-i ndol none (133) 3-Z-[1 -(4-(N -(2-methylaminoethyl)-N-acetylamino)anilino)-1 -(4-(2 0 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (134) 3-Z-I1 -(4-(N-(3-dimethylaminopropyl)-N-acetylamino)anilino)-1 -(4-(2 ca rboxyethyl)ph en yl)m ethyl en e]-6-bromo-2-i nd olin one (135) 3-Z-[1 -(4-(N -(3-methylaminopropyl)-N-acetylamino)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone 5 (136) 3-Z-[1 -(4-(3-dimethylaminopropyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (137) 3-Z-[1 -(4-ethylaminomethylanilino )-1 -(4-(2-carboxyethyl)phenyl )methylene]-6 bromo-2-indolinone (138) 3-Z-[1 -(4-methylaminomethylanilino)-lI-(4-(2-carboxyethyl )phenyl)methylenej 0 6-bromo-2-indolinone (139) 3-Z-[1 -(4-(N -(4-methylpiperazin-1 -ylmethylcarbonyl)-N-methylamino)anilino)-1 (4-(2-carboxyethyl )phenyl)methylene]-6-bromo-2-indolinone (140) 3-Z-[1 -(4-(4-methylpiperazin-1 -ylcarbonyl)anilino)-1 -(4-(2 ca rboxyethyl)ph en yl)m ethyl en e]-6-bromo-2-i nd olin one 5 (141) 3-Z-[1 -(4-(N-(3-dimethylaminopropyl)-N-methylsulphonylamino)anilino)-1 -(4 (2-ca rboxyethyl)phenyl)methylene]-6-bromo-2-i ndol none (142) 3-Z-[1 -(4-(N-(2-dimethylaminoethyl)-N-propylsulphonylamino)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (143) 3-Z-[1 -(4-aminomethylanilino)-1 -(4-(2-carboxyethyl)phenyl )methylene] -6 0 bromno-2-indolinone (144) 3-Z-[1 -(3-(dimethylaminomethyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indo i none 134 (145) 3-Z-[1 -(3-(methylaminomethyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (146) 3-Z-[1 -(3-(2-dimethylaminoethyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-i ndol none 5 (147) 3-Z-[1 -(3-(3-dimethylaminopropyl )anilino)-1 -(4-(2 ca rboxyethyl)phenyl)methylene]-6-bromo-2-i ndol none (148) 3-Z-[1 -(4-(2-dimethylaminoethyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-i ndol none (149) 3-Z-[1 -(4-(N-(dimethylaminocarbonylmethyl)-N-methylsulphonylamino)anilino) 0 1 -(4-(2-carboxyethyl )phenyl)methylene]-6-bromo-2-indolinone (150) 3-Z-[1 -(4-(N-methyl-N-methylsulphonylamino)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-i ndol none (151) 3-Z-[1 -(4-(N-methyl-N-acetylamino)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone 5 (152) 3-Z-[1 -(4-(1 -methylimidazol-2-y)anilino)-1 -(4-(2 ca rboxyethyl)phenyl)methylene]-6-bromo-2-indo i none (153) 3-Z-[1 -(4-(N -(N-(2-dimethylaminoethyi)-N-methylaminomethylcarbonyl )-N methylamino)anilino)-1 -(4-(2-carboxyethyl )phenyl )methylene]-6-bromo-2 indolinone 0 (154) 3-Z-[1 -(4-(2-diethylaminoethylsulphonyl)anilino)-1 -(4-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-i ndol none (155) 3-Z-[1 -(4-(N -(2-dimethylaminoethylcarbonyl)- N-methylamino)anilino)-lI-(4-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (156) 3-Z-[1 -(4-(N -(2-dimethylaminoethyl)-N-methylaminomethyl )anilino)-1 -(4-(2 5 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (157) 3-Z-[1 -(4-(2-dimethylaminoethoxy)anilino)- I-(4-(2 ca rboxyethyl)ph en yl)methyl en e]-6-bromo-2-i ndol none (158) 3-Z-[1 -(4-(N -(4-dimethylaminobutylcarbonyl)-N-methylamino)anilino)-lI-(4-(2 ca rboxyethyl)phenyl)methylene]-6-bromo-2-i ndol none 0 (159) 3-Z-[1 -(4-(N -(3-dimethylaminopropylcarbonyl)-N-methylamino)anilino)-lI-(4-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (160) 3-Z-[1 -(4-(methylethylaminomethyl)anilino)-1 -(4-(2 ca rboxyethyl)ph enyl)methyl en e]-6-bromo-2-i nd ol none 135 (161) 3-Z-[1-(4-(methylpropylaminomethyl)anilino)-1-(4-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (162) 3-Z-[1-(4-(methylbenzylaminomethyl)anilino)-1-(4-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone 5 (163) 3-Z-[1-(4-(diethylaminomethyl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene] 6-b romo-2-indol i none (164) 3-Z-[1-(4-(N-(2-dimethylaminoethyl)-N-methylaminomethyl)anilino)-1-(4-(2 carboxyethyl)-phenylmethylene]-6-bromo-2-indolinone 0 (165) 3-Z-[1-(4-(pyrrolidin-1-ylmethyl)anilino)-1-(4-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (166) 3-Z-[1-(4-(azetidin-1-ylmethyl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene] 6-bromo-2-indolinone (167) 3-Z-[1-(4-((4-methylpiperazin-1-yl)methyl)anilino)-1-(4-(2 5 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (168) 3-Z-[1-(4-(piperazin-1-ylmethyl)anilino)-1-(4-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (169) 3-Z-[1-(4-(morpholin-4-ylmethyl)anilino)-1-(4-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone 0 (170) 3-Z-[1-(4-(thiomorpholin-4-ylmethyl)anilino)-1-(4-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (171) 3-Z-[1-(4-(imidazol-1-ylmethyl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene] 6-bromo-2-indolinone (172) 3-Z-[1-(4-dimethylaminomethylanilino)-1-(3-(2 5 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (173) 3-Z-[1-(4-(N-(2-dimethylaminoethyl)-N-methylsulphonylamino)anilino)-1-(3-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (174) 3-Z-[1-(4-(N-(dimethylaminomethylcarbonyl)-N-methylamino)anilino)-1-(3-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone 0 (175) 3-Z-[1-(4-(N-(2-dimethylaminoethyl)-N-acetylamino)anilino)-1-(3-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (176) 3-Z-[1-(4-(N-(2-methylaminoethyl)-N-acetylamino)anilino)-1-(3-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone 136 (177) 3-Z-[1 -(4-(N -(3-dimethylaminopropyl)-N-acetylamino)anilino)-lI-(3-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (178) 3-Z-[1 -(4-(N -(3-methylaminopropyl)-N-acetylamino)anilino)-1 -(3-(2 carboxyethyl)ph enyl)methylene]-6-bromo-2-indoli none 5 (179) 3-Z-I1-(4-(3-dimethylaminopropyl)anilino)-1 -(3-(2 ca rboxyeth yl)ph en yl)methyl en e]-6-bromo-2-i ndol none (180) 3-Z-[1 -(4-ethylaminomethylanilino )-1 -(3-(2-carboxyethyl)phenyl)methylene]-6 b romo-2-indol none (181) 3-Z-[1 -(4-methylaminomethylanilino)-l1-(3-(2-carboxyethyl)phenyl)methylene] 0 6-bromo-2-indol none (182) 3-Z-[1 -(4-(N-(4-methylpiperazin-1 -ylmethylcarbonyl)-N-methylamino)anilino)-1 (3-(2-ca rboxyethyl)phenyl)methylene]-6-bromo-2-i ndol none (183) 3-Z-[1 -(4-(4-methylpiperazin-1 -ylcarbonyl)anilino)-1 -(3-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone 5 (184) 3-Z-[1 -(4-(N-(3-dimethylaminopropyl)-N-methylsulphonylamino)anilino)-1 -(3 (2-ca rboxyethyl)phenyl)methylene]-6-bromo-2-i ndol none (185) 3-Z-[1 -(4-(N -(2-d imethylamninoethyl)-N-propylsu lphonyla mino)a nil ino)-1 -(3-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (186) 3-Z-[ 1 -(4-a min omethyla n ilIino) -1 -(3-(2-carboxyethyl)phenyl )methylene] -6 0 bromo-2-indolinone (187) 3-Z-[1 -(3-(dimethylaminomethyl)anilino)-1 -(3-(2 ca rboxyethyl)phenyl)methylene]-6-bromo-2-i ndol none (188) 3-Z-[1 -(3-(methylaminomethyl)anilino)-1 -(3-(2 carboxyethyl)phenyl)methyl en e]-6-bromo-2-i ndol none 5 (189) 3-Z-[1 -(3-(2-dimethylaminoethyl)anilino)-1 -(3-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-i ndol none (190) 3-Z-[1 -(3-(3-dimethylaminopropyl )anilino)-1 -(3-(2 ca rboxyethyl)phenyl)methylene]-6-bromo-2-i ndol none (191) 3-Z-[1 -(4-(2-dimethylaminoethyl)anilino)-1 -(3-(2 0 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (192) 3-Z-[1 -(4-(N-(dimethylaminocarbonylmethyl)-N-methylsulphonylamino)anilino) 1 -(3-(2-ca rboxyethyl)phenyl )methylene]-6- bromo-2-indol none 137 (193) 3-Z-[1-(4-(N-methyl-N-methylsulphonylamino)anilino)-1-(3-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (194) 3-Z-[1-(4-(N-methyl-N-acetylamino)anilino)-1-(3-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone 5 (195) 3-Z-[1-(4-(1-methylimidazol-2-yl)anilino)-1-(3-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (196) 3-Z-[1-(4-(N-(N-(2-dimethylaminoethyl)-N-methylaminomethylcarbonyl)-N methylamino)anilino)-1 -(3-(2-carboxyethyl)phenyl)methylene]-6-bromo-2 indolinone 0 (197) 3-Z-[1-(4-(2-diethylaminoethylsulphonyl)anilino)-1-(3-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (198) 3-Z-[1-(4-(N-(2-dimethylaminoethylcarbonyl)-N-methylamino)anilino)-1-(3-(2 carboxyethyl)phenyl)methylenel-6-bromo-2-indolinone (199) 3-Z-[l-(4-(N-(2-dimethylaminoethyl)-N-methylaminomethyl)anilino)-1-(3-(2 5 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (200) 3-Z-[1-(4-(2-dimethylaminoethoxy)anilino)-1-(3-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (201) 3-Z-[1-(4-(N-(4-dimethylaminobutylcarbonyl)-N-methylamino)anilino)-1-(3-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone 0 (202) 3-Z-[1-(4-(N-(3-dimethylaminopropylcarbonyl)-N-methylamino)anilino)-1-(3-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (203) 3-Z-[1-(4-(methylethylaminomethyl)anilino)-1-(3-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (204) 3-Z-[1-(4-(methylpropylaminomethyl)anilino)-1-(3-(2 5 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (205) 3-Z-[1-(4-(methylbenzylaminomethyl)anilino)-1-(3-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (206) 3-Z-[1-(4-(diethylaminomethyl)anilino)-1-(3-(2-carboxyethyl)phenyl)methylene] 6-bromo-2-indolinone 0 (207) 3-Z-[1-(4-(N-(2-dimethylaminoethyl)-N-methylaminomethyl)anilino)-1-(3-(2 carboxyethyl)phenylmethylene]-6-bromo-2-indolinone 138 (208) 3-Z-[1-(4-(pyrrolidin-1-ylmethyl)anilino)-1-(3-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (209) 3-Z-[1-(4-(azetidin-1-ylmethyl)anilino)-1-(3-(2-carboxyethyl)phenyl)methylene] 6-bromo-2-indol i none 5 (210) 3-Z-[1-(4-((4-methylpiperazin-1-yl)methyl)anilino)-1-(3-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (211) 3-Z-[1-(4-(piperazin-1-ylmethyl)anilino)-1-(3-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (212) 3-Z-[1-(4-(morpholin-4-ylmethyl)anilino)-1-(3-(2 0 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (213) 3-Z-[1-(4-(thiomorpholin-4-ylmethyl)anilino)-1-(3-(2 carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone (214) 3-Z-[1-(4-(imidazol-1-ylmethyl)anilino)-1-(3-(2-carboxyethyl)phenyl)methylene] 6-bromo-2-indolinone 5 (215) 3-Z-[1-(4-dimethylaminomethylanilino)-1-(4-carboxymethylaminophenyl) methylene]-6-fluoro-2-indolinone (216) 3-Z-[1-(4-dimethylaminomethylanilino)-1-(3-carboxymethylamino-phenyl) methylene]-6-fluoro-2-indolinone (217) 3-Z-[1-(4-dimethylaminomethylanilino)-1-(4-(N-methyl 0 carboxymethylamino)phenyl)methylene] -6-fluoro-2-indolinone (218) 3-Z-[1-(4-dimethylaminomethylanilino)-1-(3-(N-methyl carboxymethylamino)phenyl)methylene] -6-fluoro-2-indolinone (219) 3-Z-[1-(4-dimethylaminomethylanilino)-1-(4-carboxymethoxyphenyl) methylene]-6-chloro-2-indolinone 5 (220) 3-Z-[1-(4-dimethylaminomethylanilino)-1-(3-carboxymethoxyphenyl) methylene]-6-chloro-2-indolinone (221) 3-Z-[1-(4-dimethylaminomethylanilino)-1-(4-carboxymethylaminophenyl) methylene]-6-chloro-2-indolinone (222) 3-Z-[1-(4-dimethylaminomethylanilino)-1-(3-carboxymethylaminophenyl) 0 methylene]-6-chloro-2-indolinone (223) 3-Z-[1-(4-dimethylaminomethylanilino)-1-(4-(N-methyl carboxymethylamino)phenyl)methylene] -6-chloro-2-indolinone - 139 (224) 3-Z-[1-(4-dimethylaminomethylanilino)-1-(3-(N-methyl carboxymethyla mino)phenyl)methylene]-6-chloro;2-indolinone (225) 3-Z-1-(4-dimethylaminomethylanilino)-1-(4-carboxymethoxyphenyl) methylene-6-bromo-2-indolinone (226) 3-Z-[i-(4-dimethylaminomethylanilino)-1-(3-carboxymethoxyphenyl) methylen e]-6-bromo-2-indol none (227) 3-Z-[1-(4-dimethylarriinomethylanilino)-1-(4-carboxymethylaminophenyl) .methylene]-6-bromo-2-indolinone (228) 3-Z-[1~(4-dimethylaminomethylanilino)-1-(3-carboxymethylaminophenyl) methylene]-6-bromo-2-indolinone (229) 3-Zd1 -(4-dimethylaminomethyanilino)-1-(4-(N-methyl carboxymethylamino)phenyl)methylene]-6-bromo-2-indolinone (230). 3-Z-[1-(4-dimethylaminornethylanilino)-1-(3-(N-methy ca rboxymethylamino)phenyl)methylerieJ-6-bromo-2-indolf one In the tables above, Me is methyl, Et is ethyl, Pr is propyl, nPr is n-propyl, Pr is isopropyl, nBu is n-butyl, tBu is tert-butyl and Bn is benzyl. Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
C:\NRPonb]\DCOAM"Ih304-945-_.DOC-,10mo1P - 140 The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general 5 knowledge in the field of endeavour to which this specification relates.
Claims (18)
1. Compounds of general formula R 3 /R4 N R \R5 - Ri () 5 in which X is an oxygen atom, R' is a hydrogen atom, 10 R 2 is a fluorine, chlorine or bromine atom or a cyano group, R3 is a phenyl group which is substituted by a C 1 - 2 -alkyl-carbonyl-amino group, 15 by a carboxy-C 1 . 3 -alkyl, carboxy-C 1 . 4 -alkoxy, Cw alkoxy-carbonyl-C1. 3 -alkyl, Cw -alkoxy-carbonyl-C 1 3 -alkoxy, aminocarbonyl-C 1 - 3 -alkyl, Cw 2alkylamino) carbonyl-C 1 . 3 -alkyl, di-(Cwralkyl)-aminocarbonyl-C1. 3 -alkyl, (C 1 . 2 -alkyl- CQNAPN-bl\CCLAMI\04494Sj DOC-5/712010 - 142 carbonyl)-amino-C 3 -alkyl, (CI-4alkoxy-carbonyl)-amino-C. 3 -alkyl, (phenyl carbonyl)-amino-C 3 -alkyl, (C3.-cycloalkyl-carbonyl)-amino-C.-alkyl, (C 3 . 6 cycloalkyl-Cl-3alkyl-carbonyl)-amino-Cj 3 -alkyl, (thiophen-2-yI-carbonyl) amino-C-s-alkyl, (furan-2-yI-carbonyl)-amino-C-ralkyl, (phenyl-C1.-alkyl 5 carbonyl)-amino-CI-3ralkyl, 2-(C 1 . 4 -alkoxy)-benzoyl-carbonyl)-amino-C-s alkyl, (pyridin-2-yl-carbonyl)-amino-Cl 3 -alkyl, (pyridin-3-yl-carbonyl)-amino C 13 -alkyl, (pyridin-4-yl-carbonyl)-amino-C3-alkyl or C-3alkyl-piperazin-1 yl-carbonyl-C 1 . 3 -alkyl group, 10 by an aminocarbonyl-C2. 3 -alkenyl, (Cl 3 -alkylamino)-carbonyl-C 2 . 3 -alkenyl, di-(C 1 3 -alkyl)-amino-carbonyl-C2-yalkenyi or C 4 -alkoxy-carbonyl-C2-r alkenyl group, R4 is a phenyl group or a phenyl group which is monosubstituted 15 by a C 13 -alkyl group which is terminally substituted by an amino, guanidino, mono- or di-(Ci- 2 -alkyl)-amino-N-[o-di-(Cr-alkyl)-amino-C 2 3 -alkyl]-N-(Cv alkyl)-amino, N-methyl-(C 3 . 4 -alkyl)-amino, N-(C 3 -alkyl)-N-benzylamino, N (C 1 . 4 -alkoxycarbonyl)-amino, N-(C 1 4 -alkoxycarbonyl)-C- 4 -alkylamino, 20 4-(C 3 -alkyl)-piperazin-1-yl, imidazol-1-yl, pyrrolidin-1-yl, azetidin-1-yl, morpholin-4-yl, piperazin-1-yl, thiomorpholin-4-yl group, by a di-(Ctalkyl)-amino-(C1.-alkyl)-sulphonyl, 2-[di-(C 3 -alkyl)-amino] ethoxy, 4 -(Ci 3 -alkyl)-piperazin-1-yl-carbonyl, {(o-[di-(C1 3 -alkyl)-amino]-(C2,s- - 143 alkyl)}-N-(C3-alkyl)-amino-carbonyl, 1-(C1.-aIkyl)lmIdazol-2-yl, (Cw .- alkyl) sulphonyl group, or by a group of the formula /R11 -N \R7 in which Rk is a C. 2 -alkyl, Ciwalkyl-carbonyl, di-(C 2 -alkyl)-amino-carbonyl-C1- alky! or C.ralkylsulphonyl group and R 8 is C 13 alkyl, w-[di-(C1. 2 -alkyl)-amino]-C 2 -alkyl, o-[mono-(Ca2-lkyl) amino]-C2-alkyl group, or a (Cw 4 alkyl)-carbonyl, (C4 6 -alkyl)-carbonyl or carbonyl-(Cj.s-alkyl) group which is terminally substituted by a di-(Ciwalkyl)-amino, piperazin-1 -yf or 4-(Cw. 3 -alkyl)-piperazin-1 -yl group, where all dialkylamino groups present in the radical R 4 may also be present in quaternized form, for example as an N-methyl-(N,N-dialkyl)-ammonium group, where the counterion is preferably selected from the group consisting of iodide, chloride, bromide, rmethylsulphonate, para-toluenesulphonate and trifluoroacetate, R 6 is a hydrogen atom and R5 is a hydrogen atom, where the abovementioned alkyl.groups Include linear and branched alkyl groups.in which additionally one to 3 hydrogen atoms may be replaced by fluorine atoms. CNfP-hWpCCAMTU0444_ I .DOC-SI/7/2610 -144 where additionally a carboxyl, amino or imino group present may be substituted by an in vivo cleavable radical or may be present in the form of a group which can be converted in vivo into a carboxyl group or in the form of a group which can be convered in vivo into an imino or amino group, 5 and its tautomers, enantiomers, diastereomers, mixtures thereof and salts thereof.
2. Compounds of general formula I according to Claim 1, in which X, R 1 , R 2 , R 4 , R 5 and Re are as defined in Claim 1 and 10 R 3 is a phenyl group substituted by a carboxy-C 1 .3-alkyl or C 1 . 4 -alkoxy-carbonyl C 1 .. 3 -alkyl group.
3. Compounds of general formula I according to Claim 1 or Claim 2, in 15 which X, R', R 3 , R 4 , R 5 and R 6 are as defined in Claim 1 or Claim 2 and R 2 is a fluorine or chlorine atom.
4. The following compounds of general formula I according to Claim 1: 20 (a) 3-Z-[I -(4-dimethylaminomethylanilino)-1 -(3-(2-carboxyethyl)phenyl)methylene] -6-chloro-2-indolinone (b) 3-Z-[1 -(4-dimethylaminomethylanil i no)- 1 -(4-(2-carboxyethyl)phenyl)methylene] - 6-fluoro-2-indolinone 25 (c) 3-Z-[1 -(4-dimethylaminomethylanilino)-I -(3-(2-carboxyethyl)phenyl)methylene -6-fluoro-2-indolinone (d) 3-Z-[1-(4-(N-(4-methylpiperazin-1-ylmethylcarbonyl)-N-methylamino)anilino)-1 (4-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone 30 (e) 3-Z-[1-(4-(N-(2-dimethylaminoethyl)-N-methylsulphonylamino)anilino)-1-(4-(2 ca rboxyeth yl)p h enyl) methyl ene]-6-fl uoro-2-i nd olin one (f) 3-Z-f[-(4-(N-(3-dimethylaminopropyl-N-acetylamino)anilino)-1-(4-(2- C'NRPolb[\CkAML3044945_1. OC-59A7/201a - 145 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone (g) 3-Z-[1-(4-(1-methylimidazol-2-yl)anilino)-1-(4-(2-carboxyethyl)phenyl) methylene]-6-fluoro-2-indolinone (h) 3-Z-[1 -(4-(N-(dimethylaminomethylcarbonyl)-N-methylamino)anilino)-i-(4-(2 5 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone (i) 3-Z-[l-(4-(N-(2-dimethylaminoethylcarbonyl)-N-methylamino)anilino)-1-(4-(2 carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone (j) 3-Z-[1-(4-(pyrrolidin-1-ylmethyl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene] -6-fl uoro-2-indolinone 10 (k) 3-Z-[l -(4-(diethylarminomethyl)anilino)-I -(4-(2-carboxyethyl)phenyl)methylene] -6-fluoro-2-indolinone (1) 3-Z-[I-(4-(2-dimethylaminoethyl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene -6-chloro-2-indolinone (m) 3-Z-[1-(4-dimethylaminomethyl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene] 15 -6-chloro-2-indolinone (n) 3-Z-[1-(4-(pyrrolidin-1-ylmethyl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene] -6-chloro-2-indolinone (o) 3-Z-[l-(4-(pyrrolidin-1-ylmethyl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene] -6-bromo-2-indolinone 20 (p) 3-Z-[1 -(4-(dimethylaminomethyl)anilino)-1 -(4-(2-carboxyethyl)phenyl) methylene]-6-bromo-2-indolinone (q) 3-Z-[1-(4-(diethylaminomethyl)anilino)-1-(4-(2-carboxyethyl)-methylene]-6 bromo-2-indol i none 25 and their salts.
5. Physiologically acceptable salts of the compounds according to any one of Claims 1 to 4. 30
6. A medicament, comprising a compound of general formula I -146 according to any one of Claims 1 to 4 or a physiologically acceptable salt according to Claim 5, if appropriate in addition to one or more inert carrier materials and/or diluents. 5
7. The use of a compound of general formula I according to any one of Claims 1 to 4 or of a physiologically acceptable salt according to Claim 5 for preparing a medicament suitable for treating excessive or abnormal cell proliferation. 10
8. Method of treating excessive or abnormal cell proliferation comprising administering an effective amount of a compound of general formula I according to any one of Claims 1 to 4 or a physiologically acceptable salt according to Claim 5 to a subject in need thereof. 15
9. A process for preparing a medicament according to Claim 6, wherein, by a non-chemical route, a compound of the formula I according to any one of Claims 1 to 4 or a physiologically acceptable salt according to Claim 5 is incorporated into one or more inert carrier materials and/or diluents. 20
10. A process for preparing a compound according to any one of Claims 1 to 4, wherein a. a compound of the formula C: FRPanbl\DCCMAMTUO 4 4945_]. DOO.6107/J 610 - 146A z-1 ReRY R2 N Rf (V), in which the radicals Z' and R 3 may, if appropriate, change their positions, 5 X, R 2 , R 3 and R5 are as defined in Claim 1, R' has the meanings mentioned at the outset for R' or is a protective group for the nitrogen atom of the lactam group, where R' may also, if appropriate, represent a bond, formed via a spacer, to a solid phase, and Z' is a halogen atom, a hydroxyl, alkoxy or arylalkoxy group, for 10 example a chlorine or bromine atom, a methoxy, ethoxy or benzyloxy group, is reacted with an amine of general formula R4x~ R$ H (Vi), 15 147 in which R 4 and R 5 are defined as mentioned at the outset, and, if required, the product is subsequently cleaved from a protective group used for the nitrogen atom of the lactam group or from a solid phase, 5 b. for preparing a compound of the formula I in which R 3 is a phenyl or naphthyl group substituted by a carboxy-C 2 - 3 -alkenyl, aminocarbonyl-C 2 - 3 -alkenyl, (C 1 - 3 -alkyl amino)-carbonyl-C 2 . 3 -alkenyl, di-(C1. 3 -alkylamino)-carbonyl-C 2 - 3 -alkeny or C 1 . 4 alkoxy-carbonyl-C 2 - 3 -alkenyl group, 0 a compound of the formula Z3 /R4 N R5 R6 X R N Ri' (IX), in which 5 R 2 , R 4 , R , R 6 and X are as defined in Claim 1, R' has the meanings mentioned at the outset for R1 or is a protective group for the nitrogen atom of the lactam group, where R, may also, if appropriate, represent a bond, formed via a spacer, to a solid phase, and Z 3 is a leaving group, for example a halogen atom or an alkyl- or arylsulphonyloxy 0 group, such as a chlorine, bromine or iodine atom or a methylsulphonyloxy, ethylsulphonyloxy, p-toluenesulphonyloxy or trifluoromethanesulphonyloxy group, is reacted with an alkene of general formula 0 R3l"n 148 (X), in which R 3 ' is an amino, (C1- 3 -alkylamino), di-(C 1 - 3 -alkylamino) or C 1 . 4 -alkoxy group and n is the number 0 or 1, 5 c. to prepare a compound of the formula 1, in which R 3 is a phenyl or naphthyl group substituted by a carboxy-C 1 - 3 -alkyl, C 1 .4-alkoxy-carbonyl-Cl- 3 -alkyl, aminocarbonyl C 1 - 3 -alkyl, (C1- 3 -alkylamino)-carbonyl-C. 3 -alky or di-(C 1 - 3 -alkyl)aminocarbonyl-C1- 3 alkyl group, 0 a compound of general formula R3' O A R4 N R5 R 6 X N R R1' (XI), in which 5 R 2 , R 4 , R', R 6 and X are as defined in claim 1, R"' has the meanings mentioned at the outset for R' or is a protective group for the nitrogen atom of the lactam group, where R 1 ' may also, if appropriate, represent a bond, formed via a spacer, to a solid phase, A is a C 2 - 3 -alkenyl group and 0 R 3 -is a hydroxyl, C 1 - 4 -alkoxy, amino, (C 1 - 3 -alkylamino) or di-(C 1 - 3 -alkyl)amino group, is hydrogenated and the product is subsequently cleaved from any protective groups used for the nitrogen atom of the lactam group or from a solid phase, as described above under 5 process (a), 149 and an alkoxycarbonyl group is, if appropriate, subsequently converted by hydrolysis into a corresponding carboxyl compound, or 5 an amino or alkylamino group is converted by reductive alkylation into a corresponding alkylamino or dialkylamino compound, or a dialkylamino group is converted by alkylation into a corresponding trialkylammonium compound, or 0 an amino or alkylamino group is converted by acylation or sulphonation into a corresponding acyl or sulphonyl compound, respectively, or a carboxyl group is converted by esterification or amidation into a corresponding 5 ester or aminocarbonyl compound, respectively, or a nitro group is converted by reduction into a corresponding amino compound, or a cyano group is converted by reduction into a corresponding aminomethyl 0 compound, or an arylalkyloxy group is converted with an acid into a corresponding hydroxyl compound, or 5 an alkoxycarbonyl group is converted by hydrolysis into a corresponding carboxyl compound, or a phenyl group substituted by an amino, alkylamino, aminoalkyl or N-alkyl-amino group is converted by reaction with an appropriate amidino-group-transferring 0 compound or by reaction with an appropriate nitrile into a corresponding guanidine compound of general formula 1. C\NAqPthl\DCCAMT\3O44945I DOC-510712010 - 150
11. The compound of general formula I according to Claim 1 which is 3-Z-[1-(4-dimethylaminomethylanilino)-1-(4-(2 ethoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone. 5
12. The compound 1-acetyl-6-fluoro-2-indolinone.
13. Compound according to Claim 1 substantially as hereinbefore described with reference to any one of the examples. 10
14. Physiologically acceptable salts according to Claim 5 substantially as hereinbefore described with reference to any one of the examples.
15. Medicament according to Claim 6 substantially as 15 hereinbefore described with reference to any one of the examples.
16. Use according to Claim 7 substantially as hereinbefore described with reference to any one of the examples. 20
17. Method according to Claim 8 substantially as hereinbefore described with reference to any one of the examples.
18. Process according to Claim 9 or Claim 10 substantially as hereinbefore described with reference to any one of the examples. 25
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2010202845A AU2010202845A1 (en) | 2002-07-23 | 2010-07-06 | Indoline derivatives substituted in position 6, production and use thereof as medicaments |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10233366.1 | 2002-07-23 | ||
| DE10233366A DE10233366A1 (en) | 2002-07-23 | 2002-07-23 | Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments |
| DE10328533A DE10328533A1 (en) | 2003-06-24 | 2003-06-24 | New 6-amino-substituted indolinone derivatives, useful e.g. for treating tumours and angiogenesis, are inhibitors of receptor tyrosine kinases |
| DE10328533.4 | 2003-06-24 | ||
| PCT/EP2003/007961 WO2004009547A1 (en) | 2002-07-23 | 2003-07-22 | Indoline derivatives substituted in position 6, production and use thereof as medicaments |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010202845A Division AU2010202845A1 (en) | 2002-07-23 | 2010-07-06 | Indoline derivatives substituted in position 6, production and use thereof as medicaments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003254557A1 AU2003254557A1 (en) | 2004-02-09 |
| AU2003254557B2 true AU2003254557B2 (en) | 2010-07-22 |
Family
ID=30771725
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003254557A Ceased AU2003254557B2 (en) | 2002-07-23 | 2003-07-22 | Indoline derivatives substituted in position 6, production and use thereof as medicaments |
| AU2010202845A Ceased AU2010202845A1 (en) | 2002-07-23 | 2010-07-06 | Indoline derivatives substituted in position 6, production and use thereof as medicaments |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010202845A Ceased AU2010202845A1 (en) | 2002-07-23 | 2010-07-06 | Indoline derivatives substituted in position 6, production and use thereof as medicaments |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1523473B1 (en) |
| JP (1) | JP4401291B2 (en) |
| KR (2) | KR20050052456A (en) |
| CN (1) | CN1318403C (en) |
| AR (1) | AR041188A1 (en) |
| AU (2) | AU2003254557B2 (en) |
| BR (1) | BR0312799A (en) |
| CA (1) | CA2493436C (en) |
| DK (1) | DK1523473T3 (en) |
| EA (1) | EA008623B1 (en) |
| EC (1) | ECSP055567A (en) |
| ES (1) | ES2409062T3 (en) |
| HK (1) | HK1081554A1 (en) |
| HR (1) | HRP20050069A2 (en) |
| IL (1) | IL166404A0 (en) |
| MX (1) | MXPA04012937A (en) |
| MY (1) | MY138141A (en) |
| NO (1) | NO20050937L (en) |
| PE (1) | PE20040701A1 (en) |
| PL (2) | PL374879A1 (en) |
| RS (1) | RS20050047A (en) |
| SA (1) | SA03240430B1 (en) |
| TW (1) | TWI343375B (en) |
| UY (1) | UY27903A1 (en) |
| WO (1) | WO2004009547A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7514468B2 (en) | 2002-07-23 | 2009-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions |
| US7169936B2 (en) | 2002-07-23 | 2007-01-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments |
| US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| PE20061155A1 (en) * | 2004-12-24 | 2006-12-16 | Boehringer Ingelheim Int | INDOLINONE DERIVATIVES AS AGENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES |
| JP5053997B2 (en) * | 2005-04-28 | 2012-10-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Novel compounds for the treatment of inflammatory diseases |
| WO2007057399A2 (en) * | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Treatment of cancer with indole derivatives |
| RU2010135198A (en) * | 2008-01-25 | 2012-02-27 | Бёрингер Ингельхайм Интернациональ Гмбх (De) | SALT FORMS OF THE 6-fluoro-1,2-dihydro-2-oxo-3n-indol-3-ylidene derivative, process for the preparation thereof and containing pharmaceutical compositions thereof |
| WO2009092580A1 (en) * | 2008-01-25 | 2009-07-30 | Boehringer Ingelheim International Gmbh | Process for the manufacture of a 6-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene derivative |
| TW201011002A (en) | 2008-07-29 | 2010-03-16 | Boehringer Ingelheim Int | New compounds |
| JP6263124B2 (en) * | 2012-10-17 | 2018-01-17 | 国立大学法人 岡山大学 | Compound, tautomer, geometric isomer thereof, salt thereof, production method thereof, antibacterial agent, and infectious disease therapeutic agent |
| US9642851B2 (en) | 2012-12-06 | 2017-05-09 | Kbp Biosciences Co., Ltd. | Indolinone derivative as tyrosine kinase inhibitor |
| CN105461609B (en) * | 2015-12-25 | 2019-08-23 | 杭州新博思生物医药有限公司 | A kind of preparation method of Nintedanib |
| CN114213396B (en) * | 2022-01-27 | 2023-03-24 | 深圳市乐土生物医药有限公司 | Indole-2-ketone compound and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000018734A1 (en) * | 1998-09-25 | 2000-04-06 | Boehringer Ingelheim Pharma Kg | Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/cdk complexes |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9904933D0 (en) * | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
| WO2003027102A1 (en) * | 2001-09-27 | 2003-04-03 | Allergan, Inc. | 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
| US6559173B1 (en) * | 2001-09-27 | 2003-05-06 | Allergan, Inc. | 3-(heteroarylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
-
2003
- 2003-07-21 PE PE2003000724A patent/PE20040701A1/en not_active Application Discontinuation
- 2003-07-22 PL PL03374879A patent/PL374879A1/en unknown
- 2003-07-22 WO PCT/EP2003/007961 patent/WO2004009547A1/en active Application Filing
- 2003-07-22 CA CA2493436A patent/CA2493436C/en not_active Expired - Fee Related
- 2003-07-22 AU AU2003254557A patent/AU2003254557B2/en not_active Ceased
- 2003-07-22 ES ES03765079T patent/ES2409062T3/en not_active Expired - Lifetime
- 2003-07-22 DK DK03765079.3T patent/DK1523473T3/en active
- 2003-07-22 BR BR0312799-0A patent/BR0312799A/en not_active Expired - Fee Related
- 2003-07-22 JP JP2004522540A patent/JP4401291B2/en not_active Expired - Fee Related
- 2003-07-22 TW TW092119987A patent/TWI343375B/en not_active IP Right Cessation
- 2003-07-22 EP EP03765079A patent/EP1523473B1/en not_active Expired - Lifetime
- 2003-07-22 KR KR1020057001222A patent/KR20050052456A/en active IP Right Grant
- 2003-07-22 MX MXPA04012937A patent/MXPA04012937A/en active IP Right Grant
- 2003-07-22 EA EA200500148A patent/EA008623B1/en not_active IP Right Cessation
- 2003-07-22 KR KR1020117030702A patent/KR20120003025A/en not_active Application Discontinuation
- 2003-07-22 RS YUP-2005/0047A patent/RS20050047A/en unknown
- 2003-07-22 PL PL397821A patent/PL397821A1/en unknown
- 2003-07-22 CN CNB038173174A patent/CN1318403C/en not_active Expired - Fee Related
- 2003-07-22 MY MYPI20032755A patent/MY138141A/en unknown
- 2003-07-23 UY UY27903A patent/UY27903A1/en not_active Application Discontinuation
- 2003-07-23 AR ARP030102634A patent/AR041188A1/en not_active Suspension/Interruption
- 2003-12-07 SA SA3240430A patent/SA03240430B1/en unknown
-
2005
- 2005-01-20 IL IL16640405A patent/IL166404A0/en not_active IP Right Cessation
- 2005-01-21 HR HR20050069A patent/HRP20050069A2/en not_active Application Discontinuation
- 2005-01-24 EC EC2005005567A patent/ECSP055567A/en unknown
- 2005-02-21 NO NO20050937A patent/NO20050937L/en not_active Application Discontinuation
-
2006
- 2006-02-16 HK HK06101988A patent/HK1081554A1/en not_active IP Right Cessation
-
2010
- 2010-07-06 AU AU2010202845A patent/AU2010202845A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000018734A1 (en) * | 1998-09-25 | 2000-04-06 | Boehringer Ingelheim Pharma Kg | Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/cdk complexes |
Also Published As
| Publication number | Publication date |
|---|---|
| TW200413314A (en) | 2004-08-01 |
| AU2003254557A1 (en) | 2004-02-09 |
| PE20040701A1 (en) | 2004-11-30 |
| HK1081554A1 (en) | 2006-05-19 |
| AU2010202845A1 (en) | 2010-07-22 |
| CA2493436C (en) | 2011-11-08 |
| RS20050047A (en) | 2007-09-21 |
| IL166404A0 (en) | 2006-01-15 |
| WO2004009547A1 (en) | 2004-01-29 |
| ES2409062T3 (en) | 2013-06-24 |
| JP4401291B2 (en) | 2010-01-20 |
| MY138141A (en) | 2009-04-30 |
| CA2493436A1 (en) | 2004-01-29 |
| EP1523473B1 (en) | 2013-02-27 |
| PL374879A1 (en) | 2005-11-14 |
| SA03240430B1 (en) | 2008-03-23 |
| EA200500148A1 (en) | 2005-08-25 |
| MXPA04012937A (en) | 2005-05-16 |
| CN1318403C (en) | 2007-05-30 |
| EP1523473A1 (en) | 2005-04-20 |
| ECSP055567A (en) | 2005-04-18 |
| UY27903A1 (en) | 2004-02-27 |
| NO20050937L (en) | 2005-02-21 |
| HRP20050069A2 (en) | 2005-12-31 |
| JP2005533841A (en) | 2005-11-10 |
| DK1523473T3 (en) | 2013-06-03 |
| EA008623B1 (en) | 2007-06-29 |
| KR20050052456A (en) | 2005-06-02 |
| PL397821A1 (en) | 2012-03-12 |
| AR041188A1 (en) | 2005-05-04 |
| CN1668589A (en) | 2005-09-14 |
| TWI343375B (en) | 2011-06-11 |
| BR0312799A (en) | 2005-05-03 |
| KR20120003025A (en) | 2012-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010202845A1 (en) | Indoline derivatives substituted in position 6, production and use thereof as medicaments | |
| US7858616B2 (en) | Indolinone derivatives substituted in the 6 position, their preparation and their use as medicaments | |
| JP3952369B2 (en) | Novel substituted indolinones, their production and their use as pharmaceuticals | |
| KR100857734B1 (en) | 6-Position substituted indolinone, pharmaceutical compositions containing the same, and process for preparing the same | |
| US20020082270A1 (en) | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | |
| US5693655A (en) | 3-indolylpiperidines | |
| JP2004507533A (en) | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and methods for their production | |
| US6858641B2 (en) | Substituted indolinones | |
| US7166615B2 (en) | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions | |
| NZ519977A (en) | Substituted N-benzylindol-3-ylglyoxylic acid derivatives having antitumor action | |
| JP2007534733A (en) | 3,4-disubstituted maleimides used as vascular injury agents | |
| CA2493721A1 (en) | Indoline derivatives substituted in position 6, production and use thereof as medicaments | |
| NZ538337A (en) | Indolinone derivatives substituted in position 6, production and use thereof as medicaments for treating abnormal cell proliferation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |